docetaxel anhydrous has been researched along with Carcinoma, Non-Small Cell Lung in 1472 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 98 (6.66) | 18.2507 |
| 2000's | 601 (40.83) | 29.6817 |
| 2010's | 616 (41.85) | 24.3611 |
| 2020's | 157 (10.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, L; Wang, F; Wen, X; Zhao, C; Zheng, Q | 1 |
| Auliac, JB; Bizieux, A; Chouaid, C; Falchero, L; Geier, M; Greillier, L; Guisier, F; Lamy, R; Le Garff, G; Monnet, I; Ricordel, C; Vergnenegre, A | 1 |
| Fukushima, K; Hashida, N; Hirata, H; Iwahori, K; Koyama, S; Kuge, T; Kumanogoh, A; Matsumoto, K; Miyake, K; Nagatomo, I; Naito, Y; Shiroyama, T; Suga, Y; Takeda, Y; Yamamoto, M; Yamamoto, Y; Yoneda, M | 1 |
| Atagi, S; Inagaki, Y; Kawachi, H; Matsuda, Y; Matsumoto, K; Suzuki, H; Tamiya, A; Tamiya, M; Taniguchi, Y; Tanizaki, S; Uchida, J; Ueno, K; Yanase, T | 1 |
| Han, C; Li, H; Li, Z; Liu, Z; Sun, Z; Wu, Y; Zhang, J; Zhang, X | 1 |
| Arora, P; Gupta, A; Ramagopalan, S; Ray, J; Subbiah, V; Thorlund, K | 1 |
| Chihara, Y; Hiranuma, O; Ishida, M; Iwasaku, M; Morimoto, K; Morimoto, Y; Shiotsu, S; Takayama, K; Takeda, T; Tokuda, S; Yamada, T | 1 |
| Batbold, U; Liu, JJ | 1 |
| Chen, Y; Katayose, T; Nagaoka, S; Sekine, N | 1 |
| Ballinger, M; Fuhlbrück, F; Gandara, D; Jiang, Y; Palma, JF; Patil, NS; Peters, E; Shames, DS; Yaung, SJ; Zou, W | 1 |
| Atz, J; Blau, W; Gleiber, W; Grohé, C; Haas, S; Hammerschmidt, S; Kaiser, R; Krüger, S; Müller-Huesmann, H; Schulze, M; Wehler, T | 1 |
| Kawachi, H; Kumagai, T; Matsumoto, K; Tamiya, A; Tamiya, M; Tanizaki, S; Yanase, T | 1 |
| Cai, XW; Feng, W; Fu, XL; Yu, W; Zhang, Q | 1 |
| Adamchuk, H; Blayney, DW; Chen, M; Du, L; Ginn, G; Huang, L; Kirtbaya, DV; Mohanlal, R; Ogenstad, S; Zhang, Q | 1 |
| Chan, AL; Chang, CW; Lang, HC; Leung, JH | 1 |
| Chen, XW; Li, JQ; Liu, Y; Song, L; Wang, H | 1 |
| Addeo, A; Betticher, DC; Curioni-Fontecedro, A; Eboulet, EI; Früh, M; Furrer, K; Guckenberger, M; Hayoz, S; König, D; Mark, M; Ochsenbein, A; Opitz, I; Peters, S; Pless, M; Ris, HB; Rothschild, SI; Schär, S; Stupp, R; Thierstein, S; Vuong, D; Weder, W; Zippelius, A | 1 |
| Aprile, G; Bernardi, D; Bonanno, L; Bonetti, A; Bortolami, A; Calvetti, L; Conte, P; Crivellaro, G; Favaretto, A; Giovanis, P; Guarneri, V; Lorenzi, M; Mandarà, M; Marino, V; Morandi, P; Oliani, C; Palazzolo, G; Pasello, G; Pavan, A; Sinigaglia, G; Tognazzo, S; Zustovich, F | 1 |
| Gong, H; Guo, J; Han, X; Hua, Y; Huang, W; Liu, Z; Meng, X; Sun, Y; Tang, X; Wang, L; Wang, Z; Yuan, S; Zhang, P; Zhang, X; Zhang, Y; Zhu, D; Zhu, H | 1 |
| Kato, A; Kato, J; Kondo, Y; Miyake, Y; Mizuno, T; Sakakibara, T; Tachi, T; Teramachi, H | 1 |
| Ando, M; Asami, K; Atagi, S; Kawahara, M; Minato, K; Mori, M; Nishimura, T; Ogushi, F; Tamura, A; Yamamoto, A; Yokoi, T; Yoshioka, H | 1 |
| Hashimoto, M; Hojo, M; Iikura, M; Ishida, A; Ishii, S; Izumi, S; Naka, G; Sugiyama, H; Ushio, A | 1 |
| Al Baghdadi, T; Dragnev, KH; Everhart, L; Faller, B; Gandara, DR; Gray, JE; Herbst, RS; Highleyman, L; Hines, S; Kelly, K; Minichiello, K; Papadimitrakopoulou, V; Patel, JD; Reckamp, KL; Redman, MW; Villaruz, LC; Waqar, SN | 1 |
| Fan, S; Huang, W; Jiang, Y; Liang, Z; Liu, J; Liu, Y; Liu, Z; Shi, J; Sun, X; Wang, J; Wu, Y; Yang, N; Yang, X; Zheng, J | 1 |
| Haratake, N; Mitsudomi, T; Nakagawa, K; Seto, T; Shimokawa, M; Yamamoto, N; Yoshioka, H | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Addeo, A; Banna, GL; Borghaei, H; Cortellini, A; D'Alessio, A; Fulgenzi, CAM; Naqash, AR; Pinato, DJ; Ricciuti, B | 1 |
| Gu, Q; Li, S | 1 |
| Baker, S; Blanchard, E; Brahmer, JR; Celano, P; Duma, N; Elkins, IB; Ellis, PM; Haddad, RY; Hesketh, PJ; Jain, D; Jaiyesimi, IA; Johnson, DH; Leighl, NB; Mamdani, H; Masters, G; Moffitt, PR; Phillips, T; Riely, GJ; Robinson, AG; Rosell, R; Schiller, JH; Schneider, BJ; Singh, N; Spigel, DR; Temin, S | 1 |
| Du, D; Ji, J; Ma, H; Qiu, Y; Xie, B; Zhang, W; Zhou, J; Zhu, L | 1 |
| Carlisle, J; Chen, Z; Dhodapkar, M; Leal, T; Liu, Y; Osta, BE; Owonikoko, T; Pakkala, S; Ramalingam, S; Steuer, C | 1 |
| Rodriguez, E; Santos, ES | 1 |
| Bessho, A; Furuya, N; Goto, Y; Harada, T; Kawashima, Y; Misumi, T; Miura, S; Nakahara, Y; Nakamura, Y; Naoki, K; Okamoto, H; Seike, M; Shimokawa, T; Shiraishi, Y; Takiguchi, Y; Tanaka, H; Taniguchi, Y; Tokito, T; Uchiyama, A | 1 |
| Albuquerque de Almeida, F; Cooper, M; Iadeluca, L; Inês, M; Smith, S | 1 |
| Jiang, W; Liu, L; Song, L; Wang, Z; Xia, Q; Xiong, Y; Xu, Q; Yang, H; Yang, N; Zeng, L; Zhang, Y; Zhou, C | 1 |
| Lin, J; Wang, H; Wang, K; Zhang, C | 1 |
| Ando, M; Goto, Y; Harada, T; Hirano, K; Hosomi, Y; Iwasawa, S; Kato, T; Kishimoto, J; Kondo, M; Kubo, T; Miura, S; Morita, S; Nakamura, A; Nakanishi, Y; Oguri, T; Okamoto, I; Takeshita, M; Yamamoto, N; Yoneshima, Y; Yoshioka, H | 1 |
| Carr, SR; Chen, YZ; Fietkau, R; Frey, B; Gaipl, US; He, SS; Hecht, M; Jin, SH; Ma, H; Schrump, DS; Shen, B; Shen, G; Tan, F; Wang, H; Wang, R; Wong, AH; Zhou, JG | 1 |
| Akopov, A; Cheng, Y; Disel, U; Dvorkin, M; Fan, Y; Hu, S; Huang, D; Li, S; Liu, Y; Liu, Z; Ma, Y; Ma, Z; Poddubskaya, E; Rivalland, G; Shu, Y; Wang, J; Wang, Y; Wang, Z; Yu, C; Yu, X; Zheng, W; Zhou, C | 1 |
| Asano, F; Hayashi, T; Hirashita, T; Inoue, K; Ito, K; Katagiri, N; Mano, S; Masuda, A; Miyazaki, K; Oguri, R; Ohno, H; Sekiya, Y; Tsuzuku, A | 1 |
| Guo, S; Li, S; Ma, K; Wang, J; Wei, S; Xu, Y; Zhang, F | 1 |
| Borisyuk, BO; Bororov, LV; Ganul, AV; Maliarchuk, K; Shevchenko, AI; Sovenko, VM | 1 |
| Igai, H; Kamiyoshihara, M; Matsuura, N; Numajiri, K; Ohsawa, F | 1 |
| An, G; Chen, Y; Chen, Z; Cheng, Y; Fang, Y; Feng, J; Guo, Q; Hu, W; Hu, Y; Huang, J; Li, W; Li, X; Liu, Y; Mancao, C; Niu, H; Peng, B; Shi, J; Shi, Y; Shu, Y; Song, Y; Sun, J; Sun, L; Sun, S; Sun, T; Wang, A; Wang, C; Wang, J; Wang, L; Wang, M; Wang, Y; Wang, Z; Wu, G; Wu, L; Wu, Z; Xing, P; Ye, F; Yu, X; Yuan, Y; Zhang, S; Zhang, Y; Zhao, Y; Zhou, C; Zhou, J | 1 |
| Lin, GH; Liu, XX; Wang, BC | 1 |
| Hua, X; Liu, H; Lv, T; Song, Y; Wu, X; Xu, K; Zhan, P; Zhang, F | 1 |
| Dong, X; Gai, F; Gong, H; Guo, J; Han, X; Hua, Y; Huang, W; Huang, Z; Liu, Z; Meng, X; Sun, Y; Tang, X; Wang, L; Wang, Z; Yuan, S; Zhang, P; Zhang, X; Zhang, Y; Zhu, C; Zhu, D; Zhu, H | 1 |
| Aggarwal, H; Muehlenbein, CE; Ndirangu, K; Thom, H; Tongbram, V; Winfree, KB; Zhu, E | 1 |
| Cappelleri, JC; Chu, H; Harari, O; Heeg, B; Roychoudhury, S; Soltanifar, M; Tremblay, G; Verhoek, A | 1 |
| Ahmadu, C; Al Khayat, MNMT; Armstrong, N; Duffy, S; Howick, J; Konings, SRA; O'Meara, S; Posadzki, P; Postma, MJ; Ryder, S; van Asselt, ADI; Wolff, RF | 1 |
| Kenmotsu, H | 1 |
| Kawachi, H; Matsuda, Y; Matsumoto, K; Okishio, K; Suzuki, H; Tamiya, A; Tamiya, M; Taniguchi, Y; Tanizaki, S; Uchida, J; Ueno, K; Yanase, T | 1 |
| Balbach, ML; Bestvina, C; Camidge, DR; Hsu, R; Iams, WT; Kim, C; Leal, T; Marmarelis, ME; Mehta, K; Nieva, J; Patil, T; Phillips, S; Robinson, MA; Sacher, A; Sackstein, PE; Sethakorn, N; Velcheti, V; Wang, X | 1 |
| Arai, D; Ito, K; Kaira, K; Kajiwara, T; Kobayashi, K; Kodama, H; Miura, K; Miyanaga, A; Mizutani, H; Mori, K; Nakamura, A; Ninomiya, T; Oba, T; Tamiya, M; Yamaguchi, O; Yanagitani, N | 1 |
| Chi, Z; Shao, T; Tang, W; Zhao, M | 1 |
| Andrikou, K; Bonetti, A; Borra, G; Cappuzzo, F; Conti, L; D'Andrea, MR; Delmonte, A; Giannarelli, D; Gori, S; Landi, L; Laudisi, A; Mangiola, D; Mazzoni, F; Metro, G; Minuti, G; Pasello, G; Resuli, B; Vidiri, A | 1 |
| Flieswasser, T; Freire Boullosa, L; Hermans, C; Jacobs, J; Lardon, F; Lau, HW; Melis, J; Merlin, C; Pauwels, P; Smits, E; Van Audenaerde, J; Van den Eynde, A | 1 |
| Bittoni, MA; Carbone, DP; Divan, HA; Krishna, A | 1 |
| Chihara, Y; Hiranuma, O; Inoue, K; Kimura, H; Kita, T; Minato, K; Nakao, A; Takayama, K; Takemoto, S; Takumi, C; Tanimura, K; Tanzawa, S; Uchino, J; Yoshimura, K | 1 |
| Kubota, K; Kunitoh, H; Maruyama, R; Matsuda, A; Ohira, T; Okamoto, H; Seto, T; Tsuboi, M; Yamaoka, K | 1 |
| Chen, H; Danchaivijtr, P; Dang, T; Feng, J; Ge, J; He, J; Huang, C; Li, B; Ma, S; Ma, Z; Orlandi, F; Ren, S; Sriuranpong, V; Vynnychenko, I; Wang, C; Wang, CC; Wang, K; Zhang, L; Zhou, C; Zhou, J | 1 |
| Stinchcombe, TE | 1 |
| Akerley, WL; Burns, TF; Dragnev, KH; Gadgeel, SM; Gandara, DR; Gerstner, GJ; Gray, JE; Kelly, K; Laudi, N; Mack, PC; Miao, J; Moon, J; Redman, MW; Riess, JW; Taj, A | 1 |
| Amhaz, G; Assi, HI; El Karak, F; Hodroj, M; Khoury, M; Naji, NS; Zeidane, RA; Zerdan, MB | 1 |
| Chia, V; Gray, JE; Hsu, H; Johnson, M; Spira, A; Suri, G; Younan, D | 1 |
| Garrison, LP; Gomes, M; Longworth, L; Meunier, A; Popat, S; Ramagopalan, S | 1 |
| Fu, Y; Xue, G | 1 |
| Banstola, A; Duwa, R; Emami, F; Kwon, TK; Woo, SM; Yook, S | 1 |
| Ahn, C; Bhalla, S; Brekken, RA; Dowell, JE; Fattah, FJ; Gerber, DE; Macchiaroli, A; McCracken, N; Micklem, D; Padro, J; Pogue, M; Putnam, WC; Williams, J | 1 |
| Aggarwal, C; Cantor, DJ | 1 |
| Li, R; Tao, W; Zhang, Y; Zhou, S | 1 |
| Liu, S; Ouyang, M; Sun, L; Wang, L; Xing, S; Yu, H; Zhao, S | 1 |
| Hayashi, H; Kasahara-Kiritani, M; Nishio, M; Takahashi, M; Tsuchiya, H | 1 |
| Barnes, G; Huang, D; Li, S; Ma, Y; Tang, B; Zhan, L; Zhou, C | 1 |
| Atagi, S; Daimon, T; Kawahara, M; Kim, YH; Komuta, K; Minato, K; Okano, Y; Okishio, K; Tabata, C; Tamura, A; Usui, R | 1 |
| Aerts, J; Akerley, W; Andric, Z; Berghmans, T; Cobo, M; Delmonte, A; Eaton, M; Gerber, DE; Greil, R; Havel, L; Iqbal, M; Kalmadi, S; Kloecker, G; Kotecha, R; Langer, C; Leal, T; Milanowski, J; Panikkar, R; Petruzelka, L; Pless, M; Ramlau, R; Rolfo, C; Roubec, J; Ward, J; Zhang, L | 1 |
| Badovinac, S; Bitar, L; Jakopovic, M; Janzic, U; Korsic, M; Kukulj, S; Ljubicic, L; Mohorcic, K; Plestina, S; Samarzija, M; Seiwerth, F; Terglav, AS; Unk, M | 1 |
| Lorence, RM; Radonjic, D; Reck, M; Schuette, W; Urban, T; von Wangenheim, U; Westeel, V | 1 |
| Breadner, D; Verma, S; Vincent, M | 1 |
| Massuti, B; Provencio, M; Romero, A | 1 |
| Ai, X; Hao, X; Lei, S; Li, W; Wang, Y; Xu, H; Yang, G; Yang, Y; Zhang, S | 1 |
| Hirate, D; Kinoshita, I; Saito, Y; Sakakibara-Konishi, J; Shimizu, Y; Sugawara, M; Takada, S; Takahashi, K; Takekuma, Y; Tamaki, S | 1 |
| Agrawal, S; Antonia, SJ; Borghaei, H; Brahmer, J; Burgio, MA; Butts, C; Chow, LQM; Crinò, L; De Castro Carpeño, J; Drilon, A; Garassino, M; Gettinger, S; Horn, L; Li, A; Otterson, GA; Penrod, JR; Planchard, D; Pluzanski, A; Ramalingam, SS; Wojcik-Tomaszewska, J | 1 |
| Botti, G; Carillio, G; Cecio, R; Costanzo, R; Daniele, G; Esposito, G; Luca, G; Manna, C; Manzo, A; Montanino, A; Morabito, A; Muto, P; Normanno, N; Palumbo, G; Piccirillo, MC; Picone, C; Sandomenico, C; Sforza, V; Totaro, G | 1 |
| Chai, Z; Dong, J; Gong, W; Guan, J; Hu, Y; Liu, L; Lu, L; Lu, W; Wang, X; Ying, M; Zhang, M; Zhang, Y; Zhao, Z | 1 |
| Asakura, Y; Harada, D; Kozuki, T; Mori, S; Moriki, S; Nogami, N; Ohno, T; Takata, K; Takechi, Y | 1 |
| Iwata, T; Yamamoto, A | 1 |
| Atagi, S; Hirashima, T; Mitsudomi, T; Morita, S; Nakagawa, K; Okamoto, I; Saito, H; Satouchi, M; Seto, T; Shibata, K; Shimokawa, M; Toyooka, S; Tsurutani, J; Yamamoto, N; Yatabe, Y; Yoshioka, H | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Asher, R; Cho, D; Hong, JH; Lee, CK; Lord, S; Marschner, I; Snyders, K | 1 |
| Kim, C; Liu, SV | 1 |
| Liu, Q; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Chen, W; Ma, G; Ma, M | 1 |
| Chen, Y; Cheng, L; Cui, X; Du, X; Sheng, L | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Ikeda, T; Kinoshita, A; Kitazaki, T; Mukae, H; Nagashima, S; Nakatomi, K; Senju, H; Soda, H; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y; Yamaguchi, H | 1 |
| Alexandris, E; Brustugun, OT; Cuyun Carter, G; Gans, S; Garon, EB; Gautschi, O; Iglesias Docampo, L; Kalofonos, H; Kim, JH; Lee, P; Orlov, SV; Oton, AB; Pérol, M; Reck, M; Scagliotti, GV; Socinski, MA; Stefaniak, VJ; Thomas, M; Wolff, K; Zimmermann, AH | 1 |
| Asao, T; Hara, K; Hisada, T; Imai, H; Jingu, A; Kaira, K; Kasahara, N; Kitahara, S; Koga, Y; Kuwako, T; Maeno, T; Masuda, T; Mori, K; Naruse, I; Sakurai, R; Sunaga, N; Tsukagoshi, Y; Tsurumaki, H; Yatomi, M | 1 |
| Casillas, AL; Chauhan, SS; Jensen, CC; Kashatus, DF; Toth, RK; Warfel, NA | 1 |
| Costa, JL; Junqueira-Neto, S; Machado, JC; Marques, JF; Pinheiro, J | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Akazawa, Y; Chiba, Y; Ebi, N; Fujimoto, D; Hataji, O; Hayashi, H; Kato, R; Kozuki, T; Miyawaki, E; Nakagawa, K; Nakamura, A; Nishino, K; Okuno, M; Ota, K; Ozaki, T; Saeki, S; Shimizu, J; Tanaka, K; Teraoka, S; Toyozawa, R; Usui, K; Yamamoto, N | 1 |
| Funaki, S; Goto, K; Haruna, M; Hirata, M; Iwahori, K; Kanazawa, T; Kawashima, A; Kumanogoh, A; Morimoto-Okazawa, A; Shintani, Y; Wada, H; Yamamoto, Y | 1 |
| Guo, B; Huangfu, Z; Meng, F; Sun, Y; van Hest, JCM; Wei, Y; Xia, Y; Yuan, J; Zhong, Z; Zou, Y | 1 |
| Ando, M; Atagi, S; Azuma, K; Fujita, Y; Horiike, A; Horinouchi, H; Hosomi, Y; Murakami, H; Nakagawa, K; Niho, S; Nokihara, H; Nomura, S; Ohe, Y; Okamoto, H; Okamoto, I; Ozaki, T; Sugawara, S; Yamamoto, N; Yoneshima, Y | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Chen, X; Cui, C; Cui, N; Cui, S; Shao, Y; Wang, L; Zhang, X | 1 |
| Acevedo-Delgado, JA; Acosta-Espinoza, A; Alatorre-Alexander, JA; Astorga-Ramos, AM; Barriguete-Parra, L; Campos-Gomez, S; Capdeville-García, D; Cázarez-Price, JC; Ceja-García, JP; Fernández-Garibay, VM; Flores-Anaya, N; Flores-Mariñelarena, RR; García-Montes, V; Gerson-Cwilich, R; González-Espinoza, IR; Gonzalez-Villanueva, JI; Kuri-Exsome, R; Magallanes-Maciel, M; Martínez-Barrera, L; Noriega-Iriondo, MF; Perales-Rodríguez, E; Perez-Lozano, Y; Rodríguez-Cid, JR; Rodríguez-Silva, C; Suárez-García, D; Vázquez-Cortés, L; Villalobos-Prieto, A; Zuloaga-Fernandez, CJ | 1 |
| Dercle, L; Du, S; Fojo, AT; Fronheiser, M; Guo, P; Hayes, W; Leung, DK; Lu, L; Roy, A; Schwartz, LH; Wilkerson, J; Zhao, B | 1 |
| Charitandi, A; Fountzilas, G; Kalogera-Fountzila, A; Koliou, GA; Kosmidis, P; Linardou, H; Mavropoulou, X; Mountzios, G; Samantas, E | 1 |
| Sidaway, P | 1 |
| Aldaco, F; Arrieta, O; Barrón, F; Bautista, Y; Cardona, AF; Carmona, A; Díaz-García, D; Gerson, R; Mota-Vega, B; Peralta Álvarez, MP; Ramírez-Tirado, LA; Rolfo, C; Rosell, R; Yamamoto Ramos, M; Zatarain-Barrón, ZL | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Furuya, N; Hataji, O; Hida, N; Inoue, T; Ito, K; Komase, Y; Mineshita, M; Morikawa, K; Sakaguchi, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Arriola, E; Cui, ZL; Garon, EB; Levy, B; Mekhail, T; Molife, C; Pérol, M; Winfree, KB | 1 |
| Hiraki, T; Kanazawa, S; Katayama, N; Katsui, K; Kiura, K; Kuroda, M; Maeda, Y; Ogata, T; Toyooka, S; Watanabe, K | 1 |
| Blakely, CM; McCoach, CE | 1 |
| Gu, K; Han, BH; Hu, F; Li, CH; Lu, J; Nie, W; Qian, FF; Qian, J; Wang, HM; Wang, SY; Xu, MD; Yan, B; Zhang, B; Zhang, XY; Zhong, H | 1 |
| Amino, Y; Ariyasu, R; Gemma, A; Hasegawa, T; Horai, T; Kitazono, S; Nishio, M; Sakamoto, H; Seike, M; Tozuka, T; Uchibori, K; Uematsu, S; Yanagitani, N; Yoshida, H; Yoshizawa, T | 1 |
| Ando, M; Gemma, A; Hagiwara, K; Hino, M; Kobayashi, K; Kubota, K; Miyanaga, A; Nishitsuji, M; Noro, R; Seike, M; Shimokawa, T; Usuki, J; Yomota, M | 1 |
| Hashida, T; Hosohata, K; Hosomi, S; Ikesue, H; Maegawa, N; Mori, Y; Muroi, N; Nakamura, T; Sato, Y; Takano, A; Tomii, K; Uchida, M; Yamaguchi, Y | 1 |
| Adnet, J; Bertaut, A; Coudert, B; Favier, L; Foucher, P; Kaderbhaï, CG; Lagrange, A; Martin, E; Mettey, L; Peignaux-Casasnovas, K; Tharin, Z | 1 |
| Furuya, N; Hataji, O; Hida, N; Inoue, T; Ito, K; Kakinuma, K; Komase, Y; Mineshita, M; Morikawa, K; Sakaguchi, T | 1 |
| Ding, X; Han, X; Jiang, M; Li, Q; Shu, W; Yang, Z | 1 |
| Fang, L; Fu, P; Li, J; Liu, J; Liu, W; Liu, Z; Song, B; Wang, F; Xie, C; Yi, Y | 1 |
| Haddada, MB; Movia, D; Prina-Mello, A; Spadavecchia, J | 1 |
| Arthur, P; Bagde, A; Gebeyehu, A; Kutlehria, S; Mondal, A; Nottingham, E; Patel, N; Singh, M; Surapaneni, SK | 1 |
| Hase, T; Hasegawa, Y; Hashimoto, N; Koyama, J; Matsui, A; Matsuzawa, R; Morise, M; Ozone, S; Sato, M; Tanaka, I | 1 |
| Chen, H; Lin, Y; Xie, B; Zhuang, X | 1 |
| Akdeniz, N; Alan, Ö; Bilen, E; Ebinç, S; Ercelep, Ö; Işıkdoğan, A; Kaplan, MA; Karhan, O; Küçüköner, M; Laçin, Ş; Sezgin, Y; Teke, F; Urakçı, Z; Yumuk, PF | 1 |
| Amano, H; Watabe, D | 1 |
| Chen, Z; Ge, L; Hu, R; Hui, K; Li, T; Wang, N; Wu, X; Zhou, L | 1 |
| Patel, B; Patel, MM; Rawal, S | 1 |
| Buchner, H; Fischer, JR; Kaiser, R; Kerr, K; Kitzing, T; Miliauskas, S; Radonjic, D; Reck, M; Syrigos, K; Zöchbauer-Müller, S | 1 |
| Jha, A; Mahto, SK; Mehata, AK; Muthu, MS; Neogi, K; Poddar, S; Priya, V; Reddy Adena, SK; Viswanadh, MK | 1 |
| Li, H; Rui, M | 1 |
| Aberlenc, A; Bawa, O; Chauchereau, A; Farace, F; Faugeroux, V; Honore, A; Lacroix, L; Laplace-Builhe, C; Marty, V; Oulhen, M; Pawlikowska, P; Pommier, AL; Rouffiac, V; Scoazec, JY; Tayoun, T | 1 |
| Aarons, L; Lombard, A; Mistry, H; Ogungbenro, K | 1 |
| Huang, L; Jiang, T; Sun, Y; Wang, L; Wang, X; Wen, M; Xia, J; Yang, S; Zhang, Y; Zhang, Z | 1 |
| Bruno, R; Chan, P; Jin, JY; Liu, Q; Wang, N; Zhou, X | 1 |
| Harada, D; Hosomi, Y; Kasai, T; Kato, T; Kishi, K; Kubota, K; Misumi, T; Nakamura, Y; Okamoto, H; Otani, S; Saito, H; Shimokawa, T; Takiguchi, Y; Tanaka, H; Yamada, K; Yamanaka, T | 1 |
| Chang, J; Cheng, Y; Chia, YH; Feng, J; Hu, C; Li, A; Lu, S; Lu, Y; Luft, A; Ma, Z; Mok, T; Poddubskaya, E; Shi, Y; Soo, RA; Tu, HY; Wang, J; Wu, L; Wu, YL; Ying, K; Zhang, L; Zhang, Y; Zhong, H; Zhou, JY | 1 |
| Burke, T; Chen, C; Jemielita, T; Li, XN; Piperdi, B; Zhou, W | 1 |
| Antonia, S; Arrieta, O; Barlesi, F; Borghaei, H; Brahmer, J; Burgio, MA; Butts, C; Chiari, R; Chow, LQM; Coudert, B; Crino, L; Czyzewicz, G; de Castro Carpeno, J; Domine, M; Eberhardt, WEE; Felip, E; Frontera, OA; Garassino, MC; García, MA; Gerber, DE; Gettinger, S; Li, A; Marimuthu, S; Pluzanski, A; Ready, N; Spigel, DR; Vokes, EE; Waterhouse, D; Wohlleber, M; Wójcik-Tomaszewska, J | 1 |
| Adeberg, S; Debus, J; Eichkorn, T; Herfarth, K; Hörner-Rieber, J; König, L; Regnery, S; Schunn, F; Shafie, RE | 1 |
| Cao, SH; Chen, SQ; Gan, L; Gu, K; Han, BH; Hu, MJ; Li, CH; Li, JW; Lu, J; Nie, W; Qian, FF; Wang, SY; Wang, X; Wang, Y; Xu, MD; Yang, P; Zhang, B; Zhang, D; Zhang, XY; Zhong, H | 1 |
| Beijnen, JH; Dorlo, TPC; Huitema, ADR; Marchetti, S; Pluim, D; van Eijk, M | 1 |
| Hiraki, T; Kanazawa, S; Katsui, K; Kiura, K; Kuroda, M; Maeda, Y; Ogata, T; Sugiyama, S; Tada, A; Toyooka, S; Yoshio, K | 1 |
| Aa, JY; Cao, B; Guo, SH; Li, SJ; Lu, ZY; Sun, RB; Wang, GJ; Xie, Y | 1 |
| Ballinger, M; Cardona, A; Gadgeel, S; Gandara, D; Mazieres, J; Mendus, D; Moro-Sibilot, D; Morris, S; Peters, S; Reck, M; Rittmeyer, A | 1 |
| Dakhlallah, D; Eubank, TD; Gencheva, M; Guo, NL; Hu, G; Ivanov, AV; Kolluri, SK; Marsh, CB; Mohamed, R; Pearce, MC; Ye, Q | 1 |
| Chen, X; Huang, X; Liang, W; Lin, Q; Lin, Y; Ma, Y; Salamone, SJ; Wang, C; Wu, K; Yang, Y; Zhang, L; Zhao, H; Zhao, X; Zhou, X | 1 |
| Baumgart, M; Fathallah, AM; Gabrail, N; Heineman, T; Mager, DE; Maneval, DC; Nanavati, C; Sekulovich, RE; Van Wart, SA | 1 |
| Bai, X; Dong, ZY; Duan, ZJ; Fu, QJ; Guo, XJ; Guo, ZQ; Long, LL; Ma, SC; Tang, XR; Wang, J; Wu, DH; Zhang, YP; Zhou, JG; Zhu, HB | 1 |
| Baas, P; Boyer, M; Cho, BC; Forster, MD; Garon, EB; Gervais, R; Gubens, MA; Han, JY; Herbst, RS; Jensen, EH; Kim, DW; Kobie, J; Majem, M; Monnet, I; Novello, S; Perez-Gracia, JL; Piperdi, B; Samkari, A; Su, WC | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Wu, D; Zhang, J; Zhang, Z | 1 |
| Hiraki, T; Kanazawa, S; Katsui, K; Kiura, K; Kuroda, M; Maeda, Y; Ogata, T; Toyooka, S; Watanabe, K; Yoshio, K | 1 |
| Ballinger, M; Barlesi, F; Bhatia, N; Gadgeel, S; Gandara, DR; Hirsch, FR; Kerr, K; Koeppen, H; Matheny, C; McCleland, M; Park, K; Paul, SM; Rittmeyer, A; Shames, D; Yi, J; Zou, W | 1 |
| Bu, S; Lin, J; Wang, H; Wang, X; Zhang, C; Zhao, C | 1 |
| Guo, M; Liang, D; Lin, D; Wang, Y; Zhao, L; Zhao, R | 1 |
| Shang, X; Shi, J; Wang, H; Wang, X; Yu, H; Zhao, C | 1 |
| Cheng, Y; Nie, L; Zhang, M | 1 |
| Liu, H; Mao, K; Yu, L; Yu, Y; Zhang, W; Zhang, X | 1 |
| Hosotani, S; Igawa, S; Mitsufuji, H; Nakahara, Y; Naoki, K; Sasaki, J; Sato, T; Takakura, A; Yokoba, M | 1 |
| Cho, SG; Choi, YJ; Hwang, HH; Jeong, MS; Joo, YJ; Jung, SE; Kim, YG; Ko, SG; Lee, JH; Lee, KW; Lee, SY; Park, SA | 1 |
| Chen, Q; Guo, Q; Li, Y; Shi, W; Wang, C; Yang, S; Zhang, W | 1 |
| Griebsch, I; Hastedt, C; Mellemgaard, A; Popat, S; Reck, M | 1 |
| Hisada, T; Imai, H; Kaira, K; Kotake, M; Minato, K; Miura, Y; Mori, K; Saito, R; Sakurai, R; Tomizawa, Y | 1 |
| Chinet, T; Dumenil, C; Dumoulin, J; Giraud, V; Giroux Leprieur, E; Julie, C; Labrune, S | 1 |
| Chikamori, K; Fukuoka, M; Harada, M; Harada, T; Horio, H; Iwamoto, Y; Katakami, N; Kitagawa, H; Kudoh, S; Masuda, N; Nakagawa, K; Nogami, N; Okamoto, H; Saito, H; Saka, H; Seto, T; Sunaga, N; Takahashi, T; Takeda, K; Tanaka, H; Yamamoto, N; Yamanaka, T; Yoshioka, H | 1 |
| Akita, T; Kiuchi, Y; Kogo, M; Kurihara, T; Nakajima, H; Nakamura, S; Shikama, Y; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Go, T; Liu, D; Matsuura, N; Nakano, J; Nakano, T; Nakashima, N; Nii, K; Tarumi, S; Tokunaga, Y; Yokomise, H | 1 |
| Barlesi, F; Blackhall, F; Bowen, K; Carlile, DJ; Cobo, M; Crinò, L; Garrido, P; Ghiorghiu, D; Jänne, PA; Kilgour, E; Kohlmann, A; Lawrence, D; Mariani, G; Mazieres, J; Orlov, S; Poltoratskiy, A; Smith, P; van den Heuvel, MM; Vansteenkiste, J; Wolf, J | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Goldberg, KB; Khozin, S; Kim, G; Pazdur, R; Suzman, D; Tang, S; Wahby, S; Weinstock, C; Zhang, L | 1 |
| Imamura, CK; Kenmotsu, H; Murakami, H; Naito, T; Nakashima, K; Omori, S; Ono, A; Taira, T; Takahashi, T; Tanigawara, Y; Wakuda, K | 1 |
| Casaluce, F; Gridelli, C; Maione, P; Sacco, PC; Santabarbara, G; Sgambato, A | 1 |
| Hashigaki, S; Kim, DW; Mok, T; Nakagawa, K; Nishio, M; Ohki, E; Paolini, J; Polli, A; Shaw, AT; Solomon, BJ; Usari, T; Wilner, KD; Wu, YL | 1 |
| Ahonen, I; Åkerfelt, M; Nees, M; Oswald, E; Schüler, J; Toriseva, M | 1 |
| Belevich, YV; Dygai, AM; Goldberg, AV; Goldberg, VE; Miroshnichenko, LA; Polyakova, TY; Popova, NO; Simanina, EV; Simolina, EI; Tuzikova, TP; Udut, EV; Vysotskaya, VV; Zhdanov, VV; Zyuz'kov, GN | 1 |
| Che, K; Li, M; Li, R; Liu, Z; Wang, L; Xiang, S; Yu, Y | 1 |
| Asano, T; Fukuda, S; Inoue, Y; Ito, K; Ito, Y; Kanemitsu, Y; Kitamura, Y; Maeno, K; Niimi, A; Oguri, T; Ohkubo, H; Sone, K; Takakuwa, O; Takemura, M; Takeuchi, A | 1 |
| Chowdhury, N; Doddapaneni, R; Mondal, A; Patel, K; Singh, M; Vhora, I | 1 |
| Chen, S; Chen, Y; Hu, Y; Jiao, S; Li, J; Yan, X; Zhang, G; Zhang, Y | 1 |
| Chiu, LY; Kuo, WT; Sheu, GT; Tu, DG; Wu, MF | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Ahn, C; Cheedella, N; Choy, H; Dowell, JE; Gerber, DE; Hughes, RS; Iyengar, P; Nedzi, L; Pulipparacharuvil, S; Timmerman, RD; Tumati, V; Wardak, Z; Westover, KD | 1 |
| Castelnau, O; Cohen, C; Mouroux, J; Otto, J; Pop, D; Poudenx, M; Venissac, N | 1 |
| Antonia, S; Arrieta, O; Barlesi, F; Blackwood-Chirchir, A; Borghaei, H; Brahmer, J; Burgio, MA; Crinò, L; Eberhardt, WEE; Fayette, J; Felip, E; Geese, WJ; Healey, D; Hellmann, MD; Holgado, E; Horn, L; Kohlhäeufl, M; Li, A; Paz-Ares, L; Pluzanski, A; Poddubskaya, E; Ready, N; Reck, M; Reckamp, KL; Rizvi, N; Spigel, DR; Steins, M; Vokes, EE; Waterhouse, D | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Bowen, K; Carlile, DJ; Eberhardt, WEE; Fischer, JR; Fülöp, A; Girotto, G; Jänne, PA; Kilgour, E; Kohlmann, A; Lago, S; Lishkovska, P; Lovick, S; Maciel, C; Mariani, G; McKeown, A; Ostoros, G; Smit, E; Smith, P; Soria, JC | 1 |
| Chang, J; Cheng, Y; Goto, K; Ichinose, Y; Lim, WT; Lu, S; Maemondo, M; Mok, TSK; Morita, S; Nakagawa, K; Nishio, M; Nokihara, H; Shi, YK; Soo, RA; Sugawara, S; Takahashi, T; Tamura, T; Yamamoto, N; Yang, JC; Zhang, L | 1 |
| Calpe-Armero, P; Ferriols-Lisart, F; Ferriols-Lisart, R; Pérez-Pitarch, A | 1 |
| Bazan, V; Galvano, A; Incorvaia, L; Listì, A; Passiglia, F; Rizzo, S; Russo, A | 1 |
| Bojko, P; Hentrich, M; Jäger, H; Schipek-Voigt, K; Schmid, P; Schulz, S; Stötzer, O | 1 |
| Cipelli, R; Dangoor, A; Hodgson, M; Lester, JF; Naik, J; Newsom-Davis, T; Patel, A; Shah, R; Summerhayes, M; Talbot, D; Talbot, T | 1 |
| Dastani, H; DeRosa, M; Gralla, RJ; Morrissey, L; Orsini, L; Penrod, JR; Reck, M; Taylor, F | 1 |
| Daraee, H; Jaferian, S; Soleymaninejad, M | 1 |
| Fukase, K; Fukino, K; Hirai, F; Kogure, Y; Niho, S; Saka, H; Sasai, M; Seto, T; Shimada, H; Yoh, K | 1 |
| Gu, H; Hao, K; Jiang, W; Li, P; Li, S; Lu, Q; Pei, X; Sun, Y; Wang, G; Xu, H | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Alexandris, E; Arrieta, O; Carter, GC; Ciuleanu, TE; Garon, EB; Göksel, T; Kowalyszyn, RD; Lee, P; Lewanski, CR; Park, K; Paz-Ares, LG; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Syrigos, K; Zimmermann, A | 1 |
| Alexandris, E; Bidoli, P; Borghaei, H; Cappuzzo, F; Carter, GC; Chan-Diehl, F; Dakhil, S; Johnson, M; Jotte, R; Lee, P; Moro-Sibilot, D; Paz-Ares, L; Pennell, NA; Pérol, M; Reck, M; Sashegyi, A; Shepherd, FA; Thomas, M; Tsao, A; Zimmermann, A | 1 |
| Jia, L; Wang, L; Wang, T; Yang, Z; Zhang, S; Zhang, X; Zhang, Y | 1 |
| Acheson, A; Aung, S; Coffey, T; Fisher, B; Fox, BA; Hilton, T; Hu, HM; Moudgil, T; Neuberger, M; Paustian, C; Puri, S; Ross, HJ; Sanborn, RE; Urba, WJ; Walker, E | 1 |
| Gao, G; Ren, S; Wu, F; Zhang, S; Zhao, J; Zhou, C | 1 |
| Aguiar, P; Haaland, B; Lopes, G; Tan, PS | 1 |
| Filip-Psurska, B; Kutner, A; Maj, E; Milczarek, M; Psurski, M; Wietrzyk, J | 1 |
| Alexandris, E; Carter, GC; Cho, EK; Czyzewicz, G; Dakhil, S; Garon, EB; Gautschi, O; Grigorescu, A; Karaseva, N; Kimmich, M; Kowalyszyn, RD; Lee, P; Pérol, M; Ramalingam, SS; Reck, M; Sashegyi, A; Winfree, KB; Zimmerman, A | 1 |
| Hu, Q; Xie, B; Xu, Z; Zhang, W; Zhang, X; Zheng, J; Zhou, J | 1 |
| Antonia, SJ; Arén Frontera, O; Arrieta, O; Barlesi, F; Blumenschein, G; Brahmer, J; Burgio, MA; Butts, C; Chow, LQM; Coudert, B; Crinò, L; Domine, M; Felip, E; Gainor, J; Garassino, M; Geese, WJ; Gettinger, S; Healey, D; Holgado, E; Horn, L; Li, A; Ready, N; Spigel, D; Steins, M; Vokes, EE; Waterhouse, D | 1 |
| Chen, B; Mei, D; Ni, X; Wang, X; Yu, Z; Zhang, Q; Zhang, X; Zhao, L | 1 |
| Guirgis, HM | 1 |
| Fujisaka, Y; Hatano, B; Hida, T; Imamura, F; Ito, M; Kagamu, H; Kiura, K; Kurata, T; Matsumoto, S; Nakagawa, K; Nishio, M; Okamoto, I; Satouchi, M; Takenoyama, M; Tokushige, K | 1 |
| Berghmans, T; Bonduelle, Y; Colinet, B; Giner, V; Lafitte, JJ; Leclercq, N; Meert, AP; Paesmans, M; Roelandts, M; Scherpereel, A; Sculier, JP; Van Cutsem, O; Van Houtte, P | 1 |
| Bastos, BR; Brahmer, JR; Chai, F; Dietrich, MF; Gerber, DE; Hesketh, PJ; Huang, C; Johnson, ML; Kazakin, J; Kelly, RJ; Lilenbaum, RC; Neal, JW; Rosovsky, RP; Schiller, JH; Schwartz, B; Sequist, LV; Shirai, K; Socinski, MA; Subramaniam, DS; Wakelee, HA; Wang, Y | 1 |
| Ecstein-Fraisse, E; Hida, T; Horiike, A; Horio, Y; Nishio, M; Satouchi, M; Sunaga, Y | 1 |
| Hida, T; Horiike, A; Ikeda, N; Kaji, R; Kawakami, T; Kubo, T; Nakagawa, S; Nokihara, H; Satouchi, M; Seto, T | 1 |
| Miyoshi, S; Namba, K; Sakaguchi, M; Sato, H; Shien, K; Soh, J; Suzawa, K; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Tsukuda, K; Yamamoto, H; Yoshioka, T | 1 |
| Fillon, M | 1 |
| Han, SM; Kong, TH; Seo, YJ | 1 |
| Bondiau, PY; Chamorey, E; Cohen, C; Doyen, J; Gal, J; Gérard, A; Guerder, C; Ianessi, A; Leysalle, A; Naghavi, AO; Otto, J; Padovani, B; Poudenx, M; Schiappa, R | 1 |
| Adamo, V; Battaglia, A; Berenato, R; Franchina, T; Giordano, A; Ricciardi, GRR; Russo, A; Scimone, A | 1 |
| Brauer, M; Hertel, N; Jansen, J; Lees, M; Penrod, JR; Shafrin, J; Skornicki, M; Villeneuve, J | 1 |
| Ayoub, JP; Blais, N; Bradbury, PA; Feilotter, H; Goffin, JR; Goss, G; Gregg, RW; Hao, D; Keith, BD; Korpanty, GJ; Kuruvilla, S; Laurie, SA; Lee, C; Leighl, N; Mates, M; Melosky, BL; Morris, DG; Nicholas, G; Rothenstein, J; Sederias, J; Seymour, L; Shepherd, FA; Tehfe, M; Torri, V; Tu, D | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Bidoli, P; Bondarenko, I; Boyer, M; Gerber, DE; Germonpre, P; Ghizdavescu, D; Horn, L; Kallinteris, NL; Kotsakis, A; Lai, J; Lena, H; Losonczy, G; Natale, R; Palmero, R; Park, K; Reck, M; Sanborn, R; Shan, JS; Spigel, DR; Su, WC; Tang, M | 1 |
| Ballinger, M; Barlesi, F; Cobo, M; Cortinovis, DL; Danner, B; De Marinis, F; Fehrenbacher, L; Felizzi, F; Gadgeel, SM; Gandara, DR; Gandhi, M; Han, JY; He, P; Hida, T; Kowalski, DM; Kowanetz, M; Matheny, C; Park, K; Patel, H; Ponce Aix, S; Rittmeyer, A; Sandler, A; von Pawel, J | 1 |
| Geng, C; Ji, Y; Lan, K; Liu, S; Nie, K; Wang, S; Xu, X; Zhang, C; Zhang, L; Zhang, Z; Zhuang, X | 1 |
| Kaneko, Y; Takayama, K; Tamiya, N; Tanimura, K; Uchino, J; Yamada, T; Yoshimura, K | 1 |
| Turki, T; Wang, JTL; Wei, Z | 1 |
| Ballinger, M; Bordoni, R; Ciardiello, F; Cortinovis, D; Felizzi, F; He, P; Karagiannis, T; Matheny, C; Rittmeyer, A; Sandler, A; von Pawel, J; Yu, W | 1 |
| Bennett, B; Brahmer, J; Dastani, H; DeRosa, M; Gralla, RJ; Penrod, JR; Reck, M; Spigel, DR; Taylor, F | 1 |
| Kang, JH; Kim, JO; Kim, YS; Lee, HY; Lee, KY; Park, JK; Shin, JH; Sung, SW | 1 |
| Cai, Y; Cao, S; Chen, H; Gao, X; He, W; Wang, Z; Xu, R | 1 |
| Hata, A; Katakami, N; Mitsudomi, T; Nakagawa, K; Shimokawa, M; Yamamoto, N | 1 |
| Chen, S; Fisher, A; Li, J; Li, Z; Mai, J; Ramirez, MR; Shen, H; Shen, Q; Wu, X; Zhang, Z | 1 |
| Arén Frontera, O; Bajars, M; Barlesi, F; Calabrò, L; de Marinis, F; Ellers-Lenz, B; Garassino, M; Ishii, H; Krzakowski, M; Lee, JS; Özgüroğlu, M; Park, K; Polychronis, A; Ruisi, M; Spigel, D; Szczesna, A; Uslu, R; Vansteenkiste, J | 1 |
| Karachaliou, N; Rosell, R | 1 |
| Lin, S; Weng, X; Xie, R; You, X; Zhao, Q | 1 |
| An, HJ; Chae, YS; Hong, SH; Jang, TW; Kang, JH; Kim, K; Lee, SS; Lee, YG; Park, IC; Yuh, YJ | 1 |
| Bracht, JWP; Camps, C; Carcereny, E; Chaib, I; Cobo, M; Domine, M; Drozdowskyj, A; Fernandez Bruno, M; Gimenez Capitan, A; Karachaliou, N; Lopez-Vivanco, G; Majem, M; Massuti, B; Moran, T; Provencio, M; Ramirez, JL; Rosell, R; Vergnenegre, A | 1 |
| Ballinger, M; Bordoni, R; Cobo, M; Conkling, P; Fehrenbacher, L; Gandara, DR; Gandhi, M; Han, JY; Hida, T; Kowanetz, M; Matheny, C; Moro-Sibilot, D; Park, K; Patel, H; Rittmeyer, A; Sandler, A; Satouchi, M; von Pawel, J; Yu, W | 1 |
| Fukuda, Y; Harada, T; Koga, S; Mukae, H; Ogawara, D; Okuno, D; Soda, H; Taniguchi, H; Tomono, H; Umemura, A; Yamaguchi, H; Yoshida, M | 1 |
| Hashemi Sadraei, N; Patil, PD; Pennell, NA; Shapiro, M | 1 |
| Wei, Y; Xu, J; Xu, Z; Yi, F; Yu, D; Zhang, W | 1 |
| Ahn, MJ; Baas, P; de Castro, G; Dubos Arvis, C; Emancipator, K; Felip, E; Fidler, MJ; Garon, EB; Garrido, M; Han, JY; Herbst, RS; Jensen, EH; Kim, DW; Kim, JH; Lubiniecki, GM; Majem, M; Molina, JR; Perez-Gracia, JL; Samkari, A; Shentu, Y; Surmont, V | 1 |
| Baudelet, C; Cai, J; Chang, J; Cheng, Y; Feng, J; Hu, C; Lu, S; Lu, Y; Luft, AV; Ma, Z; Mok, T; Shi, Y; Tu, HY; Wang, J; Wu, L; Wu, YL; Zhang, L; Zhang, Y; Zhou, C; Zhou, J | 1 |
| Iwami, E; Kuroda, A; Matsuzaki, T; Nakajima, T; Sasahara, K; Terashima, T | 1 |
| Ru, CH; Zhuang, YB | 1 |
| Ahn, MJ; Barlesi, F; de Castro, G; Deitz, AC; Felip, E; Fidler, MJ; Garon, EB; Gubens, MA; Han, JY; Herbst, RS; Kim, DW; Kim, JH; Li, Q; Lubiniecki, GM; Surmont, V | 1 |
| Cao, L; Chen, X; Cheng, S; Gao, Q; Huang, L; Li, F; Maimela, NR; Wang, D; Wang, L; Wang, S; Yang, Y; Yu, J; Yue, D; Zhang, B; Zhang, Y; Zhang, Z; Zhou, B | 1 |
| Barrueco, J; Grohé, C; Hilberg, F; Huber, RM; Kaiser, R; Kerr, KM; Manegold, C; Park, K; Pavlakis, N; Paz-Ares, L; Popat, S; Reck, M; Thatcher, N | 1 |
| Chiba, Y | 1 |
| Carcereny, E; Corral, J; Cortes, ÁA; Domine, M; García, Y; Llorente, M; López Criado, MP; López Picazo, JM; Majem, M; Rodríguez-Abreu, D | 1 |
| Hashimoto, K; Kagamu, H; Kaira, K; Kobayashi, K; Miura, Y; Mouri, A; Murayama, Y; Nishihara, F; Shiono, A; Uchida, T; Yamaguchi, O | 1 |
| Gemma, A; Goto, K; Ichinose, Y; Imamura, F; Inoue, A; Kiura, K; Maemondo, M; Morita, S; Nakagawa, K; Nishio, M; Nokihara, H; Ohe, Y; Okamoto, I; Saka, H; Sakai, H; Seto, T; Shingyoji, M; Sugawara, S; Takahashi, T; Takeda, K; Tamura, T; Yamamoto, N | 1 |
| Kagamu, H; Kaira, K; Kobayashi, K; Mouri, A; Murayama, Y; Shiono, A; Yamaguchi, O | 1 |
| Fukuda, S; Fukumitsu, K; Ito, Y; Kanemitsu, Y; Maeno, K; Niimi, A; Oguri, T; Ohkubo, H; Sone, K; Takakuwa, O; Takemura, M; Takeuchi, A; Uemura, T | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Matsumoto, Y; Murakami, S; Ohe, Y; Sekine, K; Tamura, N; Yamamoto, N | 1 |
| Liu, H; Piao, H; Qi, H; Sun, H; Yan, M | 1 |
| Bowman, L; Cuyun Carter, G; Garon, EB; Lin Cui, Z; Pérol, M; Winfree, KB | 1 |
| Fang, J; Huang, C; Li, Z; Luo, W; Wang, M; Yao, X; Yu, D | 1 |
| Asai, Y; Gon, Y; Nakagawa, Y; Shimizu, T; Takahashi, N; Tsujino, I | 1 |
| Arpa, D; Burgio, MA; Gavelli, G; Genestreti, G; Ghigi, G; Monti, M; Parisi, E; Polico, R; Romeo, A; Rossi, A; Sarnelli, A; Scarpi, E; Tesei, A | 1 |
| Asai, K; Chiba, Y; Hayashi, H; Kasai, T; Kawaguchi, T; Kijima, T; Kimura, T; Kogure, Y; Nakagawa, K; Nakanishi, Y; Niwa, T; Oguri, T; Ono, A; Tanaka, H; Watanabe, K; Yamamoto, N; Yano, S; Yoshimura, N; Yoshioka, H | 1 |
| Fang, XD; Hu, X; Jiang, Q; Ma, DY; Tan, BX; Zhang, NL | 1 |
| Fujii, Y; Iwasa, K; Shibata, K; Shimizu, M; Takahashi, M; Takase, M | 1 |
| Abraham, I; Alkhatib, N; Almutairi, AR; Babiker, HM; Garland, LL; Martin, J; McBride, A | 1 |
| An, Q; Guo, H; Liu, YN; Liu, ZH; Niu, FJ; Shi, CX; Xie, SM; Yang, YY; Zhou, CZ | 1 |
| Choi, CM; Choi, MG; Ji, W; Kim, HR; Lee, GD; Lee, JC; Oh, DK; Park, S | 1 |
| Behera, M; Chen, Z; Fu, H; Gal, AA; Govindan, R; Harvey, RD; Khuri, FR; Klass, CM; Kono, SA; Owonikoko, TK; Ramalingam, SS; Saba, NF; Shin, DM; Sica, G; Subramanian, J; Sun, SY | 1 |
| Cai, Y; Feng, J; Gu, J; Huang, J; Liu, H; Qin, J; Qin, Y; Wu, X; Xu, L; Zhu, H | 1 |
| Adjei, A; Brenner, DE; Cease, KB; Daignault-Newton, S; Dy, GK; Elingrod, VL; Johnson, CS; Kalemkerian, GP; Muindi, JR; Ramnath, N; Stella, PJ; Troeschel, S; Trump, DL | 1 |
| Fleitas, T; Gómez-Codina, J; Martín, M; Martínez-Sales, V; Mesado, D; Montalar, J; Reganon, E; Reynés, G; Vila, V | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Andreu, F; Arellano, A; Arnaiz, Mdel M; Calvo, F; Cardenal, F; Cobo, M; Delgado, R; Dómine, M; García-Gómez, R; Garrido, P; Isla, D; Massutí, B; Morán, T; Morera, R; Perez-Casas, A; Ramos, A; Rosell, R; Valencia, J; Zamora, J | 1 |
| Hwang, KE; Jeong, ET; Kim, BR; Kim, HR; Kim, YS; Lee, MK; Park, DS; Park, SH; Park, SN; Yoon, KH | 1 |
| Chen, B; Cheng, H; Cheng, L; Li, F; Lu, Z; Qin, Q; Sun, N; Sun, X | 1 |
| Kang, JH; Kim, HK; Park, JC; Park, SY; Yang, YJ | 1 |
| Ji, M; Li, J; Zhu, LN | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Antonia, S; Bepler, G; Brahmer, J; Chen, W; Chiappori, A; Fischer, JR; Gadgeel, S; Gray, J; Haura, E; Pinder-Schenck, M; Schell, MJ; Schreiber, F; Simon, G; Tanvetyanon, T; Williams, C; Zhao, X; Zheng, Z | 1 |
| Bunn, PA; Paz-Ares, L; Shepherd, FA | 1 |
| Ahn, MJ; Besse, B; Blackhall, F; Camidge, DR; Crinó, L; De Pas, T; Hirsh, V; Iyer, S; Jänne, PA; Kim, DW; Mok, T; Moro-Sibilot, D; Nakagawa, K; O'Byrne, KJ; Polli, A; Riely, GJ; Seto, T; Shaw, AT; Solomon, BJ; Tassell, V; Thomas, M; Wilner, KD; Wu, YL | 1 |
| Fan, KX; Guo, YJ; Huang, A; Wang, B; Zhang, B; Zhang, F | 1 |
| Derks, J; Dingemans, AM; Heideman, DA; Mellema, WW; Smit, EF; Snijders, PJ; Thunnissen, E; Van Suylen, R | 1 |
| Chida, K; Inui, N; Karayama, M; Kuroishi, S; Masuda, M; Shirai, T; Suda, T; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Gemma, A | 1 |
| Hosomi, Y; Ikeda, N; Kaburagi, T; Kato, T; Kunitoh, H; Michimae, H; Minato, K; Niho, S; Okamoto, H; Oshita, F; Sakai, H; Seto, T; Shimizu, K; Suzuki, K; Takeuchi, M; Tsuboi, M; Watanabe, K | 1 |
| Dziadziuszko, R; Jassem, J | 1 |
| Bettini, A; Bianchi, F; Broggini, M; Farina, G; Floriani, I; Ganzinelli, M; Garassino, MC; Giaccone, G; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Scanni, A; Tomirotti, M; Torri, V; Veronese, S | 1 |
| Eroglu, C; Kaplan, B; Kurtul, N; Oguz, A; Tasdemir, A; Unal, D | 1 |
| Dong, X; Du, J; Hao, Y; Wei, Y; Yin, Q; Zhao, X | 2 |
| Chansky, K; Edelman, MJ; Franklin, WA; Gandara, DR; Hirsch, FR; Kelly, K; Lara, PN; Mack, PC; Williamson, SK; Wozniak, AJ | 1 |
| Stinchcombe, TE; Weiss, JM | 1 |
| Che, CL; Dong, FS; Lu, B; Lv, FZ; Sang, YL; Zhang, HH; Zhang, LJ; Zhang, YM | 1 |
| Alonso, MJ; Rivera-Rodríguez, GR; Torres, D | 1 |
| Kolek, V | 1 |
| Azzoli, CG; Chaft, JE; Kris, MG; Rekhtman, N; Rusch, V; Sima, CS; Zakowski, M | 1 |
| Aerts, JG; Biesma, B; Burgers, S; Codrington, H; Dalesio, O; Dingemans, AM; Groen, HJ; Lankheet, NA; Smit, EF; Vincent, AD | 1 |
| He, X; Zhang, T | 1 |
| Fiegl, M; Gamerith, G; Hilbe, W; Mian, M; Mohn-Staudner, A; Pircher, A; Studnicka, M; Ulsperger, E; Wasle, IK | 1 |
| Parlak, C; Selek, U; Topkan, E | 1 |
| Brito, RA; Childs, BH; Karr, M; Kennah, A; Raez, LE; Santos, ES; Wade, J; Webb, RT | 1 |
| Chen, ZL; Han, BH; Jiang, LY; Lu, F; Yan, B; Zhang, W | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Kim, KS; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Brautnick, L; Dotson, T; Laudadio, J; Lovato, J; Miller, AA; Petty, WJ; Streer, NP; Weaver, KE | 1 |
| Cho, YJ; Choi, JY; Hwang, YS; Jeong, YY; Kang, JH; Kim, HC; Kim, HG; Kim, MG; Kim, MJ; Kim, SH; Lee, GW; Lee, JD | 1 |
| Asami, K; Atagi, S; Fujita, Y; Fukuoka, K; Kawahara, M; Kawasaki, M; Komuta, K; Kubota, K; Minato, K; Nogami, N; Ogushi, F; Shibata, K; Tomizawa, Y; Tsuchiya, M; Yamanaka, T; Yonei, T; Yoshioka, H | 1 |
| Kim, HK; Kim, MJ; Lee, HY; Lee, YH | 1 |
| Baresic, T; Bearz, A; Borsatti, E; Del Conte, A; Franchin, G; Gobitti, C; Minatel, E; Rumeileh, IA; Talamini, R; Trovò, M | 1 |
| Gisbert, R; Gómez-Codina, J; Juan, O; Maciá, S; Muñoz, J; Vidal, J | 1 |
| Fushiki, H; Jitsuoka, M; Matsunari, I; Mitsuoka, K; Miyoshi, S; Murakami, Y; Nishimura, S; Noda, A; Sasaki, H | 1 |
| Caton, J; Chittoor, S; Cohn, A; Garbo, L; Katz, T; Kim, ES; Neubauer, M; Reynolds, C; Robert, F; Saxman, S; Schwartzberg, L; Simms, L | 1 |
| Barraclough, H; Cheng, R; Kim, JH; Orlando, M; Pereira, JR | 1 |
| Ding, CM; He, ZY; Li, K; Li, WL; Liu, W; Mao, WD; Sun, T; Wang, HM; Wang, J; Yao, Q; Zhang, MJ; Zhang, Y; Zhou, XL | 1 |
| Adams, JW; Berger, MS; Chiappori, A; Edelman, MJ; Haura, EB; Malik, S; Northfelt, DW; Rosen, P; Van Echo, DA; Williams, C | 1 |
| Chen, W; Feng, J; Gao, S; Miao, H; Tao, X; Yun, Y; Zhang, F; Zhou, J | 1 |
| Afonso, J; Amenedo, M; Casal, J; Fírvida, JL; Lázaro, M; Santomé, L; Vázquez, S | 1 |
| Dhanda, R; Mallick, R; Nadler, E; Pan, IW | 1 |
| Dong, L; Feng, ZH; Han, ZF; Jia, ZY | 1 |
| Barrueco, J; Bondarenko, I; Douillard, JY; Gann, CN; Gaschler-Markefski, B; Gottfried, M; Kaiser, R; Krzakowski, M; Liao, M; Mellemgaard, A; Novello, S; Orlov, S; Reck, M; von Pawel, J | 1 |
| Yaqub, F | 2 |
| Bahng, A; Black, A; Britten, CD; Christofk, HR; Crabtree, MJ; Dubinett, SM; Garon, EB; Hong, CS; Hosmer, W; Kabbinavar, F; Kamranpour, N; Michelakis, ED; Patel, C; Pitts, S; Slamon, DJ; von Euw, E | 1 |
| Azuma, K; Hoshino, T; Mizoguchi, Y; Naito, Y; Okayama, Y; Takeoka, H; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Ai, B; Cheng, G; Nie, X; Zhang, S | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Pan, YY; Wu, M; Yuan, Y; Zhang, Y | 1 |
| Gemma, A; Harada, T; Inoue, A; Ishimoto, O; Kambe, M; Maemondo, M; Minegishi, Y; Miwa, K; Morikawa, N; Nukiwa, T; Sakakibara, T; Sugawara, S; Ube, K; Usui, K; Watanabe, K | 1 |
| Dafni, U; Karlis, D; Peters, S; Smit, E | 1 |
| Li, X; Lin, W; Wang, H; Xu, Q | 1 |
| Benhabbour, SR; Feng, L; Mumper, RJ; Peng, L; Yuan, H | 1 |
| Fang, Q; Jiang, Y; Yuan, Q | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| Audigier Valette, C; Cadranel, J; Chabaud, S; Moro-Sibilot, D; Perol, D; Perol, M | 1 |
| Chinn, DC; Holland, WS; Mack, PC | 1 |
| Cai, R; Liu, T; Lu, D; Wang, W; Wu, H; Zhuang, X | 1 |
| Amann, A; Gächter, A; Gamerith, G; Gastl, G; Hilbe, W; Jamnig, H; Pall, G; Pircher, A; Popper, H; Reinold, S; Wolf, AM; Wolf, D; Wöll, E | 1 |
| Atagi, S; Fukuoka, M; Hirashima, T; Murakami, H; Nakagawa, K; Nakanishi, Y; Okamoto, I; Sawa, T; Seto, T; Sugio, K; Takeda, K; Yamamoto, N; Yamanaka, T | 1 |
| Ando, M; Asami, K; Endo, T; Fukuda, M; Ibata, H; Isa, S; Kamimura, M; Kawaguchi, T; Kozuki, T; Kubo, A; Nakagawa, H; Okano, Y; Saka, H; Sakamoto, K; Soejima, Y; Takada, M; Tamura, A; Tomizawa, Y; Yoshimi, M | 1 |
| Leighl, NB; Zer, A | 1 |
| Duan, XF; Huang, L; Li, F; Li, JY; Liu, JY; Wang, F; Wang, LP; Xu, YJ; Yue, DL; Zhang, B; Zhang, TF; Zhang, Y; Zhang, Z | 1 |
| Di, BS; Ge, L; Huang, WH; Li, Y; Tian, JH; Wei, KP; Xiao, XJ; Yang, KH; Yu, Q; Zhang, FW; Zhang, XH | 1 |
| Bauman, JE; Becker, D; Bowles, DW; Camidge, DR; Evans, T; Halmos, B; Hausman, D; Levy, B; Nemunaitis, J; Rudin, CM; Schnadig, I; Spira, A; Walker, L | 1 |
| Lin, GN; Liu, DY; Peng, JW; Xia, ZJ; Xiao, JJ | 1 |
| Alexandris, E; Arrieta, O; Bidoli, P; Cappuzzo, F; Ciuleanu, TE; Czyzewicz, G; Dakhil, S; Gans, S; Garon, EB; Goksel, T; Gorbunova, V; Grigorescu, A; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lewanski, CR; Orlov, SV; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Sashegyi, A; Syrigos, KN; Thomas, M; Yurasov, S | 1 |
| Han, ZF; Hong, J; Jiang, Y; Liu, LS; Shen, LP | 1 |
| Jayakumar, R; Lakshmanan, VK; Maya, S; Menon, D; Sarmento, B; Seabra, V | 1 |
| Chan, EC; Chen, KT; Huang, CY; Lan, CC; Lee, CH; Wu, YK; Yang, MC | 1 |
| Gandara, DR; Jett, JR; Keller, SM; Kernstine, KH; Kraut, MJ; Lyss, AP; Moon, J; Pisters, KM; Rusch, VW; Sonett, JR; Thomas, CR; Waddell, TK | 1 |
| Daimon, T; Eto, T; Hatori, M; Hayashi, H; Ikeda, M; Inoue, K; Itoh, K; Kamezato, M; Taku, K; Tsuji, D | 1 |
| Al-Massarani, G; Alali, A; Alammar, M; Almalla, N; Altahan, M; Bachour, M; Najjar, F | 1 |
| Duller, W; Eckmayr, J; Fiegl, M; Greil, R; Hilbe, W; Kocher, F; Mohn-Staudner, A; Pircher, A; Romeder, F; Schmid, T; Steinmaurer, M | 1 |
| Herbst, RS; Heymach, JV; Johnson, BE; Lockwood, SJ; Ryan, AJ | 1 |
| Arrieta, O; Dorantes-Gallareta, Y; Flores-Estrada, D; Macedo-Pérez, EO; Mendoza-García, VO; Morales-Oyarvide, V | 1 |
| Dang, J; Li, G; Yao, L; Zang, S; Zhang, S | 1 |
| Auliac, JB; Berard, H; Bizieux, A; Bota, S; Chouaid, C; Corre, R; Descourt, R; Falchero, L; Fournel, P; Greiller, L; Greillier, L; Labrunie, A; Le Caer, H; Marin, B; Monnet, I; Schott, R; Vergnenegre, A | 1 |
| Chen, H; Fang, C; Lu, A; Qin, L; Wong, BC; Yang, Z; Zhang, H | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Heigener, D; Reck, M; Reinmuth, N | 2 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Al Husaini, H; ALHusaini, H; Aparisi, F; Arriola, E; Baize, N; Ballesteros, I; Barneto, I; Berchem, G; Bernabé, R; Blasco, A; Bombaron, P; Bosch-Barrera, J; Botia-Castillo, M; Bover, I; Calvo de Juan, V; Camps, C; Carcereny, E; Catot, S; Chaib, I; Chen, H; Chen, X; Chouaid, C; Cobo, M; Colinet, B; Dansin, E; De Grève, J; de Las Peñas, R; Domine, M; Drozdowskyj, A; Du, J; Felip, E; Fournel, P; Fraboulet, G; Gao, Y; García-Campelo, MR; García-Girón, C; García-Gómez, R; Garcia-Sevila, R; Garde, J; Gasco, A; Germonpre, P; Gervais, R; Gil, J; González-Larriba, JL; Hernando-Polo, S; Hominal, S; Hu, J; Hu, W; Insa, A; Isla, D; Jantus, E; Jiménez, B; Kahlout, S; Karachaliou, N; Kong, W; Lecaer, H; Lena, H; LeTreut, J; Li, L; Li, R; Li, X; Lianes, P; Liu, B; Liu, J; Locher, C; López-López, R; López-Martín, A; Lopez-Vivanco, G; Lu, H; Macias, JA; Majem, M; Marti-Ciriquian, JL; Massuti, B; Mate, JL; Mijangos, E; Molinier, O; Monnet, I; Montoyo, R; Morales-Espinosa, D; Moran, T; Moreno, MA; O'Brate, R; Ocaña, J; Oliviero, G; Pallares, C; Parera, M; Pereira, E; Perez-Cano, M; Pérez-Carrión, R; Porta, R; Provencio, M; Qian, X; Ramirez, JL; Rauh, S; Reguart, N; Ren, W; Robinet, G; Rosell, R; Rosillo, F; Sala, MA; Sanchez, JJ; Sanchez, JM; Sanchez-Rodriguez, B; Sanchez-Ronco, M; Schoot, R; Shao, J; Song, Y; Sullivan, I; Sun, X; Taron, M; Terrasa, J; Thomas, P; Tierno-Garcia, M; Trigo, JM; Valdivia, J; Vergnenegre, A; Viñolas, N; Viteri, S; Wang, L; Wei, J; Wen, L; Wu, Q; Xiao, X; Xu, X; Yan, J; Yang, J; Yang, M; Yang, Y; Yin, J; You, C; Yu, L; Yue, X; Zhang, F; Zhang, J; Zhou, Y; Zhu, L; Zou, Z | 1 |
| Blumenthal, GM; Chen, HY; He, K; Justice, R; Kazandjian, D; Keegan, P; Patel, M; Pazdur, R | 1 |
| Hagiwara, S; Horai, T; Horiike, A; Kawano, Y; Kudo, K; Nishio, M; Nishizawa, H; Ohyanagi, F; Sakatani, T; Tanimoto, A; Yanagitani, N | 1 |
| Antonia, S; Chiappori, A; Dilling, TJ; Extermann, M; Gray, J; Haura, E; Kim, J; Kim, S; Pinder-Schenck, M; Stevens, CW; Tanvetyanon, T; Thompson, LM; Williams, C; Yue, B | 1 |
| Georgoulias, V; Giagkas, G; Ioannidis, G; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Trypaki, M; Tsakalaki, E; Voutsina, A | 1 |
| Hong, W; Jin, Y; Shi, L; Shi, X; Sun, Y; Yu, X; Zhao, J | 1 |
| Boukovinas, I; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalogera-Fountzila, A; Karavasilis, V; Klouvas, G; Kosmidis, P; Kotoula, V; Mavropoulou, P; Papandreou, CN; Pectasides, D; Syrigos, KN | 1 |
| Azuma, K; Hayashi, H; Hirai, F; Kaiser, R; Kaneda, H; Konishi, K; Kurata, T; Miyazaki, M; Nakagawa, K; Okamoto, I; Sarashina, A; Seto, T; Takeda, M; Terashima, M; Tsurutani, J; Yagi, N | 1 |
| Ando, M; Gemma, A; Hino, M; Iwasawa, S; Minato, K; Miura, Y; Noro, R; Okamoto, H; Shingyoji, M; Takiguchi, Y; Yoshimori, K | 1 |
| Feng, J; Gu, J; Huang, J; Ni, S; Wang, H; Xu, L; Zhang, S; Zhang, W; Zhu, H | 1 |
| Ando, M; Goto, K; Harada, M; Ohe, Y; Saijo, N; Shibata, T; Shinkai, T; Tamura, T; Tsukada, H; Yokoyama, A | 1 |
| Besse, B; Blackhall, F; Han, JY; Hirsh, V; Iyer, S; Kim, DW; Nokihara, H; Reisman, A; Shaw, AT; Wilner, KD | 1 |
| André, V; Bepler, G; Blackhall, F; Callies, S; Danson, S; Das, M; Gadgeel, SM; Grossi, F; Kowalski, D; Lahn, M; Lerchenmüller, C; Mezger, J; Natale, R; Pinder-Schenck, M; Ramlau, R; Summers, Y; Talbot, D | 1 |
| de Mayolo, JA; Edelman, MJ; Evans, TL; Feliciano, J; Fidler, MJ; Keresztes, R; Medeiros, M; Otterson, G; Rogers, JS; Sanborn, RE; Schneider, BJ; Sequist, LV; Tan, MT; Yang, Y; Zaknoen, SL | 1 |
| Chen, B; Li, B; Xie, B; Zeng, Y; Zhang, W; Zheng, J; Zhou, J | 1 |
| Fahrbach, K; Griebsch, I; Kaiser, R; Martin, A; Mellemgaard, A; Popat, S; Reck, M; Rizzo, M | 1 |
| Bakogeorgos, M; Bournakis, E; Dimopoulos, MA; Economopoulou, P; Fytrakis, N; Kentepozidis, N; Kotsantis, G; Kouvatseas, G; Mountzios, G | 1 |
| Bao, Y; Chen, L; Chen, M; Chen, YY; Cheng, ZB; Deng, XW; Hu, X; Li, JC; Lu, RB; Ma, HL; Peng, F; Wang, J; Wang, Y; Xu, ZM; Yu, ZH; Zhou, QC | 1 |
| D'Incecco, A; Giovannetti, E; Leon, GL; Tibaldi, C; Vasile, E | 1 |
| Barrueco, J; Bondarenko, I; Douillard, JY; Gaschler-Markefski, B; Gottfried, M; Griebsch, I; Kaiser, R; Krzakowski, M; Liao, M; Mellemgaard, A; Novello, S; Orlov, S; Palmer, M; Reck, M; von Pawel, J | 1 |
| Ali, JA; Changelian, P; Douglas, M; Fritz, CC; Hafeez, N; Kutok, JL; McGovern, K; O'Callaghan, K; O'Connell, BC; Palombella, VJ; Stern, H; Tillotson, B; West, KA | 1 |
| Aparisi, F; Esquerdo, G; García-Sánchez, J; Garde, J; Giner, V; Juan, Ó; López, A; Muñoz-Langa, J; Sánchez-Hernández, A | 1 |
| Liang, H; Liu, E; Pan, F; Qin, H; Ruan, Z; Zhang, K | 1 |
| Owonikoko, TK; Ramalingam, SS | 1 |
| Abe, T; Ando, M; Ichinose, Y; Iwamoto, Y; Kudoh, S; Minato, K; Mizusawa, J; Nakagawa, K; Nakamura, S; Ohe, Y; Okamoto, H; Saijo, N; Saka, H; Sawa, T; Shibata, T; Takeda, K; Tamura, T; Yamamoto, N; Yokoyama, A; Yoshioka, H | 1 |
| Izzo, C | 1 |
| Li, XN; Liu, DL; Qi, Y; Wu, K; Yang, Y; Zhang, CY; Zhao, J; Zhao, S; Zhou, XD; Zhu, DY | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Emmanouilidis, Ch; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katsaounis, P; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Nintos, G; Polyzos, A; Stoltidis, D; Vamvakas, L; Vaslamatzis, M; Vetsika, EK | 1 |
| Liu, D; Qian, J; Su, B; Xu, W; Zhang, J; Zhang, ZW; Zheng, H | 1 |
| Barlesi, F; Braun, D; Debieuvre, D; Des Guetz, G; Fraboulet, G; Landre, T; Milleron, B; Molinier, O; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Uzzan, B; Vaylet, F; Westeel, V | 1 |
| Liu, J; Liu, L; Ma, N; Pang, H; Shen, W; Zhang, F; Zhang, H; Zhang, N; Zhou, J | 1 |
| Fitzgerald, TJ; Gandara, DR; Gaspar, LE; Kelly, K; Mack, PC; Moon, J; Pandya, KJ; Raben, D; Thomas, CR; Wozniak, AJ | 1 |
| Ahn, MJ; Baas, P; Blumenschein, GR; Cadranel, J; De Pas, T; Dunphy, F; Hanna, NH; Jänne, PA; Kim, DW; Kim, JH; Kim, SW; Mazieres, J; Planchard, D; Puski, A; Rappold, E; Redhu, S; Smit, EF; Udud, K; Wu, FS | 1 |
| Chen, L; Chen, Y; Huang, G; Tao, L | 1 |
| Auquier, P; Barlesi, F; Chouaid, C; Crequit, J; Fabre-Guillevin, E; Le Caer, H; Le Treut, J; Legodec, J; Loundou, A; Pujol, JL; Simeoni, MC; Thomas, PA; Vergnenegre, A | 1 |
| Han, S; Pu, R; Shi, LW; Zhao, YL | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Dhillon, S | 1 |
| Dang, Y; Fan, F; Gao, Y; Geng, J; Jia, H; Li, E; Li, M; Ma, X; Shang, L; Song, Y; Ti, X; Xue, X; Zhang, K; Zhang, W; Zhang, Y; Zhou, W | 1 |
| Bartolotti, M; Brandes, AA; Cavallo, G; Dalpiaz, G; De Biase, D; Denicolò, F; Di Battista, M; Genestreti, G; Lazzari-Agli, LA; Trisolini, R; Valli, M | 1 |
| Fukuda, M; Gemma, A; Inoue, A; Isobe, H; Katakami, N; Kobayashi, K; Kubota, K; Kudoh, S; Kunitoh, H; Michimae, H; Minato, K; Nakamura, Y; Nishio, M; Ohmatsu, H; Okamoto, H; Sakai, H; Sugawara, S; Takeuchi, M; Takiguchi, Y; Yokoyama, A | 1 |
| Chiu, LY; Hsin, IL; Hu, ME; Ko, JL; Sheu, GT; Tsai, KJ; Yang, TY | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Ohmatsu, H; Umemura, S; Watanabe, N; Yoh, K | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Andric, Z; Bondarenko, I; Ceric, T; Ciuleanu, T; Felip, E; Fennell, D; Goss, G; Hirsh, V; Khuri, F; Komov, D; Ramalingam, S; Rosell, R; Salgia, R; Samarzija, M; Schmid-Bindert, G; Shapiro, G; Sheldon, E; Spicer, J; Teofilovici, F; Vukovic, V; Wehler, T; Zaric, B | 1 |
| Fiegl, M; Freund, M; Gächter, A; Hilbe, W; Jamnig, H; Kendler, D; Kocher, F; Manzl, C; Pall, G; Pircher, A; Popper, H; Schmid, T; Schumacher, M; Wöll, E; Zabernigg, A; Zelger, B | 1 |
| Aerts, JG; Antonia, S; Arén Frontera, O; Baas, P; Baudelet, C; Brahmer, J; Crinò, L; Domine, M; Eberhardt, WE; Gainor, J; Garassino, MC; Harbison, CT; Havel, L; Holgado, E; Lestini, B; Paz-Ares, L; Pluzanski, A; Poddubskaya, E; Ready, N; Reck, M; Reckamp, KL; Spigel, DR; Steins, M; Vokes, EE; Waterhouse, D | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Hata, A; Hattori, Y; Imamura, F; Kaneda, T; Katakami, N; Kumagai, T; Morita, S; Negoro, S; Nishimura, T; Nishino, K; Okuda, C; Satouchi, M; Tachihara, M; Urata, Y; Yokota, S | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Barrios, CH; Crinò, L; Dougherty, B; Franke, FA; Hodgson, DR; Jänne, PA; Jeannin, G; Mann, H; McWalter, G; Orr, MC; Pereira, JR; Shaw, AT; Smith, I; Smith, P; Vansteenkiste, J; Walker, J | 1 |
| Cao, L; Cheng, HR; Li, RQ; Long, HL; Mao, WK; Xiao, BR; Zhai, XJ | 1 |
| Fujita, S; Hata, A; Iwasaku, M; Katakami, N; Korogi, Y; Mori, M; Morita, S; Namba, Y; Nishino, K; Nishiyama, A; Okuyama, T; Otsuka, K; Takeshita, J; Uchida, J; Yoshioka, H | 1 |
| Bartoń, S; Biernacka, B; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T | 1 |
| Aksoy, A; Aliustaoglu, M; Alkis, N; Aydin, K; Dane, F; Demirci, NS; Ekinci, AS; Gumus, M; Inal, A; Inanc, M; Odabas, H; Sevinc, A; Turkeli, M; Ulas, A; Uysal, M; Yazilitas, D; Yuksel, S | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Chen, M; Cho, EK; Choi, JH; Choi, YL; Jung, SH; Kang, JH; Kim, DW; Kim, HK; Kim, JH; Kim, SR; Kim, SW; Lee, CG; Lee, KC; Lee, KH; Min, YJ; Park, K; Song, HS; Sun, JM; Wu, YL; Zhu, G | 1 |
| Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y | 1 |
| Cao, W; Chen, H; Huang, L; Liu, Y; Mei, L; Ming, P; Wang, T; Zhang, B; Zhang, H; Zhang, R; Zhu, X | 1 |
| Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Behera, M; Belani, CP; Chen, Z; Khuri, FR; Kim, S; Owonikoko, TK; Pillai, RN; Ramalingam, SS; Saba, NF; Steuer, C | 1 |
| Asano, H; Hashida, S; Maki, Y; Miyoshi, S; Miyoshi, Y; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H | 1 |
| Georgoulias, V; Nintos, G; Syrios, J | 1 |
| Bettini, A; Broggini, M; Copreni, E; Farina, G; Ganzinelli, M; Garassino, MC; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Torri, V; Veronese, S | 1 |
| Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N | 1 |
| Bronte, G; Galvano, A; Passiglia, F; Russo, A | 1 |
| Ates, H; Aydin, S; Cehreli, R; Cengiz, H; Harmanci, D; Kemanli, P; Kocdor, H; Kocdor, MA; Soyarat, F | 1 |
| Honma, Y; Kanemaru, R; Kato, M; Ko, R; Koyama, R; Mori, K; Shibayama, R; Shimada, N; Shukuya, T; Takahashi, K; Yagishita, S | 1 |
| Dowlati, A; Fu, P; Gadgeel, S; Halmos, B; Kuebler, JP; Mekhail, T; Otterson, GA; Pennell, NA; Saad, S; Sharma, N; Snell, M | 1 |
| Cui, Y; Huang, C; Qi, D; Qi, XA; Tian, Y; Wang, Q; Xin, L; Xu, J; Yang, Y | 1 |
| Brandes, JC; Brodie, SA; Harvey, D; Khuri, FR; Li, G; Vertino, PM | 1 |
| Acharyya, S; Bilger, M; Haaland, B; Lopes, G; Tan, PS | 1 |
| Bessho, A; Hotta, K; Ichinose, Y; Katsui, K; Kishimoto, J; Kiura, K; Nogami, N; Saeki, S; Sasaki, J; Shioyama, Y; Takayama, K; Takigawa, N; Tanimoto, M | 1 |
| Chen, L; Gao, Z; Jin, G; Jin, M; Jin, Z; Yin, X | 1 |
| Antonia, SJ; Arrieta, O; Barlesi, F; Blumenschein, GR; Borghaei, H; Brahmer, JR; Burgio, MA; Chow, LQ; Crinò, L; Dorange, C; Fayette, J; Felip, E; Gerber, DE; Gettinger, SN; Graf Finckenstein, F; Harbison, CT; Holgado, E; Horn, L; Kohlhäufl, M; Lena, H; Paz-Ares, L; Poddubskaya, E; Ready, NE; Rizvi, N; Rudin, CM; Spigel, DR; Steins, M; Vokes, EE | 1 |
| Aboshady, H; Barrueco, J; Bennouna, J; Bondarenko, I; Cheng, Y; Douillard, JY; Gottfried, M; Hocke, J; Kaiser, R; Luft, A; Mellemgaard, A; Reck, M; von Pawel, J; Zarogoulidis, K | 1 |
| Chen, SQ; Cui, FB; Gao, EY; Jiang, BQ; Li, M; Shu, RB; Sun, P; Tang, W; Wang, H; Zhang, FL; Zhang, Y | 1 |
| Biable, M; Bloomquist, E; Blumenthal, GM; Keegan, P; Kluetz, P; Larkins, E; Pazdur, R; Scepura, B; Tang, S | 1 |
| He, X; Li, C; Wu, X; Yang, G | 1 |
| Blumenthal, G; Kazandjian, D; Keegan, P; Khozin, S; Kluetz, P; Libeg, M; Pazdur, R; Sridhara, R; Tang, S; Zhang, L | 1 |
| Aggarwal, C; Bauml, J; Brady, AK; Cohen, RB; Evans, TL; Judy, B; Langer, C; McNeill, JD; Vachani, A | 1 |
| Aono, H; Hida, N; Hosomi, Y; Kunitoh, H; Minato, K; Miura, Y; Okamoto, H; Okuma, Y; Oshita, F; Sakamaki, K; Sakamoto, T; Satoh, A; Seki, N; Shibuya, M; Takagi, Y; Watanabe, K; Yamada, K; Yomota, M | 1 |
| Hu, Q; Jiang, S; Ni, H; Qi, H; Yu, D; Zhang, J | 1 |
| Spicer, J; Wu, Y | 1 |
| Daga, H; Goto, K; Hattori, Y; Iwamoto, Y; Kaneda, H; Kawaguchi, T; Nagase, S; Nakagawa, K; Nakanishi, Y; Nishimura, T; Oguri, T; Saka, H; Seto, T; Shukuya, T; Sugawara, S; Takahashi, T; Yamamoto, N; Yamanaka, T; Yokota, S | 1 |
| Bai, Y; Chen, M; Hu, Y; Li, H; Li, J; Li, Q; Li, T; Lu, B; Lu, Y; Ma, Z; Ouyang, W; Su, S; Wang, X; Wang, Y | 1 |
| Dai, X; Jin, C; Lv, X; Xu, W | 1 |
| Bareggi, C; Bertolini, A; Broggini, M; Caiola, E; Calcagno, A; Copreni, E; Fabbri, MA; Fagnani, D; Ganzinelli, M; Garassino, MC; Labianca, R; Locatelli, MC; Longo, F; Marabese, M; Martelli, O; Pavese, I; Piva, S; Rulli, E; Sarobba, MG; Valmadre, G | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Wei, R; Zang, JP | 1 |
| Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
| Anisie, E; Antohe, I; Antoniu, S; Ulmeanu, R | 1 |
| Hou, C; Ji, C; Jiang, Y; Liu, Y; Sun, B; Yang, N; Zhang, H; Zheng, J; Zuo, P | 1 |
| Ahn, MJ; Arvis, CD; Baas, P; de Castro, G; Dolled-Filhart, M; Felip, E; Fidler, MJ; Garon, EB; Garrido, M; Han, JY; Herbst, RS; Im, E; Kim, DW; Kim, JH; Lubiniecki, GM; Majem, M; Molina, J; Pérez-Gracia, JL; Shentu, Y | 1 |
| Chang, CC; Chen, RJ; Chiou, HY; Hsieh, CC; Hsieh, CI; Lien, YC; Tai, CJ; Tzao, C; Wang, CK; Wu, CH; Wu, HC | 1 |
| Gridelli, C; Sacco, PC | 1 |
| Aliustaoglu, M; Aydin, D; Ercelep, O; Gemici, C; Gumus, M; Isik, D; Korkmaz, T; Mayadagli, A; Mert, AG; Odabas, H; Ozcelik, M; Ozdemir, P; Seker, M; Surmeli, H; Yuksel, S | 1 |
| Cha, E; Green, M; Jin, J; Stroh, M; Wada, R; Zhang, N | 1 |
| Asai, K; Hirata, K; Isa, S; Kawaguchi, T; Kimura, T; Kubo, A; Kudoh, S; Matsuura, K; Mitsuoka, S; Nakai, T; Oka, T; Sawa, K; Suzumura, T; Tanaka, H; Uji, M; Watanabe, T; Yoshimoto, N; Yoshimura, N | 1 |
| Bi, J; Cao, B; Chen, L; Dai, H; Deng, Y; Hu, J; Jia, L; Jiang, H; Li, W; Meng, C; Nan, K; Shen, K; Shen, P; Shi, J; Song, Y; Sun, Q; Sun, Y; Tang, L; Tian, F; Tong, Z; Wang, S; Wu, G; Wu, Q; Wu, Y; Xie, X; Xu, B; Yu, J; Yuan, Z; Yue, S; Zhang, B; Zhang, Q; Zhang, Y; Zhuang, W | 1 |
| Ahn, JS; Ahn, MJ; Lee, SH; Lim, SH; Park, K; Sun, JM | 1 |
| Cho, BC; Heo, SJ; Jeong, J; Jung, I; Kim, HR; Kim, JH; Lee, CK; Lim, SM; Moon, YW; Shim, HS | 1 |
| Arai, Y; Dmuchowski, C; Fakhoury, A; Infante, JR; Krivoshik, A; LoRusso, P; Luke, JJ; Schuster, R; Shapiro, GI; Yamazaki, T | 1 |
| Leslie, M | 1 |
| Azuma, K; Daga, H; Hayashi, H; Hirashima, T; Kubo, A; Miyahara, E; Murakami, H; Nakagawa, K; Nakanishi, Y; Nogami, N; Okada, M; Okamoto, I; Saito, H; Sawa, T; Seto, T; Sugawara, S; Takeda, M; Urata, Y; Yamanaka, T; Yonesaka, K | 1 |
| Ghiorghiu, D; Jänne, PA; Mann, H | 1 |
| Goeree, J; Goeree, R; Orsini, L; Penrod, JR; Tahami Monfared, AA; Villeneuve, J | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Aotani, E; Gemma, A; Hamano, T; Kobayashi, K; Takebayashi, T; Takeuchi, M | 1 |
| Fu, X; Guo, C; He, L; Hu, X; Li, G; Pan, R; Wen, S; Zhang, X; Zhao, C | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Chu, Q; Hirsh, V; Juergens, R; Leighl, N; McLeod, D; Melosky, B | 1 |
| Arrieta, O; Cappuzzo, F; Carter, GC; Ciuleanu, TE; Dakhil, S; Garon, EB; Goksel, T; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lee, P; Lewanski, CR; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Syrigos, KN; Thomas, M; Yurasov, S; Zimmermann, A | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Akerley, W; Bazhenova, LA; Borghaei, H; Camidge, DR; Cheney, RT; Chirieac, LR; D'Amico, TA; Dilling, TJ; Dobelbower, MC; Ettinger, DS; Govindan, R; Gregory, K; Hennon, M; Horn, L; Hughes, M; Jahan, TM; Komaki, R; Lackner, RP; Lanuti, M; Lilenbaum, R; Lin, J; Loo, BW; Martins, R; Otterson, GA; Patel, JD; Pisters, KM; Reckamp, K; Riely, GJ; Schild, SE; Shapiro, TA; Sharma, N; Stevenson, J; Swanson, SJ; Tauer, K; Wood, DE; Yang, SC | 1 |
| Abdel-Rahman, O | 1 |
| Artal-Cortes, A; Ballinger, M; Braiteh, F; Chen, DS; Fehrenbacher, L; He, P; Kowanetz, M; Lewanski, C; Mazieres, J; Park, K; Rittmeyer, A; Sandler, A; Smith, D; Spira, A; Vansteenkiste, J; Waterkamp, D; Yi, J; Zou, W | 1 |
| Smit, EF; van den Heuvel, MM | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Minarik, M; Pesek, M; Svaton, M; Topolcan, O | 1 |
| Blumenthal, G; He, K; Kazandjian, D; Keegan, P; Libeg, M; Mushti, S; Pazdur, R; Suzman, DL | 1 |
| Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T | 1 |
| Cheng, S; Coakley, N; Ellis, PM; Gregg, R; Kulkarni, S; Ung, YC; Vella, ET | 1 |
| Chen, S; Jia, Q; Jia, Y; Ying, Y; Zhou, D | 1 |
| Amos, CI; Biernacka, A; Black, CC; de Abreu, FB; Gutmann, EJ; Liu, X; Peterson, JD; Tafe, LJ; Tsongalis, GJ; Tsongalis, PD | 1 |
| Choi, EK; Jeong, SY; Jung, J; Kim, KM; Lim, HK | 1 |
| Chen, S; Huang, M; Li, T; Wang, Q; Zhou, XM; Zhu, JP | 1 |
| Belani, CP; Gerber, DE; Giorgadze, D; Menander, KB; Ponomarova, OV; Shan, JS; Shtivelband, M; Spigel, DR | 1 |
| Harada, T; Itoh, K; Kakuma, T; Kishimoto, J; Maemondo, M; Nakanishi, Y; Noguchi, M; Saijo, Y; Sasada, T; Sato, A; Sugawara, S; Takamori, S; Takayama, K; Yamada, A | 1 |
| Gao, Z; Jin, G; Jin, M; Jin, Z; Yin, X | 1 |
| Aebi, S; Dedes, K; Diebold, J; Gautschi, O; Klingbiel, D; Matter-Walstra, K; Pietrini, M; Schwenkglenks, M; von Moos, R | 1 |
| Früh, M; Gautschi, O; Mirimanoff, RO; Peters, S; Pless, M; Ris, HB; Stupp, R; Xyrafas, A | 1 |
| Chang, YC; Chi, KH; Chi, MS; Hsu, PS; Jiang, JS; Kao, SJ; Ko, HL; Lin, CC; Wang, HE; Yang, KL; Yeh, DY | 1 |
| Anders, CK; Bowerman, C; Chu, K; Deal, A; DeSimone, J; Karginova, O; Luft, JC; Sambade, M; Schorzman, A; Swearingen, AV; Zamboni, W | 1 |
| Gao, X; Huang, G; Li, G; Li, X; Qin, S; Ren, H; Sun, X; Wang, H; Xiao, G; Yang, C; Zhang, B | 1 |
| Bernabé, R; Blackhall, F; Carter, L; Dean, E; Patrao, A | 1 |
| Aydiner, A; Ciftci, R; Demir, A; Eralp, Y; Firat, P; Guveli, ME; Oral, EN; Ozkan, B; Ozkaya, K; Saglam, EK; Saip, P; Sen, F; Tambas, M; Toker, A | 1 |
| Aguiar, PN; Castelo-Branco, P; de Lima Lopes, G; de Mello, RA; Filardi, BA; Mountzios, G; Oliveira, P; Santoro, IL; Tadokoro, H | 1 |
| Ferrer, L; Levra, MG; Moro-Sibilot, D; Toffart, AC | 1 |
| Wang, K; Zhang, K; Zhou, F; Zhu, L; Zhu, X | 1 |
| Campo, MJ; Gainor, JF; Herzberg, B | 1 |
| Enatsu, S; Ferry, D; Hosomi, Y; Kasahara, K; Koue, T; Lee, P; Nakagawa, K; Nakamura, T; Nishio, M; Ohe, Y; Takahashi, T; Tamura, T; Yamada, K; Yamamoto, N; Yoh, K | 1 |
| Asensi Diez, R; Clopes Estela, A; Espinosa Bosch, M; García Agudo, S | 1 |
| Burke, T; Huang, M; Liu, FX; Lou, Y; Pellissier, J; Velcheti, V; Xu, R | 1 |
| Chen, S; Hu, J; Li, Q; Xia, F; Xiong, Y; Zhou, GW | 1 |
| Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Chen, W; Qiao, T; Xing, N; Yuan, S; Zhang, Q; Zhuang, X | 1 |
| Dermitzaki, EK; Georgoulias, V; Hatzidaki, D; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Matikas, A; Mavroudis, D; Samantas, E; Varthalitis, II | 1 |
| Dowlati, A; Fu, P; Pennell, NA; Sharma, N; Yi, Q | 1 |
| Daga, H; Takeda, K | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Amini, M; Belderbos, JSA; Biesma, B; Bootsma, GP; Brouns, -JWM; Bussink, J; De Ruysscher, DKM; Dingemans, AC; Hendriks, LEL; Oei, SB; Stigt, JA; Uyterlinde, W; Van den Heuvel, MM; Wijsman, R | 1 |
| Gann, CN; Kaiser, R; Morsli, N | 1 |
| Marshall, H | 1 |
| Ji, X; Ma, J; Wang, D; Wei, Y; Xu, F | 1 |
| Fang, S; Han, X; Tang, N; Wang, Z; Zhang, Q | 1 |
| Andor, G; Bergqvist, M; Bondarenko, I; Grechanaya, E; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Maximovich, A; Thureson, M | 1 |
| Blanco, R; Camps, C; de Aguirre, I; Garrido, P; Gonzalez-Larriba, JL; Insa, A; Isla, D; Moran, T; Pérez Cano, M; Provencio, M; Queralt, C; Ramirez, JL; Rosell, R; Santarpia, M | 1 |
| Durm, G; Hanna, N | 1 |
| Allegrini, G; Bidoli, P; Brighenti, M; Chella, A; DE Marinis, F; Gridelli, C; Maione, P; Migliorino, MR; Ricciardi, S; Rossi, A; Valmadre, G | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Ballinger, M; Barlesi, F; Barrios, C; Chen, DS; Ciardiello, F; Cortinovis, DL; De Marinis, F; Dols, MC; Frontera, OA; Gadgeel, SM; Gandara, DR; He, P; Hida, T; Kabbinavar, F; Kowalski, DM; Kowanetz, M; Leach, J; Lee, JS; Park, K; Polikoff, J; Rittmeyer, A; Sandler, A; Turna, H; von Pawel, J; Waterkamp, D | 1 |
| Daniluk, J; Krawczyk, P; Milanowski, J; Mlak, R; Powrózek, T; Szczyrek, M; Szudy-Szczyrek, A; Wojas-Krawczyk, K; Zwolak, A | 1 |
| Gajra, A | 1 |
| Abate, MI; Cortinovis, D; Gregorc, V; Malapelle, U; Manzo, A; Migliorino, MR; Morabito, A | 1 |
| Berghmans, T; Biesma, B; Chittazhathu Kurian Kuruvilla, Y; Ciardiello, F; Coate, L; Cobo Dols, M; Collado Martin, R; Cuffe, S; Curioni-Fontecedro, A; Dafni, U; de Hosson, S; Garde Noguera, J; Gasca-Ruchti, A; Gautschi, O; Gregorc, V; Groen, HJM; Horgan, A; Insa, A; Juan Vidal, Ó; Kassapian, M; Láng, I; López Martín, A; Mark, MT; Massutí, B; Meldgaard, P; Novello, S; Palmero Sanchez, R; Peralta, S; Peters, S; Pieterman, R; Ponce Aix, S; Rauch, D; Smit, EF; Stahel, RA; Summers, Y; Torri, V; Tsourti, Z; van den Berg, PM; van Heemst, R; van Henten, AMJ; Villa Guzmán, JC; Zielinski, CC | 1 |
| Wang, C; Wang, W; Yu, X | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Han, Y; Jia, L; Li, G; Wang, L; Wang, M; Wang, T; Yang, Z; Zhang, L; Zhang, S; Zhang, Y | 1 |
| Cadranel, J; Fabre, E; Pécuchet, N | 1 |
| Chuang, JC; Das, M; Diehn, M; Huang, J; Liang, Y; Neal, JW; Stehr, H; Wakelee, HA | 1 |
| Atagi, S; Fujita, S; Hida, T; Kato, T; Masuda, N; Nakanishi, Y; Namba, Y; Sakai, H; Satouchi, M; Takahashi, M; Takeda, K; Tamura, T; Tanaka, H | 1 |
| Ding, WQ; Gu, MM; Li, M; Li, S; Liu, B; Shang, ZF; Xiao, BB; Yu, L; Zhou, J; Zhou, PK; Zou, S | 1 |
| Barton, J; Burris, HA; Greco, FA; Infante, J; Jones, S; Patton, J; Shipley, D; Spigel, D; Thompson, D | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM | 1 |
| Aitini, E; Daniele, B; Di Maio, M; Frontini, L; Gallo, C; Gamucci, T; Gebbia, V; Gridelli, C; Mancuso, G; Morabito, A; Perrone, F; Verusio, C | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Ensley, JF; Kim, H; Kucuk, O; Lin, HS; Lonardo, F; Piechocki, MP; Stevens, T; Subramanian, G; Tulunay, OE; Won, J; Yoo, GH | 1 |
| Georgoulias, V; Saloustros, E | 1 |
| Ishizaka, A; Matsuzaki, T; Morishita, T; Naitou, A; Ogawa, R; Terashima, T | 1 |
| Al-Adhami, M; Albert, G; Gravenor, D; Hirsh, V; Krieg, AM; Leichman, CG; Manegold, C; Mezger, J; Readett, D; Woytowitz, D | 1 |
| Asamura, H; Ichinose, Y; Kato, H; Koike, T; Kunitoh, H; Mitsudomi, T; Nagai, K; Nakagawa, K; Okada, M; Saijo, N; Shibata, T; Tada, H; Tsuboi, M | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Atagi, S; Fukai, S; Kawaguchi, T; Kawahara, M; Komatsu, H; Kubo, A; Kusunoki, Y; Okishio, K; Saito, R; Takada, M; Tomizawa, Y; Uehira, K; Yumine, K | 1 |
| Borghaei, H; Cohen, RB; Huang, CH; Langer, CJ; Millenson, MM; Mintzer, DM; Ruth, KJ; Seldomridge, J; Sherman, EJ; Staddon, AP; Treat, OJ; Tuttle, H | 1 |
| Aggarwal, AN; Singh, N | 2 |
| Ross, HJ; Seung, SK | 1 |
| Eguchi, K; Fukuoka, M; Harada, M; Ichinose, Y; Imamura, F; Inoue, A; Itoh, Y; Jiang, H; Maruyama, R; Masuda, N; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Shinkai, T; Takeda, K; Tamura, T; Tomii, K; Tsuboi, M; Yamamoto, N | 1 |
| Bobokova, J; Calles Blanco, A; Custodio Carretero, AB; Díaz-Rubio García, E; García Paredes, B; García Sáenz, JA; González Larriba, JL; Hernando Trancho, F; Rodríguez Lajusticia, L | 1 |
| Belani, CP; Butler, EH; Guidice, RA; Marsland, TA; Ramalingam, SS; Schreeder, MT; Steis, RG | 1 |
| Gomi, K; Hayasaka, M; Koizumi, T; Kubo, K; Nakamura, M; Shikama, N; Tsushima, K; Yasuo, M | 1 |
| Bolger, M; Dunphy, F; Edelman, MJ; Green, MR; Gu, L; Hoffman, P; Khatri, J; Miller, AA; Vokes, EE; Wang, XF | 1 |
| Adisen, E; Benekli, M; Buyukberber, S; Coskun, U; Gureli, M; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| Amadori, D; Cecconetto, L; Dall'agata, M; Dazzi, C; Frassineti, GL; Milandri, C; Nanni, O; Oliverio, G; Pasquini, E; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Chaplen, RA; Gadgeel, SM; Heilbrun, LK; Kalemkerian, GP; Kraut, MJ; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A | 1 |
| Anderson, T; Ansari, R; Arseneau, J; Breen, T; Bruetman, D; Chowhan, N; Einhorn, L; Fisher, W; Govindan, R; Hanna, N; Johnson, C; Mantravadi, P; McGarry, R; Melnyk, A; Nattam, S; Neubauer, M; Reynolds, C; Richards, D; White, A; Yiannoutsos, C | 1 |
| Boukovinas, I; Georgoulias, V; Koutsopoulos, A; Mavroudis, D; Mendez, P; Papadaki, C; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Souglakos, J; Staphopoulos, E; Taron, M; Trypaki, M | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| Gao, YJ; Guan, XQ; Li, EX; Liu, JW; Nan, KJ; Sheng, LJ; Song, SP; Sun, Y; Wang, DL; Wang, XW; Wang, ZP; Wang, ZX; Yu, XJ; Zhang, MH; Zhang, XR | 1 |
| Cullen, M; Thatcher, N | 1 |
| Armour, AA; Douillard, JY; Gervais, R; Hirsh, V; Kim, ES; Li, LY; Liao, ML; Lippman, SM; Lowe, ES; Mok, T; Osterlind, K; Reck, M; Sellers, MV; Shepherd, FA; Socinski, MA; Sun, Y; Watkins, CL; Wu, YL | 1 |
| Chen, W; Gadgeel, SM; Kalemkerian, GP; Kraut, MJ; Schneider, BJ; Smith, DW; Worden, FP; Wozniak, AJ | 1 |
| Bromund, JL; Chen, R; Dakhil, SR; Fidias, PM; Gill, J; Hristova-Kazmierski, M; Loesch, DM; Lyss, AP; Marciniak, M; Obasaju, CK; Schiller, JH; Treat, J; Waterhouse, DM | 1 |
| Chu, DT; Sun, Y; Wang, B; Wang, HJ; Wang, Y; Zhang, XR | 1 |
| Bareschino, M; Colantuoni, G; Falanga, M; Ferrara, ML; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A; Rossi, E; Schettino, C | 1 |
| Kim, JH; Lee, CT; Lee, JS; Lee, KW; Lim, JH | 1 |
| de la Brassinne, M; Devillers, C; Henrijean, A; Ramaut, M; Vanhooteghem, O | 1 |
| Aizawa, H; Azuma, K; Hattori, S; Ichiki, M; Ikeda, J; Imamura, Y; Kage, M; Kawahara, A; Kinoshita, T; Kuwano, M; Sasada, T; Takamori, S | 1 |
| Chougule, MB; Fulzele, SV; Ichite, N; Jackson, T; Safe, S; Singh, M | 1 |
| Carloni, F; Lazzari Agli, L; Santelmo, C; Sartori, S; Tamburini, E; Tassinari, D; Tombesi, P | 1 |
| Asai, K; Hirata, K; Ichimaru, Y; Kimura, T; Kodama, T; Kudoh, S; Kyoh, S; Mitsuoka, S; Tochino, Y; Yana, T; Yoshimura, N | 1 |
| Ando, M; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Semba, H; Shibata, T; Takada, Y; Takeda, K; Tamura, T; Yokota, S | 1 |
| Deng, QF; Su, B; Zhao, YM; Zhou, CC | 1 |
| Morgan, A; Sutton, A; Wailoo, A | 1 |
| Herbst, RS; Hong, WK; Kim, ES; Lee, JJ; Liu, D; Mauer, AM; Tran, HT; Vokes, EE; William, WN; Windt, P | 1 |
| Costa, DB; Kobayashi, S | 1 |
| Bergot, E; Zalcman, G | 1 |
| Furukawa, T; Gejyo, F; Hayashi, Y; Kagamu, H; Kuriyama, H; Tanaka, H; Tanaka, J; Umezu, H; Yoshimasu, T; Yoshizawa, H | 1 |
| Blatter, J; Fossella, F; Hanna, N; Peterson, P; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K | 1 |
| Lazzari-Agli, L; Santelmo, C; Sartori, S; Scarpi, E; Tamburini, E; Tassinari, D; Tombesi, P | 1 |
| Caraglia, M; Correale, P; Francini, G; Gotti, G; Macrì, P; Migali, C; Remondo, C; Rotundo, MS; Tagliaferri, P; Tindara Miano, S | 1 |
| Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kalender, ME; Kaya, AO; Orhan, O; Ozturk, B; Sevinc, A; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Ball, D; Campeau, MP; Drummond, E; Herschtal, A; Hogg, A; Mac Manus, M; Michael, M; Wheeler, G; Wirth, A | 1 |
| Atsou, K; Chouaid, C; Hejblum, G; Vergnenegre, A | 1 |
| Abratt, R; Aitini, E; Carteni, G; Gatzemeier, U; Grodzki, T; Riska, H; Rolski, J; Schneider, CP; Tan, EH; Tsai, YH; Zatloukal, P | 1 |
| Eguchi, K; Fukuoka, M; Ichinose, Y; Imamura, F; Itoh, Y; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Sekine, I; Shinkai, T; Takeda, K; Tamura, T; Tsuboi, M; Yamamoto, N | 1 |
| Chang, JW; Chen, CH; Lin, CM; Tsao, TC | 1 |
| Crinò, L; De Marinis, F; Falcone, A; Grassivaro, N; Nardi, M; Novello, S; Rinaldi, M; Russo, F; Scagliotti, GV; Tibaldi, C; Tinazzi, A; Tonato, M | 1 |
| Moro-Sibilot, D; Sculier, JP | 1 |
| Khuri, FR; Ramalingam, SS | 1 |
| Bo, S; Cao, W; Cao, Z; Che, J; Gao, C; Guo, X; Han, K; Huang, G; Ma, L; Sun, L; Tucker, SJ; Wang, D; Zhong, B | 1 |
| Bryce, J; De Feo, G; De Maio, E; Del Giudice, A; Di Maio, M; Falasconi, F; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC | 1 |
| Bilici, A; Eren, M; Gumus, M; Karabulut, SG; Kocak, M; Mayadagli, A; Oruc, F; Oven Ustaalioglu, BB; Ozkan, A; Parlak, C; Seker, M | 1 |
| Reck, M | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Abali, H; Disel, U; Köse, F; Mertsoylu, H; Sezer, A | 1 |
| Hawkins, N; Scott, DA; Thatcher, N; Woods, BS | 1 |
| Choy, H; Dobbs, T; Dowlati, A; Hughes, RS; Jain, AK; Muldowney, NJ; Sandler, AB; Schlabach, L; Schwartzberg, LS; Wu, J | 1 |
| Aalen, OO; Aamdal, S; Brunsvig, PF; Gunnes, N; Jacobsen, AB; Seierstad, TG; Sundstrøm, S | 1 |
| Barneto, I; Blanco, R; Catot, S; Chaib, I; Cobo, M; de Las Peñas, R; Diz, P; Domine, M; Ibeas, R; Isla, D; Jimenez, U; Lopez-Vivanco, G; Macias, JA; Mendez, P; Moran, T; Oramas, J; Perez-Roca, L; Provencio, M; Reguart, N; Rosell, R; Sala, MA; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Greco, FA; Spigel, DR | 1 |
| Cassileth, BR; Coleton, M; Deng, G; Guillen, S; Kris, MG; Rizvi, N; Vickers, A; Woo, D; Yeung, KS | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| Arellano, J; Leteneux, C | 1 |
| Doral Stefani, S; Giorgio Saggia, M; Vicino dos Santos, EA | 1 |
| Minami, H; Ozawa, K; Sato, H | 1 |
| Argonza-Aviles, E; Ericson, SG; Gajra, A; Pandya, KJ; Warsi, GM; Wozniak, AJ | 1 |
| Boytim, M; Dhillon, N; Dorr, R; Hersh, E; Hong, D; Kurzrock, R; La Paglia, A; Moulder, S; Naing, A; Ng, C; Tse, S; Wheler, J | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Cunningham, CC; Eager, RM; Jones, B; Nemunaitis, J; Raju, RN; Richards, DA; Senzer, N; Uprichard, M | 1 |
| Belmontes, B; Bush, T; Freeman, DJ; Johnson, C; Juan, T; Ogbagabriel, S; Plewa, C; Radinsky, R; Van, G | 1 |
| Daniels, L; Green, MR; Iovino, L; Lemke, K; Rafferty, G; Socinski, MA; West, H; Willey, J | 1 |
| Cui, Y; Feng, K; Liu, ZJ; Qi, DL; Qiao, YF; Wang, QS; Xin, L; Yang, YZ | 1 |
| Betticher, DC; Furrer, M; Hsu-Schmitz, SF; Jost, L; Kann, R; Majno, SB; Mayer, M; Mirimanoff, RO; Peters, S; Pless, M; Ris, HB; Roth, AD; Schmid, RA; Stahel, RA; Stupp, R; Thierstein, S; Weder, W; Zouhair, A | 1 |
| Beinert, T; Binder, D; Graseck, L; Hackenthal, M; Hellriegel, KP; Krüll, M; Schäper, C; Schweisfurth, H; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Bitran, JD; Hallmeyer, S; Milton, DT; Nabhan, C; Radhakrishnan, A; Tolzien, K | 1 |
| Alpaugh, K; Borghaei, H; Cohen, RB; Dueland, S; Forsberg, G; Hawkins, R; Hedlund, G; Langer, C; Lassen, U; Rogatko, A | 1 |
| Ahn, YM; Kang, EM; Kim, BS; Kim, HJ; Kim, JH; Kim, TG; Lee, BU; Lee, HJ; Lim, BH; Nam, SH; Roh, YH; Seo, JW | 1 |
| Dueck, A; Jatoi, A; Loprinzi, CL; Luyun, RF; Mattar, BI; Nguyen, PL; Nikcevich, DA; Ritter, HL | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Fossella, FV; Glisson, BS; Herbst, RS; Khuri, FR; Kim, ES; Lee, JJ; Lippman, SM; William, WN; Zinner, RG | 1 |
| Endo, M; Igawa, S; Ito, I; Kaira, K; Kameya, T; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tsuya, A; Watanabe, R; Yamamoto, N | 1 |
| Gu, L; Kirshner, J; Lerro, K; Lilenbaum, R; Vokes, E; Wang, X | 1 |
| Burkes, RL; Chen, XE; Dick, C; Ellis, P; Goss, G; Knox, JJ; Laurie, SA; Leighl, NB; Moore, MJ; Pond, GR; Shepherd, FA; Yen, Y; Zwiebel, JA | 1 |
| Jon, S; Kim, H; Lee, E; Lee, IH | 1 |
| Lazzari-Agli, L; Sartori, S; Tassinari, D; Tombesi, P | 1 |
| Alberola, V; Camps, C; Carcereny, E; Cobo, M; de Aguirre, I; Domine, M; Isla, D; Lopez-Vivanco, G; Massuti, B; Mendez, P; Moran, T; Okamoto, T; Provencio, M; Ramirez, JL; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Wei, J | 1 |
| Gemma, A; Hino, M; Kudoh, S; Nagao, K; Niitani, H; Tada, Y; Takiguchi, Y; Yoshimori, K; Yoshimura, A | 1 |
| Bordier, V; Bras-Gonçalves, R; Chapelier, A; Daniel, C; De Cremoux, P; de Pinieux, G; Decaudin, D; Fontaine, JJ; Judde, JG; Laurent-Puig, P; Livartowski, A; Némati, F; Poupon, MF | 1 |
| Kimura, T; Nishiyama, Y; Ohkawa, M; Takashima, H; Togami, T | 1 |
| Herbst, RS | 1 |
| Cho, SH; Cho, YJ; Go, SI; Hwang, YS; Jeong, YY; Kang, JH; Kim, HC; Kim, HG; Kim, SH; Lee, GW; Lee, JD | 1 |
| Beckett, LA; Burich, RA; Davies, AM; Gandara, DR; Holland, WS; Lara, PN; Li, Y; Mack, PC; Sangha, R; Solis, LJ | 1 |
| Dalphin, JC; Depierre, A; Elleuch, R; Gainet, M; Girard, N; Jacoulet, P; Pernet, D; Westeel, V | 1 |
| Bing, F; Hai-Zhu, S; Long-Bang, C; Rui, W; Wei, D | 1 |
| Borsellino, N; Carrozza, F; Caruso M, M; Cinieri, S; Colucci, G; Ferraù, F; Galetta, D; Gebbia, V; Leo, S; Lorusso, V; Mancarella, S; Mancuso, G; Palomba, G; Riccardi, F | 1 |
| Fang, Q; Ou, W; Sun, HB; Wang, SY; Yang, H; Zhang, BB | 1 |
| Drudi, F; Lazzari-Agli, L; Sartori, S; Tassinari, D; Tombesi, P | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Hou, XH; Jiang, L; Tang, LF; Wang, DF; Wang, DY; Xie, Z; Zhao, HD; Zhu, ZH | 1 |
| Gao, F; Leong, SS; Lim, WT; Ngeow, J; Poon, D; Tan, EH; Toh, CK | 1 |
| Chiu, LY; Ko, JL; Lee, YJ; Sheu, GT; Tee, YT; Yang, TY | 1 |
| Lu, S; Yu, YF; Zhang, YF | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, AG; Simou, E | 1 |
| Asami, K; Fukuoka, M; Hirashima, T; Katakami, N; Kudoh, S; Mitsudomi, T; Morita, S; Nakagawa, K; Negoro, S; Okamoto, I; Saito, H; Satouchi, M; Seto, T; Shibata, K; Shimizu, E; Tada, H; Takada, M; Toyooka, S; Tsurutani, J; Yatabe, Y; Yoshioka, H | 1 |
| Ayala, D; Blackstock, AW; Capellari, J; Center, B; Hinson, WH; Lovato, J; Miller, AA; Oaks, T; Petty, WJ | 1 |
| Fujii, A; Hayashi, A; Hidaka, D; Hiyama, J; Ikeda, K; Koshizuka, H; Misumi, Y; Miyagawa, Y; Nakanishi, K; Nakatsubo, S; Omagari, J; Sanada, H; Sawamoto, R; Tomimitsu, S; Tsuru, M | 1 |
| Armour, AA; Bischoff, H; Douillard, JY; Gervais, R; Hirsh, V; Kim, ES; Liao, ML; Mok, T; Reck, M; Sellers, MV; Shepherd, FA; Socinski, MA; Speake, G; Watkins, CL | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Baba, K; Hasegawa, Y; Ichikawa, M; Imaizumi, K; Kataoka, K; Kondo, M; Kume, H; Matsumoto, S; Noda, Y; Shindo, Y; Shindoh, J; Suzuki, K; Suzuki, R; Takagi, K; Taniguchi, H; Tanikawa, Y | 1 |
| Fukushima, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mio, T; Misawa, A; Niimi, M; Nishimura, T; Sasaki, T; Tada, H; Teramukai, S; Yanagihara, K; Yasuda, H; Yoshimura, K | 1 |
| Goto, K; Kim, YH; Kubota, K; Nagano, T; Naito, Y; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Borgmeier, A; Bramlage, P; Debus, J; Flentje, M; Huber, RM; Manegold, C; Schmidt, M; Willner, J | 1 |
| Choi, DR; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, JH; Kwon, JH; Lee, JA; Park, YI; Shin, HC; Song, HH; Zang, DY | 1 |
| Gridelli, C; Pallis, AG | 1 |
| Awad, M; Dakhil, S; Harbison, CT; Hart, LL; Hermann, RC; Horak, CE; Khambata-Ford, S; Lynch, TJ; Weber, MR; Xu, LA | 1 |
| Dakhil, S; Dreisbach, L; Gorton, S; Heim, WJ; Hermann, RC; Iannotti, NO; Lynch, TJ; McCleod, M; Paschold, E; Patel, T; Pautret, V; Weber, MR; Woytowitz, D | 1 |
| Au, JL; Bekaii-Saab, T; Chen, L; Grever, M; Guillaume Wientjes, M; Jensen, RR; Lam, ET; Li, X; Murgo, AJ; Otterson, GA; Shen, T; Villalona-Calero, MA; Wei, Y | 1 |
| Arellano, J; Asukai, Y; Camps, C; Cassinello, A; Dilla, T; Sacristán, JA; Taipale, K; Valladares, A; Wood, E | 1 |
| Buonerba, C; Carteni', G; Di Lorenzo, G; Di Napoli, M; Monaco, G; Monaco, R; Riccardi, F; Rizzo, M; Scagliarini, S; Scognamiglio, F | 1 |
| Ahn, JS; Ahn, MJ; Kang, JH; Kim, JH; Kim, SW; Lee, DH; Lee, JS; Park, K; Shin, SW; Suh, C | 1 |
| Aamdal, S; Andersen, A; Brunsvig, PF; Børresen-Dale, AL; Edvardsen, H; Kristensen, VN; Olsen, H; Solvang, H; Syvanen, AC; Tsalenko, A; Yakhini, Z | 1 |
| Dong, X; English, JC; Evans, K; Flint, J; Gout, PW; Guan, J; Lam, S; Lam, WL; Laskin, J; Ling, V; Macaulay, C; Murray, N; Ng, RT; Wang, Y; Yee, J | 1 |
| Huang, XE; Jiang, W; Li, C; Lin, Y; Shi, MQ; Shu, YQ; Sunh, WL; Ye, Z; Zhang, Q; Zhou, JN | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Fossella, FV; Gladish, G; Hong, WK; Kies, MS; Kim, ES; Lee, JJ; Lippman, SM; Liu, DD; Tse, WH; William, WN | 1 |
| Barriger, RB; Fakiris, AJ; Hanna, N; Mantravadi, P; McGarry, RC; Yu, M | 1 |
| Cooper, J; Eaby, B; Evans, T; Kaiser, L; Kucharczuk, J; Langer, C; Rengan, R; Shrager, J; Stevenson, J; Weiss, J | 1 |
| Han, M; Liu, Q; Yu, J; Zheng, S | 1 |
| Borrill, J; Edwards, SJ | 1 |
| Bennouna, J; Biesma, B; Delgado, FM; Douillard, JY; Garrido, P; Hansen, O; Jassem, J; Krzakowski, M; Quoix, E; Ramlau, R; Salhi, Y; Santoro, A; Sun, X; Szczesna, A; Tan, EH; Vaissiere, N; Von Pawel, J; Zatloukal, P | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Bastos, BR; Gomez, J; Hatoum, GF; Lopes, G; Raez, LE; Santos, ES; Takita, C; Tolba, K; Walker, GR | 1 |
| Ellerton, JA; Gettinger, SN; Hicks, W; Murren, JR; Otterson, GA; Pan, X; Villalona-Calero, MA | 1 |
| Barlési, F; Baudrin, L; Bréchot, JM; Debieuvre, D; Gounant, V; Lebeau, B; Milleron, B; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Hsu, WH; Hung, JJ; Jeng, WJ; Liu, JS; Wu, YC | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Inhorn, RC; Lane, CM; Reeves, J; Rubinsak, J; Spigel, DR; Thompson, DS; Vazquez, ER; Webb, C | 1 |
| Fukuoka, M; Itoh, Y; Jiang, H; Negoro, S; Nishiwaki, Y; Saijo, N; Yamamoto, N | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Green, J; Greenhalgh, J; McLeod, C; Pearson, M; Tudur Smith, C | 1 |
| Harita, S; Hiraki, A; Hiraki, S; Hotta, K; Kamei, H; Kanazawa, S; Kiura, K; Matsuo, K; Nogami, N; Segawa, Y; Shibayama, T; Sugimoto, K; Tabata, M; Takata, I; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y; Yonei, T | 1 |
| Bergström, S; Brodin, O; Ekberg, L; Ewers, SB; Hallqvist, A; Holmberg, E; Lödén, B; Nilsson, K; Nyman, J; Rylander, H; Sederholm, C; Wagenius, G; Wichardt-Johansson, G | 1 |
| Andersson, K; Hillerdal, G; Sederholm, C | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Oki, Y; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Egorin, MJ; Fu, H; Harvey, RD; Kauh, J; Khuri, FR; Owonikoko, TK; Ramalingam, SS; Saba, N; Shin, DM; Strychor, S; Sun, SY; Tighiouart, M | 1 |
| Biesma, B; Eberhardt, WE; Germonpré, P; Herbst, RS; Heymach, JV; Ichinose, Y; Johnson, BE; Kabbinavar, F; Kennedy, SJ; Langmuir, P; Li, L; Qin, S; Saijo, N; Sun, Y; Tada, H; Wang, J; Zhang, L; Zhou, C | 1 |
| Azevedo, F; Baudrier, T; Duarte, AF; Ferreira, O; Mota, A | 1 |
| Govindan, R; Stinchcombe, TE | 1 |
| Aoe, K; Hayashi, H; Hotta, K; Kawai, H; Kiura, K; Maeda, T; Matsuo, K; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Socinski, MA; Stinchcombe, TE | 2 |
| Eaton, KD; Martins, RG | 1 |
| Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC | 1 |
| Akyol, F; Bakker, J; Cardenal, F; De Neve, W; Dupont, JM; Ricardi, U; Scagliotti, GV; Senan, S; Stigt, J; van Meerbeeck, JP; Vansteenkiste, J | 1 |
| Anderson, J; Chen, Y; Feins, RH; Hyrien, O; Johnstone, DW; Keng, PC; Pandya, KJ; Qazi, R; Smith, B; Smudzin, T; Watson, TJ | 1 |
| Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E | 1 |
| Ambrosio, R; Barbato, V; Bareschino, MA; Falanga, M; Gridelli, C; Maione, P; Rossi, A; Sacco, PC; Schettino, C | 1 |
| Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Shirane, M | 1 |
| Cao, YX; Fan, L; Jiang, T; Li, C; Mei, QB; Qu, Y; Zhang, F; Zhang, T | 1 |
| Aita, M; Cappuzzo, F; de Marinis, F; Douillard, JY; Gridelli, C; Grossi, F; Kubota, K | 1 |
| El Sharouni, SY; Groen, HJ; Herder, GJ; Maas, KW; Paul, MA; Phernambucq, EC; Schramel, FM; Senan, S; Smit, EF; Stigt, JA; Van Den Borne, BE | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Abe, Y; Inoue, H; Izumi, M; Matsumoto, K; Nakanishi, Y; Takayama, K; Tanaka, K | 1 |
| Agelaki, S; Georgoulias, V; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Stathopoulos, G; Vamvakas, L; Vardakis, N | 1 |
| He, X; Ru, P; Ruan, Z; Tian, J; Wang, Q; Wang, X; Yang, K | 1 |
| Gemma, A; Inage, S; Ise, Y; Katayama, S; Obayashi, M | 1 |
| Chen, L; Jiao, SC; Li, J; Lv, YL; Shi, Y; Sun, Q; Wang, LX | 1 |
| Agelaki, S; Agelidou, A; Georgoulias, V; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Pallis, AG; Pavlakou, G; Syrigos, K; Varthalitis, I | 1 |
| Chen, ZW; Jian, H; Li, ZM; Lu, S; Song, ZB; Yu, YF; Zhang, YF; Zhou, Z | 1 |
| Belani, CP; Brodowicz, T; Fossella, F; Manegold, C; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K; Vansteenkiste, J; Zielinski, C | 1 |
| Sorscher, S | 1 |
| Berard, H; Bota, S; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Paillotin, D; Robinet, G; Thomas, P; Vergnenegre, A | 1 |
| Georgoulias, V; Kaklamanis, L; Lagoudaki, E; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Tryfonidis, K; Trypaki, M; Tsaroucha, E | 1 |
| Barlesi, F; Berard, H; Chavaillon, JM; Chouabe, S; Descourt, R; Falchero, L; Fournel, P; Geriniere, L; Hureaux, J; Le Caer, H; Lena, H; Monnet, I; Robinet, G; Vergnenegre, A | 1 |
| Allen, A; Hsueh, CT; Huang, CH; Kelly, K; Mayo, M; Smith, H; Tawfik, O; Uypeckcuat, AM; Van Veldhuizen, PJ; Wick, J; Williamson, SK | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Chen, ZW; Gu, LP; Shen, SP | 1 |
| Argiris, A; Belani, CP; Gandara, DR; Gitlitz, B; Koczywas, M; Lara, PN; Lau, DH; Leighl, N; Longmate, J; Mack, PC; Ramalingam, S; Reckamp, K; Shepherd, FA; Wright, JJ | 1 |
| de Marinis, F; Gridelli, C; Rossi, A; Venturino, P | 1 |
| Amir, E; Bradbury, PA; Douillard, JY; Horgan, AM; Kim, ES; Leighl, NB; Ng, R; Shepherd, FA | 1 |
| Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB | 1 |
| Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA | 1 |
| Ashcroft, L; Blackhall, F; Burt, P; Califano, R; Chittalia, A; Faivre-Finn, C; Griffiths, R; Harris, M; Lee, L; Lorigan, P; Taylor, P; Thatcher, N | 1 |
| Li, J; Li, M; Liao, W; Song, L; Wang, L; Wu, J; Xiong, H | 1 |
| Federico, K; Lloyd, GK; Mainwaring, P; Millward, M; Mita, A; Mita, M; Nawrocki, S; Reddinger, N; Spear, MA | 1 |
| Eichelbaum, M; Finnern, HW; Kaiser, R; Shahidi, M; Song, X; Stopfer, P; Varker, H; Wilson, K | 1 |
| Hatakeyama, S; Kinoyama, I; Kita, A; Koutoku, H; Matsuhisa, A; Nakahara, T; Nakano, K; Sasamata, M; Shishido, T; Takeuchi, M; Yamanaka, K | 1 |
| Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalykaki, A; Karampeazis, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Vamvakas, L; Vardakis, N | 1 |
| Belzer, K; Burger, AM; Chen, W; Gadgeel, SM; Hackstock, D; Konski, A; Marquette, L; Patel, BB; Ruckdeschel, JC; Turrisi, A; Valdivieso, M; Wozniak, A | 1 |
| Gemba, K; Horita, N; Hotta, K; Kanazawa, S; Kiura, K; Matsuo, K; Moritaka, T; Nagata, T; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Takeda, H; Takemoto, M; Takigawa, N; Tamaoki, A; Tanimoto, M; Tokuda, Y; Ueoka, H; Watanabe, K | 1 |
| Chung, FT; Fang, YF; Feng, PH; Kuo, CH; Kuo, HP; Lee, KY; Lin, SM; Lin, TY; Lo, YL; Ni, YL; Shieh, MH; Yu, CT | 1 |
| Chen, D; Chen, S; Ning, X; Sun, Z; Wang, Y; Zhang, H; Zhou, J | 1 |
| Jiang, Z; Wang, D; Zhang, L | 1 |
| Blasco, A; Camps, C; Jantus-Lewintre, E; Rosell, R; Sanchez, JJ; Sanmartín, E; Sirera, R; Tarón, M | 1 |
| Aydiner, A; Dilege, S; Kizir, A; Oral, EN; Saglam, EK; Saip, P; Sakallioglu, B; Sen, F; Toker, A; Topuz, E | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Aita, M; Belvedere, O; Dal Bello, MG; Defferrari, C; Fasola, G; Follador, A; Gaiardo, M; Grossi, F; Meduri, S; Merlo, V; Rossetto, C; Sibau, AM | 1 |
| de Monchy, JG; Hiltermann, TJ; Luiting, J; Oude Elberink, JN | 1 |
| Chen, YM; Chou, KT; Fan, WC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Ardizzoia, A; Bertolini, A; Cortesi, E; Fagnani, D; Farina, G; Farris, A; Garassino, MC; Labianca, R; Locatelli, MC; Longo, F; Mancuso, A; Martelli, O; Moscetti, L; Pavese, I; Rulli, E; Scanni, A; Tomirotti, M; Valmadre, G | 1 |
| Wang, L; Xiao, F; Zhang, W; Zheng, J | 1 |
| Ichikawa, A; Kato, S; Kazumoto, T; Kudo, S; Kurimoto, F; Saito, Y; Saitoh, J; Sakai, H; Shibuya, K; Yoshida, D | 1 |
| Qi, WX; Shen, Z; Yao, Y | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Cheng, CY; Cherng, SH; Huang, XY; Liao, FT; Sheu, GT; Wu, MF; Wu, WJ; Yang, TY | 1 |
| Agelidou, A; Chainis, K; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Karampeazis, A; Kentepozidis, N; Pallis, AG; Vamvakas, L; Vardakis, N | 1 |
| Li, X; Lv, M; Ren, S; Wu, F; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
| Dannos, I; Dilana, K; Gkiozos, I; Kotteas, E; Makrilia, N; Saif, MW; Syrigos, KN; Syrigou, E; Tourkantonis, I | 1 |
| Berrocal, A; Blasco, A; Blasco, S; Bremnes, RM; Caballero, C; Camps, C; Del Pozo, N; Iranzo, V; Jantus-Lewintre, E; Rosell, R; Sirera, R; Tarón, M | 1 |
| Aydiner, A; Dilege, S; Eralp, Y; Oral, EN; Saglam, EK; Sen, F; Tas, F; Toker, A | 1 |
| Chen, Y; Hotta, K; Ichihara, E; Kiura, K; Ochi, N; Tabata, M; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D | 1 |
| Das, M; Donington, JS; Eclov, N; Hoang, CD; Kozak, M; Le, QT; Loo, BW; Murphy, J; Wakelee, H; Whyte, RI; Zhou, L | 1 |
| Pan, F; Pan, Y; Tian, J; Zhang, X; Zhang, Y | 1 |
| Barraclough, H; Pavlakis, N; Standfield, L; Van Kooten, M; Weston, AR | 1 |
| Boni, L; Caffo, O; de Marinis, F; Dondi, D; Ferraù, F; Galligioni, E; Gamucci, T; Gebbia, V; Grossi, F; Moscetti, L; Nardi, M; Riccardi, F | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Abe, K; Iwazawa, T; Morita, S; Nakabori, T; Osa, A; Oseto, S; Takimoto, T; Terada, H | 1 |
| Douillard, JY; Jiang, GL; Kim, ES; Li, LY; Liao, ML; Milenkova, T; Sun, Y; Wu, YL | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Blumenschein, GR; Charnsangavej, C; Fossella, FV; Fujimoto, J; Hong, WK; Kies, MS; Lee, JJ; Liu, S; Marom, EM; Papadimitrakopoulou, V; Stewart, DJ; Tran, HT; Tsao, AS; Wistuba, II | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Lara, PN; Lau, D; Li, T; Mack, PC; Perkins, N; Sangha, R | 1 |
| Milleron, B; Quoix, E; Westeel, V; Zalcman, G | 1 |
| Fink, T; Fischer, JR; Griesinger, F; Marseille, A; Salm, T; Wolf, M | 1 |
| Aamdal, S; Brunsvig, PF; Gaudernack, G; Hansen, GL; Kersten, C; Kyte, JA; Møller, M; Nyakas, M; Sundstrøm, S | 1 |
| Abe, K; Iwazawa, T; Morita, S; Nakabori, T; Osa, A; Takimoto, T; Terada, H; Watanabe, A | 1 |
| Carloni, F; Castellani, C; Drudi, F; Lazzari-Agli, L; Sartori, S; Scarpi, E; Tassinari, D; Tombesi, P | 1 |
| Bal, A; Singh, N | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Biesma, B; Dalesio, O; Groen, HJ; Hiltermann, TJ; Hochstenbag, MM; Schramel, FM; Sietsma, H; Smit, HJ; Termeer, A; van den Berg, A; van den Borne, BE; van Putten, JW; Vincent, A | 1 |
| Barraclough, H; Ganju, V; Kim, JH; Lee, DH; Magallanes, M; Martínez-Barrera, L; Orlando, M; Rodrigues-Pereira, J; van Kooten, M; Wang, J | 1 |
| Akiyama, H; Ujiie, H | 1 |
| Cromwell, I; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Deuss, B; Dickgreber, N; Nagel, S; Pabst, S; Roscher, K; Salm, T; Schuette, W; Schumann, C; von Weikersthal, LF | 1 |
| Swartman, B | 1 |
| Bessho, A; Hotta, K; Kamei, H; Kanazawa, S; Katsui, K; Kiura, K; Kozuki, T; Tada, A; Takigawa, N; Tanimoto, M; Tokuda, Y | 1 |
| Cai, JF; Chen, B; Lu, HY; Ma, SL; Su, D; Sun, WY; Wang, Z; Zhang, YP; Zheng, YQ | 1 |
| Forsyth, M; Nadler, E; Reyes, C; Satram-Hoang, S | 1 |
| Dai, X; Guo, R; Hou, Z; Xu, H; Xu, Y; Yin, H; Zhang, Z; Zheng, D; Zheng, Y | 1 |
| Agarwala, A; Ansari, R; Breen, T; Bruetman, D; Einhorn, L; Fisher, W; Govindan, R; Hanna, N; Jalal, SI; Johnson, CS; Melnyk, A; Neubauer, M; Richards, D; Riggs, HD; Yu, M | 1 |
| Cengiz, M; Kotek, A; Ozsahin, M; Parlak, C; Pehlivan, B; Topkan, E; Yuksel, O | 1 |
| Aoyagi, H; Asano, K; Matsuzaki, T; Morishita, T; Naitou, A; Ogawa, R; Terashima, T | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Blackman, RK; Foley, KP; He, S; Koya, K; Liu, Y; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Ye, S; Zhang, C; Zhou, D | 1 |
| Bahce, I; de Boer, MP; Eriksson, J; Greuter, HN; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Postmus, PE; Serné, EH; Smit, EF; Van der Veldt, AA; Verheul, HM; Walraven, M; Windhorst, AD | 1 |
| Cicenas, S; Ciuleanu, T; Gonzalez, EE; Grigorescu, AC; Hillenbach, C; Johannsdottir, HK; Klughammer, B; Miliauskas, S; Stelmakh, L | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Du, Z; Shi, M; Xu, X; Yu, Y | 1 |
| Kaneda, H; Nakagawa, K; Okamoto, I | 1 |
| Jaśkiewicz, P; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
| Date, H; Fujiwara, T; Kiura, K; Miyoshi, S; Oto, T; Takemoto, M; Takigawa, N; Toyooka, S | 1 |
| Endo, M; Kaira, K; Kenmotsu, H; Kondo, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Di Maio, M; Fougeray, R; Gridelli, C; Kowalski, DM; Krzakowski, M | 1 |
| Permsuwan, U; Thongprasert, S; Tinmanee, S | 1 |
| Endo, M; Kaira, K; Miura, S; Morii, S; Murakami, H; Naito, T; Nakamura, Y; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Jin, W; Lou, LG; Xie, CY; Xu, YP | 1 |
| Baudrin, L; Belmont, L; Cadranel, J; Danel, S; Epaud, C; Gounant, V; Lavolé, A; Milleron, B; Rosencher, L; Ruppert, AM | 1 |
| Fang, WS; Tao, JY; Wang, SR; Zhang, SE; Zhao, Y; Zhou, D | 1 |
| Nakanishi, M; Natazuka, T; Yoshida, Y | 1 |
| Hida, N; Ishii, M; Kashizaki, F; Misumi, Y; Okamoto, H; Sato, A; Shimizu, T; Shimokawa, T; Watanabe, K | 1 |
| Fukuoka, M; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Mitsudomi, T; Nishimura, Y; Saka, H; Senba, H; Tada, H | 1 |
| Cardenal, F; Eckmayr, J; Kerber, A; Manegold, C; Schuette, W; Ulsperger, E; Vansteenkiste, J; von Pawel, J; Woll, PJ | 1 |
| Jiao, X; Li, R; Qian, J; Sun, L; Wang, J; Wang, Z | 1 |
| Amoroso, D; Camerini, A; Cappuzzo, F; D'Incecco, A; Fabbri, A; Tibaldi, C; Vasile, E | 1 |
| Choi, EK; Chung, HK; Jeong, SY; Jung, J; Kang, HW; Lee, SW; Park, HJ; Park, SJ; Seo, MH; Song, SY | 1 |
| Botteman, MF; Carter, JA; Ganguli, A; Gao, X; Ray, S; Wiegand, P | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Nakagawa, K; Nakanishi, Y; Okamoto, I; Takeda, M; Yamanaka, T | 1 |
| Alexandris, E; Cao, D; Garon, EB; John, WJ; Perol, M; Yurasov, S | 1 |
| Chen, YZ; Li, PP; Li, ZD; Sun, H; Zhou, N | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Asada, Y; Fujino, S; Inoue, S; Nakano, Y; Ozaki, Y; Sawai, S; Suzumura, Y; Teramoto, K; Tezuka, N | 1 |
| Hata, Y; Homma, S; Isobe, K; Mitsuda, A; Sakaguchi, S; Sakamoto, S; Sano, G; Sato, F; Sato, K; Shibuya, K; Sugino, K; Takagi, K; Takahashi, S; Takai, Y; Terahara, A | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Beculic, H; Dervisevic, S; Imsirovic, B; Mekic-Abazovic, A | 1 |
| Liu, J; Liu, ZL; Wang, H; Wang, ZX | 1 |
| Baldotto, C; Bennouna, J; Ciuleanu, TE; Goksel, T; Gorbunova, V; Le-Guennec, S; Miller, V; Novello, S; Ozguroglu, M; Ramlau, R; Rey, A; Scagliotti, G; Shepherd, FA; Thatcher, N | 1 |
| Date, H; Hotta, K; Kanazawa, S; Katsui, K; Kiura, K; Miyoshi, S; Shien, K; Toyooka, S | 1 |
| Berdah, JF; Bondiau, PY; Castelnau, O; Chamorey, E; De Surmont Salasc, B; Michel, C; Mouroux, J; Otto, J; Pop, D; Poudenx, M; Pourel, N; Tessier, E; Venissac, N | 1 |
| Coxon, A; Kaufman, S; Polverino, A; Saffran, D; Schmidt, J; Starnes, C; Sweet, H; Wang, H; Weishuhn, D; Xu, M; Ziegler, B | 1 |
| Goto, K; Kubota, K; Niho, S; Ohe, Y; Ohmatsu, H; Yoh, K | 1 |
| Goto, K; Horinouchi, H; Mori, K; Noda, K; Sekine, I; Sumi, M; Tamura, T | 1 |
| Adamski, H; Droitcourt, C; Dupuy, A; Le Gall, F; Le Hô, H | 1 |
| Eguchi, K; Hoshi, E; Kasai, T; Kikuchi, K; Kobayashi, K; Komiyama, K; Kotajima, F; Koyama, S; Minezaki, S; Mori, K; Nakayama, M; Sutani, A; Takayanagi, N | 1 |
| Chen, S; Cheng, YL; Gu, B; Li, ST; Ni, YJ | 1 |
| Ding, X; Fan, M; Huang, W; Li, B; Sun, H; Yi, Y; Zhang, J; Zhou, T | 1 |
| Bekaii-Saab, T; Bertino, EM; Diasio, RB; Fernandez, S; Karim, NA; Otterson, GA; Villalona-Calero, MA | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Dong, HX; Ke, HG; Li, J; Liu, JH; Shen, Y; Shen, ZY; Yan, Y; You, QS | 1 |
| Ai, ZH; Guo, JZ; Liu, WC; Wang, Y; Wen, L; Zhao, SH | 1 |
| Han, L; Jiang, GL; Li, K; Liu, XY; Ma, SL; Orlando, M; Qin, SK; Quinlivan, M; Sun, Y; Wu, YL; Yu, SY; Zhang, L; Zhang, XQ; Zhou, CC | 1 |
| Barrios, C; Crinò, L; Franke, FA; Grinsted, L; Jänne, PA; Jeannin, G; Pereira, JR; Shaw, AT; Smith, I; Smith, P; Vansteenkiste, J; Zazulina, V | 1 |
| Boyer, JL; Goldberg, SB; Herbst, RS; Schlessinger, J | 1 |
| Cai, DY; Hua, D; Wu, XH; Zhang, RX | 1 |
| Chen, JH; Chen, KY; Ho, CC; Liao, WY; Shih, JY; Wu, M; Yang, JC; Yu, CJ | 1 |
| Chen, L; Chen, Y; Fang, X; Jiang, X; Ren, Q; Sha, X | 1 |
| Al-Batran, SE; Atmaca, A; Banat, AG; Bernhard, H; Brueck, P; Caca, K; Dingeldein, G; Güner, T; Günther Derigs, H; Jäger, E; Koenigsmann, M; Koepke, A; Kullmann, F; Neuhaus, T; Pauligk, C; Prasnikar, N; Wenzel, T; Werner, D | 1 |
| Bridge, S; Dharamshi, K; Jäkel, A; Johns, A; Modha, R; Plested, M | 1 |
| Agelaki, S; Agelidou, M; Chelis, L; Christophylakis, Ch; Georgoulias, V; Kentepozidis, N; Kotsakis, A; Papakotoulas, P; Samonis, G; Soultati, A; Vamvakas, L; Zafiriou, Z | 1 |
| Chougule, MB; I, T; Patel, AR; Patlolla, R; Singh, M; Wang, G | 1 |
| Gonzalez, T | 1 |
| Khuri, FR | 1 |
| Fossella, FV | 4 |
| Hong, WK | 1 |
| Khuri, FR; Kim, ES | 1 |
| Diepolder, H; Heinemann, V; Kenngotte, S; Stemmler, HJ | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Hortobagyi, GN; Kris, MG | 1 |
| Belani, CP | 7 |
| Green, MR | 2 |
| Bahlitzanakis, N; Froudarakis, M; Koukourakis, GV; Koukourakis, MI; Kyrgias, G; Retalis, G; Romanidis, K | 1 |
| O'Brien, ME; Waters, JS | 1 |
| Ichinose, Y | 1 |
| Popa, IE; Rizvi, NA; Smith, FP; Stewart, K | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Chen, YM; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW | 1 |
| Fukuoka, M; Inoue, A; Kunitoh, H; Mori, K; Nukiwa, T; Saijo, N | 1 |
| Harper, P; Marx, G | 1 |
| Balañá, C; Font, A; Guillot, M; Manzano, JL; Margelí, M; Richardet, M; Rosell, R; Sánchez, JJ; Sánchez, JM | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Depierre, A; Jacoulet, P; Westeel, V | 1 |
| Choma, D; Jacot, W; Pujol, JL; Quantin, X | 1 |
| Terao, I | 1 |
| Georgoulias, VA | 1 |
| Belani, CP; Ramalingam, S | 1 |
| Fossella, FV; Lynch, T; Shepherd, FA | 1 |
| Belani, CP; Langer, C | 1 |
| Choy, H; Gandara, D; Mattson, K; Vokes, EE | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Gridelli, C; Hainsworth, J | 1 |
| Abratt, RP; Krofta, K; Mattson, KV; ten Velde, G | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Ceciarini, F; Correale, P; Fiaschi, AI; Francini, G; Gotti, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Voltolini, L | 1 |
| Du, CW; Li, DR; Lin, W; Lin, Y; Lin, YC; Wu, MY | 1 |
| Dicker, AP; Grant, DS; Williams, TL; Zahaczewsky, M | 1 |
| Postmus, P | 1 |
| Fukushima, M; Furuse, K; Harada, H; Hosoe, S; Iwamoto, Y; Kawahara, M; Komuta, K; Morioka, T; Ohsaki, Y; Origasa, H; Shibata, K | 1 |
| Fujimura, M; Iwasa, K; Kasahara, K; Kimura, H; Myo, S; Nakao, S; Nishi, K; Shibata, K; Shintani, H; Shirasaki, H; Yasuda, U | 1 |
| Filippa, DA; Kris, MG; Krug, LM; Miller, VA; Ng, KK; Venkatraman, E | 1 |
| Curiel, TJ; Hartz, R; Kovitz, K; Mudad, R; Nedzi, LL; Ramsey, M; Weiner, RS; Zakris, EL | 1 |
| Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Bishop, JF; Boyer, MJ; Clarke, S; Goh, BC; Lehnert, M; McNeil, E; Millward, MJ; Rischin, D; Wong, J | 1 |
| Hirai, I; Honda, K; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Berille, J; Bruno, R; Chaikin, P; Hammershaimb, L; Olivares, R; Rhodes, GR; Rigas, JR; Vivier, N | 1 |
| Kalofonos, HP; Kosmas, C; Mylonakis, N; Tsavaris, N | 1 |
| Bunn, PA; Simon, GR | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Araki, T; Ishihara, H; Komiyama, T; Kuriyama, K; Nishikawa, K; Onishi, H; Tanaka, S; Yamaguchi, M | 1 |
| Aoki, Y; Furukawa, T; Haruta, Y; Hayashi, S; Iwanaga, K; Kato, O; Koyanagi, K; Kuroki, S; Nagata, M; Naitoh, K; Soejima, Y; Takahashi, K | 1 |
| Cheewakriangkrai, R; Napapan, S; Thongprasert, S | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohmatsu, H | 1 |
| Betticher, DC; Cerny, T; Egli, F; Furrer, M; Habicht, J; Hansen, E; Honegger, H; Hsu Schmitz, SF; Joss, C; Pless, M; Ris, HB; Roth, AD; Schmid, RA; Spiliopoulos, A; Stahel, R; Stupp, R; Tötsch, M; von Briel, C; Weder, W; Wernli, M | 2 |
| Berman, SM; Choi, NC; Fidias, P; Herbst, RS; Jänne, PA; Johnson, BE; Lucca, J; Lukanich, JM; Lynch, C; Mathisen, DJ; Ostler, P; Skarin, AT; Sugarbaker, DJ; Wirth, LJ | 1 |
| Albain, KS; Bearden, JD; Burris, H; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Gumerlock, P; Kuebler, JP; Lara, PN; Leigh, BR; Livingston, R | 1 |
| Alila, H; Bunn, PA; Chan, DC; Earle, KA; Fetter, J; Hartman, T; Klein-Szanto, AJ; Pamukcu, R; Piazza, G; Thompson, WJ; Whitehead, CM; Xu, S; Zhao, TL | 1 |
| Breathnach, OS; Fujishita, T; Gentler, M; Johnson, BE; Kashii, T; Loda, M; Turner, RE | 1 |
| Belani, CP; Fidias, P; Fossella, F; Gorbounova, V; Kaukel, E; Mattson, KV; Millward, M; Pereira, JR; Pluzanska, A; Ramlau, R; Szczesna, A; von Pawel, J | 2 |
| Chan, V; Guan, Z; Handoyo, P; Ho, JC; Huang, JS; Jusuf, A; Lam, WK; Leong, SS; Li, R; Liao, M; Luna, G; Sun, Y; Tan, EH; Tsang, KW; Wahid, MI; Wang, CH | 1 |
| Alberola, V; Felip, E; Massuti, B; Rosell, R; Taron, M | 1 |
| Scagliotti, GV; Turrisi, AT | 1 |
| Bessho, A; Eguchi, K; Harada, M; Harita, S; Hiraki, S; Hiraki, Y; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Kodama, T; Kubota, K; Kunitoh, H; Nakamura, Y; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Estephan, FF; Jones, DV; Lin, JT; Spell, DW | 1 |
| Busby, E; Carey, DE; Marques, MB; Reynolds, RE; Robert, F | 1 |
| Corral, N; Esteban, E; Estrada, E; Fernández, JL; Fernández, Y; Fra, J; González de Sande, L; Lacave, AJ; Muñiz, I; Palacio, I; Vieitez, JM | 1 |
| Chun, JH; Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Shin, EH; Yoon, SM | 1 |
| Abad, A; Barnadas, A; Font, A; Manzano, JL; Margelí, M; Martinez-Balibrea, E; Richardet, M; Rosell, R; Sánchez, JJ; Sánchez, JM; Tarón, M | 1 |
| Barton, JH; Bradof, JE; Erland, JB; Greco, EA; Hainsworth, JD; Stagg, MP; Thompson, DS; Twele, TW | 1 |
| Spiridonidis, CH | 1 |
| Demoly, P; Messaad, D; Pujol, JL; Sablayrolles, P | 1 |
| Im, YH; Jung, CW; Kang, WK; Kim, HJ; Kim, K; Kim, WS; Kwon, OJ; Lee, HG; Park, CH; Park, K; Rhee, CH; Song, SY | 1 |
| Asano, K; Fukunaga, K; Hasegawa, N; Nakamura, H; Oyamada, Y; Watanabe, H; Yamaguchi, K | 1 |
| Brechot, JM; Breton, JL; Clouet, P; Debieuvre, D; Depierre, A; Ducolone, A; Lebeau, B; Lemarie, E; Milleron, B; Moro-Sibilot, D; Pujol, JL; Quoix, E; Vaylet, F; Vergnenegre, A; Zalcman, G | 1 |
| Aono, H; Goto, K; Kakinuma, R; Kubota, K; Kunitoh, H; Niho, S; Nishiwaki, Y; Nokihara, H; Ohe, Y; Ohmatsu, H; Saijo, N; Tango, M; Watanabe, K; Yokoyama, A | 1 |
| Senan, S | 1 |
| Ariyoshi, Y; Fukuoka, M; Hoso, T; Katakami, N; Kawahara, M; Kudoh, S; Matsui, K; Nakagawa, K; Nakano, T; Negoro, SI; Saito, H; Senba, H; Sugiura, T; Takada, Y; Yamamoto, N | 1 |
| Manegold, C | 5 |
| Betticher, DC | 2 |
| Ichinose, Y; Isobe, T; Katakami, N; Kawahara, M; Kubota, K; Kudo, S; Kunitoh, H; Matsui, K; Niitani, H; Nishiwaki, Y; Noda, K; Ohashi, Y; Segawa, Y; Shibuya, M; Sugiura, T; Watanabe, K; Yokota, S; Yokoyama, A; Yoneda, S | 1 |
| Anderson, N; Coco, F; Lokich, J | 1 |
| Dancey, J; Gralla, RJ; Kim, YS; Shepherd, FA | 1 |
| Kazumoto, T; Kobayashi, K; Komagata, H; Kosaihira, S; Saito, Y; Sakai, H; Yoneda, S | 1 |
| Atalar, B; Dinçbas, FO; Koca, S | 1 |
| Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
| Doroshow, JH; Gandara, DR; Gandour-Edwards, R; Gumerlock, PH; Laptalo, L; Lara, PN; Lau, DH; Longmate, J | 1 |
| Aoe, M; Date, H; Fujiwara, T; Hiraki, Y; Katayama, H; Kiura, K; Kozuki, T; Shimizu, N; Tabata, M; Takemoto, M; Tanaka, N; Tanimoto, M; Ueoka, H | 1 |
| Crawford, J; Govindan, R; Green, MR; Herndon, JE; King, GW; Rizvi, NA; Rocha Lima, CM; Zhang, C | 1 |
| Guillén Grima, F; Peñuelas Sánchez, I; Sánchez Lerma, B | 1 |
| Griesinger, F; Haase, D; Metz, M; Schulz, T; Trümper, L | 1 |
| Cardaci, V; Cesario, A; D'Angelillo, RM; Galetta, D; Granone, P; Margaritora, S; Porziella, V; Russo, P; Sterzi, S; Trodella, L | 1 |
| Hanna, NH | 1 |
| Bunn, PA; De Marinis, F; Desch, C; Einhorn, L; Fossella, FV; Gatzemeier, U; Gervais, R; Hanna, N; Lim, HL; Manegold, C; Muller, T; Paoletti, P; Paul, S; Pereira, JR; Pless, M; Shepherd, FA; Szondy, K; Tsao, TC; von Pawel, J | 1 |
| Israel, V; Jeffers, S; Raghavan, D; Snyder, T; Tagawa, ST | 1 |
| Fujimoto, K; Hayasaka, M; Hirai, K; Koizumi, T; Koyama, S; Kubo, K; Takabayashi, Y; Tsunoda, T | 1 |
| Fujiwara, K; Gemba, K; Hiraki, S; Kishino, D; Kiura, K; Kozuki, T; Segawa, Y; Seki, N; Shinkai, T; Tabata, M; Takigawa, N; Tanimoto, M; Tokuda, Y; Ueoka, H; Watanabe, Y | 1 |
| Belani, CP; Bonomi, P; Cascino, M; Dobbs, TW; Einzig, AI; Ramalingam, S; Wojtowicz-Praga, S | 1 |
| Agelaki, S; Bozionelou, V; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Souglakos, J; Voloudaki, A | 1 |
| D'Amato, G; Haura, EB; Mahany, JJ; Muro-Cacho, C; Rocha Lima, C | 1 |
| Rigas, JR | 4 |
| Ashley, S; Harper-Wynne, C; Norton, A; O'Brien, M; Popat, S; Sumpter, K; Yeoh, C | 1 |
| Alonso, G; Amenedo, M; Curiel, T; Fírvida, JL; Grande, C; Huidobro, G; Lázaro, M; Mel, JR; Ramos, M; Vázquez, S | 1 |
| Le Cesne, A; Le Guen, Y | 1 |
| Gemba, K; Harita, S; Kamei, H; Kiura, K; Nogami, N; Segawa, Y; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Raez, LE; Reis, IM; Rosado, MF; Santos, ES | 1 |
| Ayers, D; Chi, KN; Chia, S; Cripps, C; Fry, D; Gelmon, KA; Huan, S; Janke, S; McIntosh, L; Seymour, LK; Shabbits, JA; Stewart, D; Walsh, W | 1 |
| Bose, U; Dunlop, D; Hemmett, L; Holmes, J; Sharplin, P | 1 |
| Agelidou, A; Agelidou, M; Alegakis, A; Ardavanis, A; Chandrinos, V; Christofilakis, C; Georgoulias, V; Kouroussis, C; Papakotoulas, P; Polyzos, A; Samaras, N; Syrigos, K; Toumbis, M; Tsaroucha, E; Ziras, N | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| Boezen, HM; Groen, HJ; van Putten, JW; Wachters, FM | 1 |
| Goto, K; Hanada, K; Kakinuma, R; Kubota, K; Minami, H; Niho, S; Nishiwaki, Y; Nokihara, H; Ogata, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I | 1 |
| Cheng, ZW; Zhang, L | 1 |
| Alonso, G; Artal, A; Barneto, I; Botia, M; Camps, C; Domine, M; Isla, D; Lianes, P; Lopez-Brea, M; Lopez-Vivanco, G; Medina, B; Nuñez, L; Paredes, A; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Sarries, C; Taron, M | 1 |
| Barron, S; Boyle, M; Diethelm, L; Fariss, A; Harrison, L; Salazar, OM; Schwarzenberger, P; Theodossiou, C; Wynn, RB | 1 |
| Amenedo, M; Firvida, JL; González, A; Losada, G; Ramos, M; Rodríguez, R; Salgado, M | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Lin, DX; Miao, XP; Tan, W; Wang, ZH; Xu, BH; Zhang, XR | 1 |
| Barón, MG; Belón, J; Casado, E; De Castro, J; Dorta, J; Feliu, J; Gallurt, PM; Lizón, J; Lorenzo, A; Madroñal, C; Morales, S | 1 |
| Cortesi, E; Dauria, G; De Pasquale Ceratti, A; Ferraldeschi, R; Lugini, A; Moscetti, L; Naso, G; Nelli, F; Picone, V; Saltarelli, R | 1 |
| Desjardins, P; Hirsh, V; Laberge, F; Langleben, A; Latreille, J; Samson, B; Whittom, R | 1 |
| Ford, J; Jatoi, A; Jett, JR; Loprinzi, CL; Novotny, P; Prabhakar, U; Sloan, J | 1 |
| Endo, S; Hasegawa, T; Otani, S; Saito, N; Sato, Y; Sohara, Y; Tetsuka, K; Tezuka, Y | 1 |
| Camlica, H; Demir, C; Tas, F; Topuz, E; Ustuner, Z | 1 |
| Jeremic, B; Molls, M; Nieder, C; Zimmermann, F | 1 |
| Souquet, PJ | 1 |
| Breton, JL; Gervais, R; Jacot, W; Pujol, JL; Quantin, X; Rebattu, P | 1 |
| Eguchi, K; Inoue, F; Nakamura, H; Semba, H; Seto, T; Takeda, K; Takezako, Y | 1 |
| Reddy, KG | 1 |
| Barbera, S; Barletta, E; Brancaccio, L; Caffo, O; Capuano, MA; Ceribelli, A; Di Maio, M; Falcone, A; Gallo, C; Gridelli, C; Illiano, A; Isa, L; Maione, P; Mazzanti, P; Palazzolo, G; Perrone, F; Piantedosi, FV; Salvagni, S | 1 |
| Gika, M; Takanami, I; Takeuchi, K | 1 |
| Biesma, B; Groen, HJ; Postmus, PE; Schramel, FM; Smit, EF; Stigt, JA; Wachters, FM | 1 |
| Caillaud, D; Clary, C; Clouet, P; Coudert, B; Couteau, C; D'Arlhac, M; Dabouis, G; Douillard, JY; Gervais, R; Le Groumellec, A; Maury, B; Monnier, A; Mornet, M; Rivière, A; Spaeth, D | 1 |
| Braun, D; Breton, JL; Clouet, P; Debieuvre, D; Ducolone, A; Gervais, R; Lebeau, B; Pujol, JL; Quoix, E; Tredaniel, J; Vaylet, F | 1 |
| Asmar, L; Boehm, KA; Garfield, DH; Khan, M; Kuerfler, PR; Lindquist, DL; Neubauer, MA; Raju, RN; Soo, EW | 1 |
| Amadori, D; Colantonio, I; Frassineti, GL; Ibrahim, T; Monti, M; Tesei, A; Zoli, W | 1 |
| Abe, Y; Abiko, T; Gika, M; Inoue, Y; Kawamura, M; Kobayashi, K; Nakamura, M; Oyama, T; Saitoh, Y; Yamazaki, H | 1 |
| De Marinis, F; De Petris, L | 1 |
| Ishizuka, N; Kodama, T; Kunitoh, H; Murakami, H; Nishio, K; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimizu, M; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N | 1 |
| Economopoulos, T; Farmakis, D; Gaglia, A; Kostopoulou, V; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M; Raptis, SA; Xiros, N | 1 |
| Akita, H | 1 |
| Hennequin, C | 1 |
| Ardizzoni, A; Tiseo, M | 1 |
| Berille, J; Derenne, JP; Gatineau, M; Jauffret, E; Khayat, D; Orcel, B; Rixe, O; Spano, JP; Vannetzel, JM | 1 |
| Dowell, J; Kirkpatrick, P; Minna, JD | 1 |
| Douillard, JY; Scagliotti, GV | 1 |
| Betticher, DC; Rosell, R | 1 |
| Belani, CP; Eckardt, J | 1 |
| Bouchaert, E; Daniel, C; Fournel, P; Kleisbauer, JP; Le Caer, H; Léna, H; Letreut, J; Paillotin, D; Pérol, M; Preux, PM; Robinet, G; Vergnenègre, A | 1 |
| Dumontet, C; Sève, P | 1 |
| Agelidou, A; Anagnostopoulou, O; Androulakis, N; Ardavanis, A; Chatzidaki, D; Christou, A; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mixalopoulou, P; Polyzos, A; Samaras, N; Samonis, G; Syrigos, K; Toubis, M; Tsiafaki, X; Ziotopoulos, P | 1 |
| Harita, S; Kikuchi, T; Kuyama, S; Mizuta, A | 1 |
| Braun, D; Breton, JL; Castéra, D; Clary, C; Debieuvre, D; Depierre, A; Gervais, R; Janicot, H; Kessler, R; Lemarié, E; Milleron, B; Morère, JF; Moro-Sibilot, D; Pujol, JL; Quantin, X; Rebattu, P; Souquet, PJ; Spaeth, D | 1 |
| Ishihara, S; Iwasaki, Y; Kaira, K; Minato, K; Mori, M; Saito, R; Sato, K; Takei, Y; Takise, A; Tsuchiya, S | 1 |
| Criswell, T; Diasio, R; Kindwall-Keller, T; Neki, A; Nuovo, G; Otterson, GA; Soong, R; Villalona-Calero, MA; Young, D | 1 |
| Belani, CP; Ramalingam, S; Wakelee, H | 1 |
| Collea, R; Gajra, A; Graziano, S; Levitan, N; Marshall, J; McCann, J; Mertens, WC; Nugent, FW | 1 |
| Ardizzoni, A; Favoni, R; Grossi, F; Loprevite, M; Pandolfi, A; Scolaro, T; Semino, C; Tiseo, M | 1 |
| Fukuoka, M; Furukawa, M; Hirashima, T; Kamoi, H; Kobayashi, M; Kudoh, S; Matsui, K; Mukohara, T; Nakagawa, K; Negoro, S; Nitta, T; Ogata, Y; Shiraishi, S; Takada, M; Takeda, K; Yamauchi, S; Yana, T; Yoshimura, N | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Kuzuya, T; Minami, H; Saka, H; Sakai, S; Shimokata, K; Watanabe, A; Yamamoto, M | 1 |
| Kamiyama, Y; Kano, Y; Kodama, T; Kondo, T; Mori, K | 1 |
| Jirajarus, M; Ratanatharathorn, V; Sirilertrakul, S; Sirisinha, T | 1 |
| Engels, FK; Verweij, J | 1 |
| Barlési, F; Pujol, JL | 1 |
| Han, JY; Hong, EK; Lee, DH; Lee, JS; Lee, SY; Yoon, SM | 1 |
| De Marinis, F; De Petris, L; Gebbia, V | 1 |
| Buchholz, E; Fandi, A; Gatzemeier, U; Manegold, C; Smith, RP | 1 |
| Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Kuhn, JG; Raefsky, EL; Thompson, DS; White, MB; Willcutt, NT | 1 |
| Bang, YJ; Heo, DS; Kim, DW; Kim, DY; Kim, NK; Kim, TY; Lee, KW; Yun, T | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Agata, N; Bamberg, M; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H; Pu, M; Weitman, S | 1 |
| Ueoka, H | 1 |
| Agelidou, A; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Ignatiadis, M; Kentepozidis, N; Mylonaki, E; Vossos, A; Zachariadis, E; Ziotopoulos, P | 1 |
| Aamdal, S; Berg, R; Brunsvig, PF; Hatlevoll, R; Lauvvang, G; Owre, K; Wang, M | 1 |
| Engels, FK; Mathot, RA; Sparreboom, A; Verweij, J | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Haura, E; Rocha-Lima, C; Simon, G; Wagner, H; Williams, C | 1 |
| Horai, T; Matsuda, M; Morikawa, A; Nakagawa, K; Nishio, M; Ohyanagi, F; Okumura, S; Sato, Y; Tabata, D | 1 |
| Au, JL; Lu, Z; Wientjes, TS | 1 |
| Cai, L; Dong, HY; Sui, GJ | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Okamura, Y; Oura, S; Tanino, H; Yoshimasu, T | 1 |
| Ando, S; Iida, T; Kimura, H; Nakajima, T; Suzuki, M | 1 |
| Chang, GC; Chang, JT; Chen, CC; Ko, JL; Lee, H; Liao, HY; Liu, HJ; Sheu, GT; Su, JM | 1 |
| Cao, CW; Gao, Y; Guo, J; Shi, ZQ; Zhu, CL | 1 |
| Argiris, A; Avram, MJ; Kut, V; Luong, L | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Maze, Y; Sato, T; Tenpaku, H | 1 |
| Alexandre, J | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Chu, Q; Evans, WK; Logan, D; Mackay, JA; Vincent, M | 1 |
| Edelman, MJ | 1 |
| Carbone, DP; Csiki, I; Dang, T; Johnson, DH; Morrow, JD; Oates, J; Sandler, A; Shyr, Y; Williams, MK | 1 |
| Allen, BJ; Beall, CL; Fridman, M; Geils, GF; Page, RD; Smith, FP | 1 |
| Lee, D | 1 |
| Kuramoto, K; Terao, I | 1 |
| Azzoli, CG; Crapanzano, J; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Patel, J; Pizzo, B; Ross, JS; Sheehan, C; Tyson, L; Venkatraman, E | 1 |
| Dimitrakopoulos, A; Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Polyzos, A; Spyropoulos, K; Tsavaris, N; Tzelepis, G | 1 |
| Belani, CP; Fossella, F | 1 |
| Hanna, N | 2 |
| Blankenburg, T; Dittrich, I; Hans, K; Lautenschlaeger, C; Nagel, S; Raghavachar, A; Reissig, A; Schmidt, EW; Schuette, W; Schweisfurth, H; Serke, M; von Weikersthal, LF | 1 |
| Chen, YM; Chiu, CH; Lai, CL; Perng, RP; Su, WJ; Tsai, CM; Wang, GS | 1 |
| Arquette, MA; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Lim, WT; Mortimer, JE | 1 |
| Dornof, W; Gatzemeier, U; Gosse, H; Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Romer, KS | 1 |
| Almenar, D; Batista, N; Blanco, R; Blasco, A; Camps, C; Carrato, A; Diz, P; Felip, E; Galán, A; Girón, CG; Gómez, RG; González, JL; Isla, D; Jiménez, A; López, M; Maestu, I; Massuti, B; Provencio, M; Rosell, R; Viñolas, N | 1 |
| Johnson, ED; Kim, ES | 1 |
| Govindan, R; Pillot, G | 1 |
| Albain, KS; Crowley, JJ; Gandara, DR; Gaspar, LE; Gumerlock, PH; Herbst, RS; Kelly, K; Lara, PN; Mack, P; Vallières, E | 1 |
| Ramalingam, S | 1 |
| Fujimura, M; Inoue, K; Isobe, K; Komagata, H; Sakai, H; Shirai, T; Tabei, T; Yoneda, S | 1 |
| Fukuoka, M; Matsui, K; Nakagawa, K; Nishimura, Y; Yamamoto, N | 1 |
| Chang, JW; Chen, CH; Lee, CH; Tsao, TC | 1 |
| de Marinis, F; De Petris, L; De Santis, S | 2 |
| Endo, Y; Fujiwara, T; Hioki, M; Ikeda, Y; Kagawa, S; Kishimoto, H; Sakai, R; Tanaka, N; Urata, Y | 1 |
| Adami, G; Belvedere, O; Ceschia, T; Fasola, G; Grossi, F; Meduri, S; Recchia, L; Rizzato, S; Rossetto, C; Sacco, C; Sibau, A; Spizzo, R; Tumolo, S; Vigevani, E | 1 |
| Chatterjee, A; Fulzele, SV; Shaik, MS; Singh, M | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Cufer, T; Erensoy, I; Gaafar, R; Pemberton, K; Vrdoljak, E | 1 |
| Belda, C; Casado, E; Castro, J; Feliu, J; Galán, A; Gonzalez-Barón, M; Lomas, M; Madroñal, C; Martín, G; Rodriguez-Jaráiz, A; Sundlov, A | 1 |
| Altavilla, G; Catot, S; Cobo, M; Etxaniz, O; Isla, D; Moran, T; Rosell, R; Sanchez, JM; Santarpia, M; Taron, M | 1 |
| Arimoto, T; Hara, H; Harada, H; Hosogi, S; Iwasaki, Y; Kohno, K; Marunaka, Y; Nakanishi, M; Natsuhara, A; Nishimura, T; Ohsugi, S; Takesako, T; Tsubokura, T; Ueda, M; Yamada, T | 1 |
| Charoentum, C; Chewaskulyong, B; Munprakan, S; Soorraritchingchai, S; Thongprasert, S | 1 |
| Anderson, H; Ashcroft, L; Baka, S; Booton, R; Dark, G; Dunlop, D; Laurence, V; Lorigan, P; Nicolson, M; O'Brien, M; O'Byrne, K; Snee, M; Thatcher, N | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 3 |
| Gotou, T; Kawashima, S; Kawashima, T; Kikkawa, K; Kuroda, T; Matsuzawa, Y; Nishi, Y; Shirai, K; Tanabe, M | 1 |
| Asmar, L; Brooker, R; Conkling, P; Ilegbodu, D; Lindquist, D; Sandbach, J; Vellek, M; Weissman, CH | 1 |
| Bakri, K; Bůzková, P; Choksi, J; Gillenwater, H; Jones, PE; Mears, A; Socinski, MA; Stinchcombe, TE; Taylor, M; Tynan, M | 1 |
| Cardenal, F; Debus, J; Lebeau, B; Manegold, C; Mattson, K; Price, A; Ramlau, R; Scagliotti, GV; Szczesna, A; Van Zandwijk, N | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Andritzky, B; Bokemeyer, C; Brandl, S; Goern, M; Laack, E; Schuch, G; Thoem, I | 1 |
| Abratt, RP; Dane, G; Dharan, B; Gervais, R; Grotzinger, KM; Kaukel, E; Krzakowski, M; Ramlau, R; Ross, G; Shepherd, FA; von Pawel, J | 1 |
| Fournel, P | 1 |
| Soria, JC | 1 |
| Biesma, B; Giaccone, G; Legrand, C; Manegold, C; Passioukov, A; Smit, HJ; van Meerbeeck, JP; Willems, L | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Carrato Mena, A; Gallego Plazas, J; Guillén Ponce, C; Maciá Escalante, S; Martínez Ortiz, MJ; Rodríguez Lescure, A | 1 |
| Ramalingam, S; Sandler, AB | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Bernardini, I; Chella, A; Falcone, A; Malventi, M; Russo, F; Tibaldi, C; Vasile, E | 1 |
| Favaretto, AG | 1 |
| Farfan, N; Hamilton-Nelson, K; Lopes, G; Negret, LM; Raez, LE; Rocha-Lima, C; Roman, E; Rosado, MF; Santos, ES; Silva, O; Tolba, K | 1 |
| Chen, Q; Chen, ZY; Chu, DT; Han, FC; Li, JL; Li, LY; Lin, YC; Liu, JW; Nan, KJ; Song, SP; Wang, YD; Zhang, XR; Zheng, YH; Zhu, YZ | 1 |
| Ando, M; Fukuoka, M; Goto, I; Katakami, N; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Satoh, T; Sawa, T; Semba, H; Seto, T; Shinkai, T; Takada, M; Takeda, K; Yoshimura, N | 1 |
| Atagi, S | 1 |
| Chatterjee, A; Fulzele, SV; Jackson, T; Shaik, MS; Singh, M | 1 |
| Katakami, N | 1 |
| Bria, E; Ciccarese, M; Cognetti, F; Cuppone, F; Facciolo, F; Giannarelli, D; Izzo, F; Milella, M; Nisticò, C; Terzoli, E | 1 |
| Baron, AD; Drachman, JG; Figlin, RA; Grove, LE; Hart, LL; Jacobs, AD; McCune, DE; Miller, DM; Rarick, MU; Rosenberg, AH; Ross, HJ; Rudin, CM; Swanson, PM; Thorn, MD | 1 |
| Cecere, F; Cuello, M; Felip, E; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| Czejka, M; Hilbe, W; Hochegger, K; Lhotta, K; Mayer, G | 1 |
| Cao, Y; Feng, FY; Guan, ZZ; Guo, Y; Hu, XH; Tang, GD; Wang, ZQ; Xiong, JP; Zhang, L | 1 |
| Buchholz, S; Datz, C; Halmos, G; Heinrich, E; Hohla, F; Kanashiro, CA; Kannadka, C; Köster, F; Rick, FG; Schally, AV; Szepeshazi, K; Varga, JL | 1 |
| Bunn, PA; Einhorn, LH; Hanna, N; Kelly, K; Langer, C; McAndrews, P; Nguyen, B; Paul, S; Rosell, R; Shepherd, F; Weiss, GJ | 1 |
| Gemba, K; Harita, S; Hiraki, S; Kishino, D; Kiura, K; Kozuki, T; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Tada, S; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Albain, KS; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Kelly, K; Lara, PN; Livingston, R | 1 |
| Gemba, K; Hiraki, S; Kamei, H; Kanazawa, S; Kiura, K; Matsuo, K; Moritaka, T; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y; Yonei, T | 1 |
| Beinert, T; Binder, D; Grah, C; Schäper, C; Schweisfurth, H; Siebert, G; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Chun, JH; Han, JY; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Yoon, SM | 1 |
| Agelaki, S; Argiraki, A; Christofillakis, Ch; Georgoulias, V; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Souglakos, J; Tselepatiotis, E; Vamvakas, L; Vardakis, N | 1 |
| Altorki, NK; Bonomi, P; Fayyad, R; Hariharan, S; Hart, LL; Keresztes, RS; Lilenbaum, R; Morrison, ME; Socinski, MA | 1 |
| Alcalde García, J; Alés Díaz, I; Benavides Orgaz, M; Bretón García, JJ; Carabantes Ocón, F; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Montesa Pino, A; Villar Chamorro, E | 1 |
| Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S | 1 |
| Lester, JF; Macbeth, FR | 1 |
| Ameshima, S; Chiba, Y; Demura, Y; Ishizaki, T; Miyamori, I; Nakanishi, M; Umeda, Y | 1 |
| Adamecz, Z; Brugós, L; Dolinay, T; Horváth, A; Kiss, M; Kiss, SS; Lengyel, L; Szántó, J; Szilasi, M | 1 |
| Aitini, E; Bajetta, E; Bidoli, P; Cortinovis, D; Cullurà, D; Formisano, B; Isa, L; Mancin, M; Mariani, L; Nova, P; Pari, F; Zilembo, N | 1 |
| Berghmans, T; Paesmans, M; Sculier, JP | 1 |
| Adachi, Y; Bandobashi, K; Ikezoe, T; Kobayashi, M; Koeffler, HP; Nishioka, C; Taguchi, H; Takeuchi, S; Takeuchi, T; Yang, Y | 1 |
| Eguchi, K; Hada, E; Izumi, Y; Kawamura, M; Kobayashi, K; Koike, T; Sakaguchi, H; Yamato, Y | 1 |
| Chatterjee, A; Fulzele, SV; Ichite, N; Jackson, T; Shaik, MS; Singh, M | 1 |
| Fujimoto, K; Koizumi, T; Komatsu, Y; Kubo, K; Saegusa, T; Urushihata, K; Yasuo, M | 1 |
| An, CH; Cho, EK; Choi, SJ; Hoon Lee, J; Jeong, SH; Kyung, SY; Lee, SP; Park, JW; Park, SH; Shin, DB | 1 |
| Fenk, R; Garcia-Pardillos, G; Haas, R; Kronenwett, R; Meier, A; Neukirchen, J; Rohr, UP; Rohrbeck, A; Steidl, U | 1 |
| Caterino, M; Cecere, FL; Ceribelli, A; Cognetti, F; Facciolo, F; Gelibter, AJ; Milella, M; Mirri, A; Pino, MS | 1 |
| d'Amato, TA; Huang, W; Landreneau, RJ; Luketich, JD; Mechetner, E; Parker, R; Ricketts, W; Yu, IR | 1 |
| Amenedo, M; Antón, LM; Casal, J; Castellanos, J; Constenla, M; González-Ageitos, A; López-López, R; Mel, JR; Rodríguez-López, R; Tisaire, JL | 1 |
| Adachi, M; Ando, K; Hirose, T; Hosaka, T; Ishida, H; Kusumoto, S; Nakashima, M; Ohmori, T; Shirai, T; Sugiyama, T | 1 |
| Alcaide, J; Alés, I; Benavides, M; Bretón, JJ; Carabantes, F; Cobo, M; Durán, G; Gil, S; Gutiérrez, V; Martínez, J; Villar, E | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Mori, M; Saito, R; Sunaga, N; Tsuchiya, S; Watanabe, S; Yanagitani, N | 1 |
| Akcali, U; Evrensel, T; Kanat, O; Keskin, K; Kurt, E; Manavoglu, O | 1 |
| Adelstein, D; Davis, M; Kalmadi, S; McNeill, G; Mekhail, T; Peereboom, D | 1 |
| Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Scott-von-Römer, K | 1 |
| Astoul, P; Auquier, P; Barlési, F; Barrau, K; Doddoli, C; Morange, S; Thirion, X; Thomas, P | 1 |
| Barata, F; Bunn, PA; Fossella, F; Hanna, N; Kelly, K; McAndrews, P; Nguyen, B; Paul, S; Perry, M; Rosell, R; Stahel, R; Weiss, GJ | 1 |
| Bassi, R; Hadari, YR; Hicklin, DJ; Joynes, C; Steiner, P; Tonra, JR; Wang, S | 1 |
| Ono, A; Yamamoto, N | 1 |
| Golemis, EA; Khazak, V; Menon, S; Skobeleva, N; Weber, L | 1 |
| Abou-Jawde, RM; Malani, AK; Singh, J; Taylor, SA | 1 |
| Jung, CS; Khuri, FR; Sun, SY; Zhou, Z | 1 |
| Auliac, JB; Barlesi, F; Bombaron, P; Chouaid, C; Crequit, J; Falchero, L; Fournel, P; Geriniere, L; LeCaer, H; Robinet, G | 1 |
| Beaumont, J; Boros, L; Chidiac, T; Dowlati, A; Du, H; Graham, P; Lilenbaum, R; Rubin, M; Samuel, J; Seigel, L | 1 |
| Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D | 1 |
| Bessho, A; Isobe, H; Katakami, N; Niitani, H; Takiguchi, Y; Yoshimori, K; Yoshimura, A | 1 |
| Chansky, K; Chapman, RA; Crowley, JJ; Doroshow, JH; Gandara, DR; Goodwin, JW; Gross, HM; Hesketh, PJ; Lau, DH; Moinpour, CM | 1 |
| Bedano, PM; Hanna, NH | 1 |
| Ishikura, S; Mori, K; Nishiwaki, Y; Nokihara, H; Saijo, N; Sekine, I; Sumi, M; Tamura, T; Tsukiyama, I | 1 |
| Hasegawa, Y; Inoue, A; Ishida, T; Ishimoto, O; Koinumaru, S; Miki, H; Munakata, M; Nukiwa, T; Saijo, Y; Sugawara, S; Suzuki, T | 1 |
| Ellis, PM; Evans, WK; Mackay, JA; Noble, J | 1 |
| Bessho, A; Fujimoto, N; Fujiwara, K; Gemba, K; Hotta, K; Kiura, K; Kuyama, S; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Takata, I; Takigawa, N; Tanimoto, M; Tokuda, Y; Ueoka, H | 1 |
| Blackstock, AW; Capellari, J; Knight, SN; Lovato, J; Miller, AA; Miller, MS; Mosley, L; Petty, WJ; Tucker, R | 1 |
| Foo, KF; Ho, J; Leong, SS; Lim, WT; Lin, X; Poon, D; Tan, EH; Tan, SB; Tay, MH; Toh, CK | 1 |
| Camps, C; Chiodini, P; Di Maio, M; Gallo, C; Gridelli, C; Perrone, F; Quoix, E; Schuette, W; Tsai, CM | 1 |
| Gridelli, C; Maione, P; Rossi, A | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Berry, DA; Chouaki, N; Moore, P; Paul, S; Peterson, P; Pujol, JL; Salzberg, M | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Hanna, WT; Hubner, KF; Long, MJ; Nahmias, C; Townsend, DW; Wahl, LM | 1 |
| Horn, L; Leighl, NB; Visbal, A | 1 |
| Li, QY; Ma, SL; Yu, XM; Zhu, LM | 1 |
| Chansky, K; Chapman, RA; Crowley, JJ; Dowlati, A; Gandara, DR; Graham, P; Hesketh, PJ; Lilenbaum, RC | 1 |
| Cicin, I; Disci, R; Duranyildiz, D; Selam, M; Soydinc, HO; Tas, F; Topuz, E; Uygun, K; Yasasever, V | 1 |
| Geick, A; Losert, D; Müller, M; Pratscher, B; Soutschek, J; Vornlocher, HP; Wacheck, V | 1 |
| An, CH; Bang, SM; Cho, EK; Choi, SJ; Hong, J; Jeong, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, KC; Lee, SH; Lee, SP; Nam, E; Park, JW; Park, SH; Shin, DB | 1 |
| Scagliotti, G | 1 |
| Azzoli, CG; Coleman, B; Dunne, M; Farmer, A; Kris, MG; Krug, LM; Lastinger, L; Miller, VA; Moore, E; Pizzo, B; Rizvi, NA; Rudin, CM; Seeger, T; Tyson, L; Venkatraman, E | 1 |
| Chouaid, C; Fournel, P; Gimenez, C; Jullian, H; LeCaer, H; Letreut, J; Paillotin, D; Perol, M; Thomas, P; Vergnenegre, A | 1 |
| Abe, M; Hamada, H; Higaki, J; Irifune, K; Ito, R; Kadowaki, T; Katayama, H; Nishimura, K; Sakai, K; Shiode, M | 1 |
| Kim, CH; Kim, HS; Kim, JH; Kim, KJ; Lee, KY; Sung, CW | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Dewhirst, MW; Ponce, AM; Rabbani, Z; Salahuddin, FK; Spasojevic, I; Vlahovic, G; Vujaskovic, Z; Zgonjanin, L | 1 |
| Bréchot, JM; Morère, JF; Pailler, M | 1 |
| Glisson, BS; Karp, DD; Oh, YW; Phan, SC; Stewart, DJ; William, WN; Zinner, RG | 1 |
| Chen, YM; Chou, KT; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kotsakis, A; Mavroudis, D; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Chak, K; Chan, AT; Chan, G; Ho, S; Ho, WM; Lam, KC; Lee, Y; Mok, TS; Wong, H; Yeo, W; Yim, AP | 1 |
| Buesa, JM; Capelan, M; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Jiménez, P; Jiménez-Lacave, A; Llorente, B; Luque, M; Muñiz, I; Vieitez, JM; Villanueva, N | 1 |
| Ann Houston, G; Anthony Greco, F; Bearden, JD; Farley, C; Gandhi, J; Hainsworth, JD; Shipley, DL; Spigel, DR | 1 |
| Charpidou, A; Dannos, I; Dilana, K; Dionellis, G; Georgatou, N; Karapanagiotou, E; Rigopoulou, A; Roussos, C; Syrigos, KN | 1 |
| Belani, CP; Bodrogi, I; Csada, E; Gadgeel, S; Herbst, RS; Heymach, JV; Hou, J; Johnson, BE; Kennedy, SJ; Pesek, M; Prager, D; Roubec, J; Spásová, I | 1 |
| Amenedo, M; Casal, J; Fírvida, JL; Grande, C; Huidobro, G; Lázaro, M; León, L; Mel, JR; Ramos, M; Salgado, M; Vázquez, S | 1 |
| Aoe, M; Date, H; Fujii, T; Fujiwara, Y; Hotta, K; Ichimura, K; Kiura, K; Kobayashi, N; Soh, J; Suehisa, H; Toyooka, S; Yoshino, T | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Ashcroft, L; Booton, R; Heighway, J; Morris, J; Thatcher, N; Ward, T | 1 |
| Albert, D; Bunn, PA; Kelly, K; Magree, L; Rusk, J; Vokes, EE; Weiss, GJ | 1 |
| Cucherat, M; Douillard, JY; Fossella, F; Georgoulias, V; Kubota, K; Kudoh, S; Laporte, S; Monnier, A; Pujol, JL; Rubio, JE | 1 |
| Jiang, Z; Ming, J; Yan, W; Yu, Y | 1 |
| Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S | 1 |
| Casal, J; Grande, C; Huidobro, G; Villanueva, MJ | 1 |
| Chen, JP; Hsu, C; Lo, Y; Shih, JY; Yang, CH; Yu, CJ | 1 |
| Hong, YS; Jo, KH; Kang, JH; Kim, YK; Kim, YS; Ko, YH; Lee, KS; Lee, KY; Lee, MA; Park, HJ; Wang, YP; Yoo, IeR | 1 |
| Aguilo, R; Artal, A; Astudillo, J; Barcelo, JR; Cardenal, F; Domine, M; Garrido, P; González-Larriba, JL; Hernando-Trancho, F; Insa, A; Isla, D; Massuti, B; Muguruza, I; Provencio, M; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Tarrazona, V; Torres, A; Varela, A | 1 |
| Aamdal, S; Andersen, A; Brunsvig, PF; Kristensen, V; Olsen, H | 1 |
| Raj Pandey, K | 1 |
| Date, H; Kiura, K; Mori, H; Toyooka, S | 1 |
| Chang, J; Cho, BC; Choi, HJ; Chung, KY; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Ploner, F | 1 |
| de Marinis, F; Fossella, F; Gralla, RJ; Jassem, J; Liepa, AM; Moore, P; Pereira, JR; Perry, MC; Peterson, P; Reck, M; Salzberg, M | 1 |
| Breton, JL; Dansin, E; Dourthe, LM; Ecstein-Fraisse, E; Hamid, A; Le Groumellec, A; Robinet, G; Rotarski, M | 1 |
| Charoentum, C; Chewasakulyong, B; Euathrongchit, J; Munprakan, S; Sorraritchingchai, S; Thongprasert, S | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Holland, W; Lara, PN; Mack, PC; Mahaffey, CM; Pryde, B | 1 |
| Charpidou, A; Dilana, K; Karapanagiotou, EM; Kosmas, E; Kotteas, E; Provata, A; Syrigos, K; Tourkantonis, I; Tzannou, I | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Di Marsico, R; Fabbri, A; Falcone, A; Innocenti, F; Lo Dico, M; Tartarelli, G; Tibaldi, C; Vasile, E | 1 |
| Begum, M; Bepler, G; Simon, GR | 1 |
| de Marinis, F; Grossi, F | 1 |
| Barlesi, F; Debieuvre, D; Fournel, P; Gervais, R; Mazieres, J; Milleron, B; Morin, F; Moro-Sibilot, D; Perol, M; Soria, JC; Souquet, PJ; Timsit, JF; Vergnenègre, A; Zalcman, G | 1 |
| Antonia, SJ; Begum, M; Bepler, G; Chiappori, A; Extermann, M; Haura, EB; Ismail-Khan, R; Kapoor, R; Schell, MJ; Simon, GR; Williams, CC | 1 |
| Fukushima, M; Hamada, C; Hosoe, S; Kawahara, M; Matsui, S; Tada, H | 1 |
| Atkins, JN; Crane, JM; Detterbeck, FC; Harper, HD; Hensing, TA; Moore, DT; Socinski, MA; Stinchcombe, TE; Willard, EM | 1 |
| Aksu, G; Binici, A; Cicin, I; Fayda, M; Karagol, H; Kocak, Z; Uygun, K; Uzunoglu, F | 1 |
| An, CH; Cho, EK; Hong, J; Jeong, SH; Kim, Y; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Karatapanis, S; Marinopoulos, S; Rasidakis, A; Skorda, L | 1 |
| Lee, R; Leighl, NB; Loreto, M; Ng, R | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Goto, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Aitini, E; Amoroso, V; Ardizzoia, A; Bajetta, E; Bandera, M; Bidoli, P; Cortinovis, D; Cullurà, D; Fusi, A; Lorusso, V; Radula, D; Zilembo, N | 1 |
| Ardizzoni, A; Ciardiello, F; De Marinis, F; De Petris, L; Di Maio, M; Gridelli, C; Hanna, N; Heymach, JV; Perrone, F; Rosell, R; Shepherd, FA; Thatcher, N; Vansteenkiste, J | 1 |
| Belda-Iniesta, C; Casado, E; Castro, J; Feliu, J; Firvida, JL; García-Mata, J; González-Barón, M; Madroñal, C; Rodríguez-Jaráiz, A; Salgado, M | 1 |
| Andritzky, B; Anige, M; Bokemeyer, C; Brandl, S; Burkholder, I; Edler, L; Görn, M; Habermann, CR; Hossfeld, DK; Laack, E; Schuch, G; Thöm, I | 1 |
| Brutsche, M; Gambazzi, F; Lieb, T; Pless, M; Stillhart, P | 1 |
| Eguchi, K; Fujiwara, Y; Hotta, K; Kiura, K; Kuyama, S; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kentepozidis, N; Lamvakas, L; Pallis, AG; Pavlakou, G; Polyzos, A; Tsiafaki, X | 1 |
| Hao, JQ; Li, Q; Shen, YX; Sun, GY; Xu, SP | 1 |
| Bandstra, B; Bischoff, H; Bonomi, P; Bover, I; Digel, W; Eisenfeld, AJ; Freitag, L; García-Campelo, R; Gatzemeier, U; Iannotti, N; Kaukel, E; O'Brien, M; Oldham, FB; Paz-Ares, L; Prendiville, J; Reiterer, P; Riviere, A; Ross, H; Singer, JW; Von Pawel, J | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Giaccone, G | 1 |
| Klastersky, J | 1 |
| Niitani, H | 1 |
| Berille, J; Fossella, FV; Hong, WK; Lee, JS | 1 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Abe, S; Fujii, M; Furuse, K; Inoue, Y; Kurita, Y; Oizumi, K; Onoshi, T; Sato, K; Sugiura, T; Watanabe, K | 1 |
| Francis, PA; Grant, SC; Heelan, RT; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR; Venkatraman, ES; Woolley, K | 1 |
| Benner, S; Calayag, M; Fossella, FV; Glisson, B; Huber, M; Lee, JS; Lippman, S; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Francis, PA; Heelan, RT; Kris, MG; Orazem, JP; Pisters, KM; Rigas, JR; Woolley, KJ | 1 |
| Benner, S; Calayag, M; Chasen, M; Fossella, FV; Glisson, B; Lee, JS; Lippman, SM; Murphy, WK; Pang, A; Shin, DM | 1 |
| Cerny, T; Epelbaum, R; Franklin, HR; Kaplan, S; Kaye, S; Pavlidis, N; Schöffski, P; van Meerbeek, J; Wanders, J | 1 |
| Ariyoshi, Y; Fukuoka, M; Furue, H; Furuse, K; Hasegawa, K; Ishitani, K; Kanamaru, R; Niitani, H; Noda, K; Taguchi, T | 1 |
| Kurita, Y; Minoda, S; Nakano, M; Negoro, S; Niitani, H; Ogura, T; Taguchi, T; Watanabe, K; Yokoyama, A | 1 |
| Arita, K; Fujita, A; Hino, M; Igarashi, T; Kudo, S; Niitani, H; Taguchi, T | 1 |
| Hisakatsu, S; Niitani, H | 1 |
| Eisenhauer, E | 1 |
| Edelman, MJ; Gandara, DR | 1 |
| Furuse, K; Kunitoh, H; Niitani, H; Onoshi, T; Taguchi, T; Watanabe, K | 1 |
| Le Chevalier, T | 1 |
| Bernacki, RJ; Ojima, I; Sharma, A; Straubinger, RM | 1 |
| Trudeau, ME | 1 |
| Boyer, R; Halme, M; Jekunen, A; Mattson, K; Pyrhönen, S; Roubille, N; Saarinen, A; Tamminen, K | 1 |
| Bishop, JF; Blanc, C; Bruno, R; Cosolo, W; James, R; Laird, J; Loret, C; Millward, MJ; Rischin, D; Toner, GC; Urch, M; Webster, LK; Zalcberg, J; Zimet, A | 1 |
| Boyer, MJ; Clarke, SJ | 1 |
| Tsukagoshi, S | 1 |
| Belani, CP; Ramanathan, RK | 1 |
| Fossella, FV; Hong, WK; Lee, JS | 1 |
| Grant, SC; Kris, MG; Miller, VA; Ng, KK | 1 |
| Jekunen, A; Mattson, K; Saarinen, A | 1 |
| Agelidou, M; Androulakis, N; Apostolopoulou, F; Bouros, D; Georgopoulou, T; Georgoulias, V; Halkiadakis, G; Hatzidaki, D; Kakolyris, S; Kourousis, C; Papadakis, E; Souglakos, J | 1 |
| Miller, VA | 2 |
| Crown, JP; Donnellan, PP | 1 |
| Androulakis, N; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Hatzidaki, D; Heras, P; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Meramveliotakis, N; Papadimitriou, C; Vardakis, N | 1 |
| Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE | 1 |
| Harper, P | 1 |
| Furuse, K | 1 |
| Aapro, MS | 1 |
| Boyer, MJ | 1 |
| Saijo, N | 1 |
| Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE; Watson, SM | 1 |
| Bruno, R; Burris, HA; Chevallier, B; Fossella, FV; Fumoleau, P; Hille, D; Kaye, SB; Ravdin, PM; Rigas, JR; Riva, A; Seidman, AD; Sheiner, LB; ten Bokkel Huinnink, WW; Valero, V; van Oosterom, AT; Verweij, J; Vivier, N | 1 |
| Büchholz, E; Drings, P; Manegold, C | 1 |
| Barter, C; Berille, J; Bishop, J; Bougan, N; Friedlander, M; James, R; Loret, C; McKeage, M; Millward, M; Rischin, D; Toner, G; Zalcberg, J; Zimet, A | 1 |
| Agelidou, M; Androulakis, N; Apostolopoulou, F; Dimopoulos, AM; Georgoulias, V; Hatzidaki, D; Heras, P; Kakolyris, S; Kourousis, C; Mavromanolakis, E; Papadakis, E; Papadimitriou, C; Tzannes, S; Vlachonicolis, J; Vossos, A | 1 |
| Bunn, PA; Kelly, K | 1 |
| Etienne, B; Guérin, JC; Nesme, P; Pérol, M; Robinet, G; Vuillermoz, S | 1 |
| Armstrong, J; Crown, J; Donnellan, P; Fennelly, D; Lynch, V; McDonnell, T; McNicholas, W; Rowan, S | 1 |
| Haraf, DJ; Hoffman, PC; Mauer, AM; Vokes, EE | 1 |
| Carney, DN | 1 |
| Schiller, JH | 1 |
| Aamdal, S; Oian, P; Semb, KA | 1 |
| Androulakis, N; Bahlitzanakis, N; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Kamilaki, M; Kotsakis, A; Koukouraki, S; Koukourakis, MI; Kourousis, C | 1 |
| Baille, P; Bruno, R; Millward, M; Montay, G; Schellens, JH; Verweij, J; Webster, LK | 1 |
| Androulakis, N; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kourousis, C; Maltezakis, G; Metaxaris, G; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K | 1 |
| Androulakis, N; Apostopoloulou, F; Bouros, D; Chatzakis, K; Georgopoulou, T; Georgoulias, V; Hatzidaki, D; Kotsakis, T; Kouroussis, C; Panagos, G; Papadakis, M; Souklakos, J; Vlachonikolis, J | 1 |
| Criée, CP; Dalichau, H; Griesinger, F; Hannemann, P; Hemmerlein, B; Herse, B; Hess, CF; Hiddemann, W; Schmidberger, H; Wörmann, B | 1 |
| Alexopoulos, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Papadakis, E; Patila, E; Samantas, E; Samelis, G; Vaslamatzis, M; Vossos, A | 1 |
| Orel, NF | 1 |
| Armand, JP; Couteau, C | 1 |
| Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Schiza, S | 1 |
| Belli, L; Bérille, J; Bougon, N; Douillard, JY; Ibrahim, N; Le Chevalier, T; Monnier, A; Ruffie, P; Sun, XS | 1 |
| Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J | 1 |
| Kuroda, M; Mizuno, A; Noguchi, S; Ohishi, A; Sakuma, F; Takagi, T; Terashima, K | 1 |
| Kris, MG; Millward, M | 1 |
| Edelman, MJ; Gandara, DR; Lau, D | 1 |
| van Oosterom, AT | 1 |
| Miller, V | 1 |
| Mattson, K | 3 |
| Rosell, R | 2 |
| Fossella, FV; Rigas, J | 1 |
| Bérille, J; Bizzari, JP; Bougon, N; Douillard, JY; James, R; Le Chevalier, T; Loret, C; McKeage, MJ; Millward, MJ; Monnier, A; Soulas, F; Zalcberg, JR | 1 |
| Rizvi, NA | 1 |
| Bahlitzanakis, N; Beroukas, K; Christodoulou, M; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kostantelos, J; Koukourakis, MI; Koumiotaki, S; Kyrias, G; Skarlatos, J | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Amadori, D; Bacci, F; Barzanti, F; Dal Susino, M; Folli, S; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Krug, LM; Miller, VA | 1 |
| Bhargava, P; Dahut, W; Davis, TH; Figuera, M; Hawkins, MJ; Marshall, JL; Rizvi, NA; Spiridonidis, CH | 1 |
| Adjei, AA; Argiris, A; Murren, JR | 1 |
| Belani, C; Bonomi, P; Carbone, D; Comis, R; Devore, R; Gandara, DR; Green, M; Karp, D; Vokes, E | 1 |
| Belani, CP; Fossella, F; Rigas, JR | 1 |
| Amorino, GP; Choy, H; Hamilton, VM | 1 |
| Goto, K; Hojo, F; Hosomi, Y; Kakinuma, R; Kodama, K; Matsumoto, T; Mito, K; Moriyama, E; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Tanaka, K; Uramoto, H | 1 |
| Aasebo, U; Berille, J; Krzakowski, M; Olivares, R; Parisi, A; Pham Tran, N; Pluzanska, A; Roszkowski, K; Saigi, E; Smith, AP | 1 |
| Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Ng, KK; Perez, W; Pizzo, B | 2 |
| Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA | 1 |
| Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A | 2 |
| Bargetzi, M; Bérille, J; Fillet, G; Gatzemeier, U; Jekunen, A; Mattson, K; Olivares, R; Saarinen, A; Soussan-Lazard, K; Stupp, R; Teixeira, M; Vansteenkiste, J | 1 |
| Agelaki, S; Androulakis, N; Dimou, T; Georgoulias, V; Giannakakis, T; Hatzidaki, D; Kakolyris, S; Mavroudis, D; Parashos, M; Sarra, E; Vlachonikolis, J; Ziras, N | 1 |
| Crown, J; O'Leary, M | 1 |
| Burris, HA | 1 |
| Kris, MG; Miller, VA | 1 |
| Berille, J; Burkes, R; Coughlin, S; Dancey, J; Gralla, R; Gressot, L; Kim, Y; Levitan, N; Mattson, K; O'Rourke, M; Ramlau, R; Shepherd, FA; Vincent, M | 1 |
| Fukuoka, M | 1 |
| Kamiya, Y; Kunitoh, H; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Langer, CJ | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Bennouna, J; Berille, J; Douillard, JY; Lemarie, E; Milleron, B; Monnier, A; Rivière, A; Soussan-Lazard, K; Trillet-Lenoir, V | 1 |
| Crawford, J; DeVore, R; Dunphy, F; Fossella, FV; Gamza, F; Gandara, D; Hammershaimb, L; Kalman, L; Karp, D; Kerr, RN; Kim, Y; Kris, M; Lee, JS; Miller, V; Moore, M; Natale, RR; Vokes, E | 1 |
| Chan, CC; Chua, ET; Goh, BC; Kong, HL; Lee, SC; Lehnert, M; Lim, HL; Ng, AW; Wee, J; Wong, JE | 1 |
| Armand, JP | 1 |
| Barton, JH; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD; Litchy, S; Morrissey, LH | 1 |
| Fiebiger, WC; Greul, R; Hejna, M; Kornek, GV; Marosi, L; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Comer, AM; Goa, KL | 1 |
| Belani, CP; Bonomi, P; Capozzoli, MJ; Cohen, LJ; Dobbs, T; Earhart, R; Einzig, A; Luketich, JD | 1 |
| Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Kremos, S; Mavroudis, D; Souglakos, J | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakagawa, K; Negoro, S; Niitani, H; Saka, H; Sugiura, T; Takada, M | 1 |
| Kubota, K | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Sandler, A | 1 |
| Berille, J; Bosquee, L; Brägas, B; Dabouis, G; Douillard, JY; Le Chevalier, T; Le Groumellec, A; Marien, S; Mattson, K; Olivares, R; Pujol, JL; Stupp, R | 1 |
| Ascherman, JA; Attkiss, K; Knowles, SL | 1 |
| Ballatori, E; Del Favero, A; Roila, F | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Bruno, R; Chaikin, P; Olivares, R; Rhodes, GR; Veyrat-Follet, C | 1 |
| Chen, YM; Chou, KC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Wang, H | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Kris, MG; Manegold, C | 1 |
| Belani, C; Lynch, T | 1 |
| Douillard, JY; Eckardt, J; Georgoulias, V; Manegold, C; Miller, V; Scagliotti, G | 1 |
| Hainsworth, JD; Vokes, EE | 1 |
| Green, M; Gumerlock, P; Rosell, R | 1 |
| Armand, JP; Fossella, FV; Kris, MG; Lynch, T; Rigas, JR; Shepherd, FA | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Kunitoh, H; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N | 1 |
| Gandara, DR; Goldberg, Z; Lara, PN; Lau, DH; Roberts, P | 1 |
| Alexopoulos, A; Georgoulias, V; Palamidas, P; Papadakis, E; Rapti, A; Tsiafaki, X; Veslemes, M; Vlachonikolis, I | 1 |
| Athanasiadis, A; Constantinidis, TC; Delis, D; Fachantidou, E; Goutsikas, J; Hatziapostolou, P; Kontakiotis, T; Patakas, D; Zarogoulidis, K | 1 |
| Bruno, R; Montay, G; Rhodes, GR; Veyrat-Follet, C; Vivier, N | 1 |
| Minato, K; Mori, M; Saitoh, R; Sato, K; Takei, Y; Tsuchiya, S; Watanabe, S | 1 |
| Green, M; Kawahara, M; Kris, MG; Kunitoh, H | 1 |
| Belani, C | 1 |
| Gandara, DR; Goldberg, Z; Lara, PN; Lau, DH | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Lynch, TJ | 1 |
| Bando, H; Miyata, J; Sano, T; Sumitomo, M | 1 |
| Murren, JR | 1 |
| Kim, KM; Larson, M; Leu, KM; Schiller, JH | 1 |
| Fujimoto, K; Hirai, K; Koizumi, T; Koyama, S; Kubo, K; Nomura, H; Okada, K; Tsunoda, T | 1 |
| Gatzemeier, U | 1 |
| Choy, H; Kim, JS; MacRae, R; Pyo, H | 1 |
| Belette, F; Blaustein, A; Davila, E; Lilenbaum, RC; Schwartz, MA; Seigel, L; Wittlin, FN | 1 |
| Satoh, H; Sekizawa, K | 1 |
| Albain, KS; Clark, JI; Fisher, S; Hantel, A; Kancharla, K; Millbrandt, L; Panganiban, J; Qamar, R | 1 |
| Bonfill, X; Losa, F; Montesinos, J; Nogué, M; Sacristán, M; Serra, C | 1 |
| Choy, H; DeVore, RF; Hande, KR; Johnson, DH; Laporte, K; Porter, LL; Rosenblatt, PA; Shyr, Y; Slovis, B | 1 |
| Perng, RP; Wang, GS; Yang, KY | 1 |
| Abratt, R; Avril, I; Krofta, K; Mattson, K; Ten, GV; Tonelli, D | 1 |
| Agosta, G; Armata, MG; Bajardi, E; Cicero, G; Gebbia, N; Grassi, N; Gulotta, G; Latteri, MA; Modica, G; Pantuso, G; Russo, A; Valerio, MR | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Alexopoulos, A; Georgoulias, V; Giannakakis, T; Grigoratou, T; Kakolyris, S; Kouroussis, C; Mavroudis, D; Palamidas, P; Papadakis, E; Rapti, A; Samonis, G; Tsiafaki, X; Veslemes, M; Vlachonikolis, J | 1 |
| Caffo, O | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Kobina, S; Moyano, A; Rubio-Terrés, C; Tisaire, JL | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Miyazaki, M; Mukohara, T; Negoro, S; Takeda, K; Takifuji, N; Terakawa, K | 1 |
| Guan, X; Li, L; Zou, Y | 1 |
| Ahn, YC; Bang, YJ; Choi, EK; Kim, YW; Lim, TH; Park, CI; Park, K; Suh, C; Wu, HG | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, A; Schiller, JH; Zhu, J | 1 |
| Doi, S; Fukuda, M; Kanda, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Narasaki, F; Oka, M; Soda, H; Suenaga, M; Takatani, H; Tsurutani, J | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H | 1 |
| Clegg, A; Hewitson, P; Scott, DA; Sidhu, M; Waugh, N | 2 |
| Dimitropoulos, D; Kalofonos, HP; Kosmas, C; Makatsoris, T; Onyenadum, A; Rokana, S; Sepsas, E; Stavroyianni, N; Tsavaris, NB; Vadiaka, M | 1 |
| Burkes, RL; Feld, R; Goodwin, PJ; Kwong, R; Leighl, NB; Shepherd, FA | 1 |
| Alila, H; Bunn, PA; Chan, DC; Earle, K; Helfrich, B; Kelly, K; Pamukcu, R; Piazza, G; Thompson, W; Whitehead, CM; Zhao, TL | 1 |
| Alila, H; Baron, A; Bunn, PA; Chan, DC; Earle, KA; Helfrich, B; Nelson, P; Pamukcu, R; Piazza, G; Thompson, WJ; Whitehead, CM; Zeng, C; Zhao, TL | 1 |
| Kato, Y; Saijo, N | 1 |
| Morere, JF | 1 |
| Mavroudis, D | 1 |
| Georgoulias, V | 1 |
| Dierlamm, T; Dürk, H; Fiedler, W; Knuffmann, C; Kurt Hossfeld, D; Laack, E; Popp, J; Schmied, B; Verpoort, K; Wacker-Backerhaus, G; Zeller, W | 1 |
| Shepherd, FA | 1 |
| Choi, YH; Hong, DS; In, KH; Jeong, TJ; Kim, HK; Kim, JS; Kim, YH; Lee, KS; Lee, SN; Lee, YY; Nam, E; Park, HS | 1 |
| Kato, H; Tsuboi, M | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Pectasides, D; Visvikis, A; Ziras, N | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Kalofonos, HP; Kosmas, C; Tsavaris, N | 1 |
| Belleguic, C; Blanchon, F; Coste, E; Fournel, P; Le Caer, H; Léna, H; Pérol, M; Pham, E; Robinet, G; Schuller-Lebeau, MP; Thomas, P; Vergnenègre, A; Vernejoux, JM | 1 |
| Takigawa, N | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Furuse, K; Kawahara, M | 1 |
271 review(s) available for docetaxel anhydrous and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Models, Statistical; Platinum Compounds; Survival Analysis; Survival Rate | 2021 |
Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyridines | 2021 |
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Neoplasm Staging; Prospective Studies | 2022 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Platinum | 2022 |
Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lactams, Macrocyclic; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors | 2023 |
A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Lung Neoplasms | 2022 |
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Network Meta-Analysis; Pemetrexed; Platinum | 2023 |
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity.
Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Network Meta-Analysis; Nivolumab | 2023 |
Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Cost-Benefit Analysis; Docetaxel; Humans; Lung Neoplasms; Multicenter Studies as Topic; Pemetrexed; Proto-Oncogene Proteins c-ret; Quality of Life; Quality-Adjusted Life Years; Technology Assessment, Biomedical | 2023 |
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Effectiveness Analysis; Docetaxel; Humans; Lung Neoplasms; Nivolumab | 2023 |
Combi-TED: a new trial testing Tedopi
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Progression-Free Survival | 2022 |
Meta-Analysis of Atezolizumab vs Docetaxel in Non-Small Cell Lung Cancer Treatment Outcomes.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Multicenter Studies as Topic; Treatment Outcome | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Indoles; Network Meta-Analysis; Nivolumab; Ramucirumab; Taxoids; Treatment Outcome | 2017 |
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Nivolumab; Programmed Cell Death 1 Ligand 2 Protein; Taxoids | 2017 |
Selumetinib for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Taxoids | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Costimulatory and Inhibitory T-Cell Receptors; Docetaxel; Humans; Incidence; Lung Neoplasms; Nivolumab; Pneumonia; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Neoplasm Staging; Pyridines; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Neoplasm Staging; Network Meta-Analysis; Survival Analysis | 2018 |
Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic | 2018 |
Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Programmed Cell Death 1 Receptor | 2018 |
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung; Lung Neoplasms; Patient Selection; Ramucirumab; Time Factors | 2019 |
Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Network Meta-Analysis; Nivolumab; Programmed Cell Death 1 Receptor; Treatment Outcome | 2019 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Lung cancer in 2013: state of the art therapy for metastatic disease.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Maintenance Chemotherapy; Molecular Targeted Therapy; Pemetrexed; Receptor Protein-Tyrosine Kinases; Taxoids | 2013 |
Second-Line Therapy for Advanced NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Mutation; Oncogene Proteins, Fusion; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2014 |
Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Taxoids | 2014 |
[A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2014 |
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Docetaxel; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Taxoids; Treatment Outcome | 2014 |
Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Survival Rate; Taxoids | 2014 |
Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Retreatment; Taxoids; Thrombocytopenia | 2014 |
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Taxoids; Treatment Outcome | 2015 |
Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Indoles; Lung Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Ramucirumab; Taxoids; Vascular Endothelial Growth Factor A | 2015 |
The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
A commentary on interstitial pneumonitis induced by docetaxel: clinical cases and systematic review of the literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents; Blood Gas Analysis; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Prednisone; Recovery of Function; Spirometry; Taxoids; Tomography, X-Ray Computed | 2015 |
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2015 |
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Survival Rate; Taxoids | 2015 |
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, hi
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Substitution; ErbB Receptors; Gemcitabine; Genetic Predisposition to Disease; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Markov Chains; Monte Carlo Method; Mutation; Neoplasm Staging; Pemetrexed; Phenotype; Protein Kinase Inhibitors; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Taxoids | 2015 |
Novel cytotoxic drugs in advanced nonsmall cell lung cancer.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Treatment Outcome | 2016 |
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Neutropenia; Prognosis; Survival Rate; Taxoids | 2016 |
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.
Topics: Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Taxoids; Treatment Outcome | 2016 |
The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Taxoids | 2016 |
Selumetinib in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Taxoids | 2016 |
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Nivolumab; Predictive Value of Tests; Prognosis; Survival Analysis; Taxoids | 2016 |
[Not Available].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Taxoids | 2016 |
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; CTLA-4 Antigen; Docetaxel; Humans; Immunotherapy; Nivolumab; Programmed Cell Death 1 Receptor; Signal Transduction; Taxoids | 2017 |
Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Retreatment; Survival Rate; Taxoids | 2016 |
Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Ramucirumab; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Ramucirumab; Taxoids | 2017 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Italy; Lung Neoplasms; Nivolumab; Ramucirumab; Randomized Controlled Trials as Topic; Taxoids | 2017 |
A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Humans; Lung Neoplasms; Nivolumab; Programmed Cell Death 1 Receptor; Survival Rate; Taxoids | 2016 |
Docetaxel in the treatment of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2008 |
New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Taxoids | 2009 |
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Fever; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Risk Factors; Taxoids | 2009 |
Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Palliative Care; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Economics of treatments for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2009 |
First- and second-line therapy for advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Meta-Analysis as Topic; Palliative Care; Patient Selection; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2009 |
The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Evidence-Based Medicine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Taxoids; Treatment Outcome | 2009 |
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2009 |
Gefitinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bias; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids; Young Adult | 2009 |
What is the role of novel taxanes in non-small-cell lung cancer?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cross-Linking Reagents; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2008 |
EGFR inhibition in NSCLC: the emerging role of cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Taxoids | 2004 |
Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2010 |
Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Global Health; Humans; Immunosuppressive Agents; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2010 |
Maintenance chemotherapy in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2010 |
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids | 2010 |
Factors driving the choice of the best second-line treatment of advanced NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Docetaxel; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids; Thymidylate Synthase | 2011 |
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids | 2010 |
[A meta analysis of aidi injection plus taxotere and cisplatin in the treatment of non-small cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Taxoids; Young Adult | 2010 |
Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2011 |
Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Randomized Controlled Trials as Topic; Reproducibility of Results; Taxoids | 2011 |
Chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Therapy; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2011 |
Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Topotecan | 2012 |
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2012 |
The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Practice Guidelines as Topic; Quality of Life; Quinazolines; Sickness Impact Profile; Taxoids; Time Factors; Treatment Outcome | 2013 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Taxoids | 2013 |
Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Taxoids | 2002 |
Docetaxel for previously treated non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Docetaxel and radiation as combined-modality therapy.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2002 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2002 |
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine | 2002 |
[Randomized controlled trials in Japan--lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2002 |
Taxanes for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
Second line chemotherapy for NSCLC: establishing a gold standard.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Taxoids; Treatment Outcome | 2002 |
First-line chemotherapy for NSCLC: an overview of relevant trials.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival; Taxoids; Treatment Outcome | 2002 |
Adjuvant and neoadjuvant treatments for NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Survival; Taxoids | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Health Status; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Survival; Taxoids; Vinblastine; Vinorelbine | 2002 |
An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Genetic testing for chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; DNA Adducts; DNA Damage; DNA Helicases; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Genetic Testing; Humans; Lung Neoplasms; Polymorphism, Genetic; Protein Biosynthesis; Repressor Proteins; RNA, Messenger; Survival Analysis; Taxoids; Transcription Factors; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2003 |
Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Education, Medical, Continuing; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pneumonectomy; Prognosis; Radiation Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
[Docetaxel (Taxotere) as first-line therapy of advanced non-small cell lung cancer (NSCLC)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2003 |
[Docetaxel in neoadjuvant therapy of early-stage non-small cell carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Taxoids | 2003 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
[Docetaxel in combination with cisplatin for first-line treatment of locally advanced or metastatic non-small cell lung cancer: meta-analysis of randomized and controlled clinical trials].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Pemetrexed; Taxoids | 2004 |
Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Docetaxel; Enterocolitis, Neutropenic; Fatal Outcome; Female; Flavonoids; Humans; Lung Neoplasms; Piperidines; Taxoids | 2004 |
Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
[Docetaxel and non-small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
[Chemotherapy of the elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Retrospective Studies; Signal Transduction; Taxoids | 2004 |
[Second-line chemotherapy in non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2004 |
[Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Pemetrexed in second-line treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Salvage Therapy; Taxoids; Thymidylate Synthase | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
[Association of taxanes and radiotherapy: preclinical and clinical studies].
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured | 2004 |
Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Pemetrexed; Prognosis; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2004 |
Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2004 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Docetaxel in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Docetaxel administration schedule: from fever to tears? A review of randomised studies.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality Control; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Taxoids | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2005 |
Novel combinations with docetaxel in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Protease Inhibitors; Protein-Tyrosine Kinases; Receptor, ErbB-2; Taxoids; Vascular Endothelial Growth Factor A | 2005 |
The role of docetaxel in N2 locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Taxoids | 2005 |
Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2005 |
First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2005 |
Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Salvage Therapy; Taxoids | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Taxoids | 2005 |
Applications of genomics in NSCLC.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Mice; RNA, Messenger; Taxoids | 2005 |
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Second-line chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dietary Supplements; Docetaxel; Glutamates; Guanine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Pemetrexed; Survival Analysis; Taxoids; Vitamins | 2006 |
Non-platinum combination of gemcitabine in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
[Combination therapy with S-1 plus docetaxel (DOC) for previously treated patients with non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Maximum Tolerated Dose; Oxonic Acid; Randomized Controlled Trials as Topic; Taxoids; Tegafur | 2006 |
Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Staging; Neutropenia; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids | 2006 |
Usefulness of predictive tests for cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; ErbB Receptors; Gemcitabine; Genes, ras; Humans; Lung Neoplasms; Membrane Glycoproteins; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; RNA, Messenger; Semaphorins; Taxoids; Ubiquitin-Protein Ligases | 2006 |
[Lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Pemetrexed; Taxoids | 2007 |
Salvage therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids | 2006 |
Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Ontario; Palliative Care; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Time Factors | 2006 |
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2007 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Drug Costs; Humans; Lung Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2007 |
Optimizing chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2007 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vindesine; Vinorelbine | 2007 |
Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Taxoids; Treatment Outcome | 2007 |
[NSCLC: update on second line therapy following ASCO 2007].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Retreatment; Survival Rate; Taxoids | 2007 |
Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Humans; Lung Neoplasms; Predictive Value of Tests; Ribonucleoside Diphosphate Reductase; Survival Analysis; Taxoids; Tumor Suppressor Proteins | 2008 |
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Considerations for second-line therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
New drugs in non-small cell lung cancer. An overview.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Design; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Phase II study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Practice Guidelines as Topic; Taxoids | 1995 |
Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 1995 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
[Antimicrotubule agents].
Topics: Aminophenols; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Leukemia, Experimental; Lung Neoplasms; Mice; Microtubules; Paclitaxel; Sulfonamides; Taxoids; Vinblastine; Vinorelbine | 1993 |
Promising new agents in the treatment of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Docetaxel: meeting the challenge of non-small cell lung cancer management.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Cricetinae; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 1995 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
[Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin | 1997 |
Chemotherapy for advanced non-small cell lung cancer: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Management strategies for recurrent non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Failure | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Taxoids | 1997 |
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 1997 |
New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
[Docetaxel (taxotere) in non-small-cell bronchial carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1997 |
Ifosfamide and docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Taxoids | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1998 |
Docetaxel in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1998 |
Single agents in the second-line treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
New agents in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Role of taxanes in lung-cancer chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1998 |
[Docetaxel (taxotere): current status of clinical development in non-small-cell bronchial carcinoma (NSCLC)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 1998 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Failure | 1999 |
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and gemcitabine in combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Taxoids | 1999 |
New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1999 |
Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
New options in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 1999 |
Paclitaxel and docetaxel combinations in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
The taxanes: an update.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel (Taxotere) in the treatment of cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advanced non-small cell lung carcinoma: the emerging role of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2000 |
Docetaxel: a review of its use in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2000 |
[Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Evidence-Based Medicine; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Health Status; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Advances in the treatment of non-small cell lung cancer: molecular markers take the stage.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasm Staging; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids | 2001 |
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2001 |
The current status of docetaxel for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Neoadjuvant therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Computer Simulation; Docetaxel; Humans; Lung Neoplasms; Models, Statistical; Neoplasms; Nonlinear Dynamics; Paclitaxel; Prospective Studies; Research Design; Taxoids | 2001 |
New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
Indications for chemotherapy in stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Guidelines as Topic; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Chemotherapy for advanced non-small cell lung cancer: standards.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Decision Making; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Patient Selection; Practice Guidelines as Topic; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Disease Models, Animal; Docetaxel; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Paclitaxel; Rats; Sulindac; Survival Analysis; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2002 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[Current status of the chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2002 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; England; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Wales | 2001 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
[Recent results of anticancer drugs acting on microtubules--navelbine, taxol and taxotere for the treatment of lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Microtubules; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1992 |
647 trial(s) available for docetaxel anhydrous and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Taxoids; Treatment Outcome | 2021 |
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2021 |
Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiation Dose Hypofractionation; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Treatment Outcome | 2022 |
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Diketopiperazines; Docetaxel; Double-Blind Method; Female; Filgrastim; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Polyethylene Glycols; Prostatic Neoplasms; Treatment Outcome | 2022 |
Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Prospective Studies | 2023 |
A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed | 2022 |
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Lung; Lung Neoplasms; Ramucirumab; Standard of Care; Vascular Endothelial Growth Factor A | 2022 |
Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed | 2022 |
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; DNA Helicases; Docetaxel; ErbB Receptors; Humans; Immunologic Factors; Immunotherapy; Inflammation; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Male; NF-E2-Related Factor 2; Nuclear Proteins; Prognosis; Proto-Oncogene Proteins p21(ras); Transcription Factors | 2022 |
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Programmed Cell Death 1 Receptor; Ramucirumab | 2022 |
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Platinum | 2022 |
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Mutation | 2022 |
Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Creatinine; Docetaxel; Humans; Lung Neoplasms | 2022 |
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.
Topics: Antineoplastic Agents; B7-H1 Antigen; Biomarkers; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms | 2023 |
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung Neoplasms; Taxoids; Transcription Factors | 2022 |
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.
Topics: Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Disease Progression; Docetaxel; Humans; Lung Neoplasms | 2022 |
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Ramucirumab; Vascular Endothelial Growth Factor A | 2023 |
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2023 |
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms | 2023 |
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2023 |
The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cough; Docetaxel; Humans; Lung Neoplasms; Quality of Life | 2023 |
A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neutropenia; Taxoids; Treatment Outcome | 2023 |
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Nivolumab | 2023 |
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Treatment Outcome | 2023 |
Pembrolizumab in lung cancer: current evidence and future perspectives.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Evaluation; Follow-Up Studies; Humans; Lung Neoplasms; Mice; Nivolumab; Prognosis; Receptors, Estrogen; Small Cell Lung Carcinoma; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Follow-Up Studies; Humans; Lung Neoplasms; Multicenter Studies as Topic; Pleural Effusion, Malignant; Prognosis; Ramucirumab; Salvage Therapy; Survival Rate | 2020 |
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Ramucirumab | 2020 |
Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Docetaxel; Female; Filgrastim; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Ramucirumab | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Pemetrexed | 2020 |
Impact of Bevacizumab
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2020 |
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Treatment Outcome | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Pleural Effusion, Malignant; Pleurodesis; Prognosis; Survival Rate | 2020 |
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Survival Rate; Tegafur; Thoracic Neoplasms | 2021 |
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Topics: Carcinoma, Non-Small-Cell Lung; China; Docetaxel; Follow-Up Studies; Humans; Lung Neoplasms; Nivolumab | 2021 |
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged | 2021 |
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tubulin Modulators; Tumor Burden | 2021 |
Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC-guided dosing in nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Monitoring; Humans; Lung Neoplasms; Pharmacogenomic Testing; Polymorphism, Single Nucleotide | 2021 |
Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Hyaluronoglucosaminidase; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2021 |
Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Retrospective Studies | 2021 |
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local | 2021 |
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunohistochemistry; Lung Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Genomics; Humans; Lung Neoplasms; Male; Mutation; Survival Rate; Transcriptome | 2021 |
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
Topics: Aged; Anthracyclines; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome | 2017 |
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras); Taxoids; Treatment Outcome | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lung Neoplasms; Male; Pemetrexed; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2018 |
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Nivolumab; Survival Rate; Taxoids; Treatment Outcome | 2017 |
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Taxoids | 2017 |
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Young Adult | 2017 |
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Quality of Life | 2018 |
Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Demography; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2018 |
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Ramucirumab; Taxoids; Treatment Outcome | 2017 |
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Ramucirumab; Retreatment; Taxoids; Treatment Outcome; Young Adult | 2017 |
A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Autophagosomes; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Intradermal; Interferon-gamma; Interleukin-10; Interleukin-5; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pleural Effusion, Malignant; Taxoids; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ramucirumab; Salvage Therapy; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2018 |
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Disease-Free Survival; Docetaxel; Female; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones; Taxoids; Treatment Outcome | 2018 |
A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Docetaxel; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2018 |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines; Survival Analysis; Treatment Outcome | 2018 |
Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Serine; Taxoids; Treatment Outcome | 2018 |
Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Treatment Outcome | 2018 |
Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiosurgery; Taxoids; Treatment Outcome | 2018 |
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Mammalian orthoreovirus 3; Middle Aged; Oncolytic Virotherapy; Oncolytic Viruses; Pemetrexed; Recurrence; Reoviridae Infections; Salvage Therapy; Young Adult | 2018 |
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2018 |
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Survival Analysis; Treatment Outcome | 2018 |
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Proportional Hazards Models | 2018 |
Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Ramucirumab; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Patient Reported Outcome Measures; Prognosis; Quality of Life | 2018 |
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Docetaxel; Health Status; Humans; Lung Neoplasms; Nivolumab; Patient Reported Outcome Measures; Predictive Value of Tests; Quality of Life; Time Factors; Treatment Outcome | 2018 |
Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Japan; Lung Neoplasms; Male; Polyethylene Glycols; Ramucirumab; Treatment Outcome | 2018 |
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Time Factors; Treatment Outcome | 2018 |
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; Fanconi Anemia Complementation Group N Protein; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models; RNA, Messenger; Survival Rate; Telomere-Binding Proteins; Treatment Outcome; Tumor Suppressor p53-Binding Protein 1; Ubiquitin-Protein Ligases | 2019 |
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Survivors | 2019 |
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Oxonic Acid; Paclitaxel; Prognosis; Ramucirumab; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur | 2019 |
An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2019 |
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Paraffin Embedding; Prognosis; Specimen Handling; Survival Rate; Young Adult | 2019 |
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab | 2019 |
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Patient Reported Outcome Measures; Programmed Cell Death 1 Receptor; Quality of Life | 2019 |
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Oxonic Acid; Quality of Life; Tegafur; Treatment Outcome | 2019 |
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ramucirumab; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2019 |
Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Radiation Dose Hypofractionation; Survival Rate | 2019 |
Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Preliminary Data; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Retreatment; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2019 |
[Measures to Ensure Safety of Docetaxel plus Ramucirumab for Advanced Non-Small-Cell Lung Cancer as the Second- or Later-Line].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Ramucirumab; Retrospective Studies | 2019 |
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Everolimus; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Sirolimus; Survival Rate; Taxoids; TOR Serine-Threonine Kinases | 2013 |
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Polymorphism, Single Nucleotide; Steroid Hydroxylases; Survival Rate; Taxoids; Treatment Outcome; Vitamin D3 24-Hydroxylase | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consolidation Chemotherapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2013 |
A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Killer Cells, Natural; Lung Neoplasms; Lymphocytes; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids; Transplantation, Autologous | 2013 |
[Cisplatin-based chronotherapy for advanced none-small cell lung cancer: a randomized controlled study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Chronotherapy; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Taxoids | 2013 |
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality of Life; Taxoids; Young Adult | 2013 |
Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Flow Cytometry; Gemcitabine; Glutamates; Guanine; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Lung Neoplasms; Male; Middle Aged; Myeloid Cells; Pemetrexed; Taxoids | 2013 |
Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endpoint Determination; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Pemetrexed; Risk Assessment; Smoking; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2013 |
[Series: Clinical study from Japan and its reflections; randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Combinations; Humans; Japan; Middle Aged; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2013 |
Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2013 |
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Drug Delivery Systems; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pemetrexed; Quinazolines; Recurrence; Taxoids | 2013 |
A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Intention to Treat Analysis; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Taxoids | 2013 |
Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Protective Agents; Recombinant Proteins; Taxoids; Treatment Outcome | 2013 |
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin D1; Cyclin D3; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Survival; Taxoids; Treatment Outcome | 2013 |
Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Positron-Emission Tomography; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Taxoids; Treatment Outcome | 2013 |
Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2013 |
Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Taxoids | 2014 |
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Severity of Illness Index; Taxoids; Treatment Failure; United States | 2013 |
Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2013 |
[Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Endostatins; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prospective Studies; Remission Induction; Taxoids | 2013 |
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Lung Neoplasms; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Pyrroles; Taxoids | 2014 |
Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Salvage Therapy; Taxoids | 2014 |
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2014 |
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dichloroacetic Acid; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxygen Consumption; Taxoids; Treatment Failure | 2014 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Precision Medicine; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Japan; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2014 |
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease-Free Survival; Docetaxel; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2014 |
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Proportional Hazards Models; Quinazolines; Taxoids; Treatment Outcome | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Docetaxel; Female; Gonanes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Survival Rate; Taxoids | 2014 |
Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Paclitaxel; Pemetrexed; Prognosis; Proportional Hazards Models; Taxoids; Treatment Outcome | 2014 |
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Platinum; Quality of Life; Ramucirumab; Survival Rate; Taxoids | 2014 |
[Effect of integrated Chinese medical treatment (as maintenance therapy) on the survival time of patients with advanced non-small-cell lung cancer: a clinical study].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Gemcitabine; Humans; Pemetrexed; Prospective Studies; Taxoids | 2014 |
Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Cisplatin; Docetaxel; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Survivin; Taxoids; Treatment Outcome | 2014 |
Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2014 |
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2014 |
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gene Dosage; Humans; Male; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2014 |
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; China; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Male; Middle Aged; Nuclear Proteins; Taxoids; Treatment Outcome; White People | 2014 |
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Drug Approval; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2014 |
Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2014 |
Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Protocols; Consolidation Chemotherapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Movement; Pneumonia; Prognosis; Prospective Studies; Quality of Life; Respiration; Taxoids | 2014 |
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2014 |
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Taxoids | 2015 |
Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2015 |
Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality of Life; Receptor Protein-Tyrosine Kinases; Self Report; Taxoids; Treatment Outcome | 2014 |
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Oligonucleotides; Survival Analysis; Taxoids | 2014 |
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Pemetrexed; Prostaglandins; Pyrroles; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Endostatins; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids | 2015 |
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Double-Blind Method; Health Status; Humans; Indoles; Lung Neoplasms; Placebos; Quality of Life; Self Report; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2015 |
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2015 |
Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Taxoids | 2015 |
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-s
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2015 |
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Taxoids; Time Factors; Treatment Outcome | 2015 |
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; France; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Quality of Life; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome | 2015 |
Recombinant mutated human TNF in combination with chemotherapy for stage IIIB/IV non-small cell lung cancer: a randomized, phase III study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Recombinant Proteins; Survival Analysis; Taxoids; Tumor Necrosis Factor-alpha | 2015 |
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Quality of Life; Survival Rate; Taxoids; Tegafur | 2015 |
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; HSP90 Heat-Shock Proteins; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Taxoids; Treatment Outcome; Triazoles | 2015 |
Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Immunoglobulin G; Lung Neoplasms; Male; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Survival Analysis; Taxoids | 2015 |
Nivolumab for squamous-cell non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Baltimore; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Invasiveness; Nivolumab; Prognosis; Proportional Hazards Models; Survival Analysis; Taxoids | 2015 |
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Platinum; Retreatment; Taxoids; Tegafur; Treatment Outcome | 2015 |
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Codon; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Taxoids | 2015 |
Effects of docetaxel plus three-dimensional conformal radiation therapy on microvessel density and apoptosis expression in local advanced squamous non-small-cell lung cancer.
Topics: Aged; Apoptosis; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Humans; Male; Microvessels; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Prognosis; Quality of Life; Radiotherapy, Conformal; Survival Rate; Taxoids | 2015 |
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids | 2015 |
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Proto-Oncogene Proteins p21(ras); Survival Rate; Taxoids | 2015 |
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Gefitinib; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Neutropenia; Patient Dropouts; Quinazolines; Taxoids | 2015 |
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Female; Folic Acid Antagonists; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Analysis; Taxoids | 2015 |
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Taxoids | 2015 |
A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Taxoids; Treatment Outcome | 2015 |
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Quinazolines; Survival Rate; Taxoids | 2016 |
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Survival Analysis; Taxoids | 2015 |
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Approval; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ramucirumab; Taxoids; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Approval; Female; Humans; Lung Neoplasms; Nivolumab; Organoplatinum Compounds; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Intention to Treat Analysis; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Proportional Hazards Models; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Disease-Free Survival; Docetaxel; Esophagitis; Female; Humans; Karnofsky Performance Status; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2015 |
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Topics: 3' Untranslated Regions; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; ras Proteins; Taxoids | 2015 |
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Patient Selection; Taxoids; Treatment Outcome | 2016 |
Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Salvage Therapy; Sunitinib; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Induction Chemotherapy; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2016 |
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2016 |
ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dimerization; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Neoplasms; Neutropenia; Nitric Oxide Synthase Type II; Pyrimidines; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Taxoids | 2016 |
Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (S
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Docetaxel; Double-Blind Method; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Placebos; Proto-Oncogene Proteins p21(ras); Research Design; Taxoids; Treatment Outcome; Young Adult | 2016 |
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cognition Disorders; Docetaxel; Drug Combinations; Gastrointestinal Diseases; Humans; Lung Neoplasms; Oxonic Acid; Quality of Life; Taxoids; Tegafur | 2016 |
Efficacy of tamoxifen in combination with docetaxel in patients with advanced non-small-cell lung cancer pretreated with platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Tamoxifen; Taxoids | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Platinum; Proportional Hazards Models; Quality of Life; Ramucirumab; Retreatment; Taxoids; Treatment Outcome | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; North America; Survival Rate; Taxoids; Treatment Outcome | 2016 |
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Approval; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nivolumab; Programmed Cell Death 1 Receptor; Taxoids; United States; United States Food and Drug Administration | 2016 |
Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Double-Blind Method; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunity, Cellular; Immunity, Humoral; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome; Vaccines, Subunit | 2016 |
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Switzerland; Taxoids; Time Factors | 2016 |
Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2016 |
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Ramucirumab; Retreatment; Risk Factors; Taxoids; Treatment Outcome | 2016 |
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Taxoids; Treatment Outcome | 2016 |
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Dyspnea; Fatigue; Female; Gastrointestinal Diseases; Greece; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2016 |
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Smoking; Taxoids | 2016 |
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2017 |
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Prognosis; Survival Rate; Taxoids | 2017 |
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Risk Factors; Smoking; Taxoids; Tomography, X-Ray Computed; Tubulin Modulators | 2017 |
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Topotecan; Treatment Outcome | 2008 |
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Quality of Life; Survival Rate; Taxoids | 2009 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligodeoxyribonucleotides; Paclitaxel; Taxoids; Toll-Like Receptor 9 | 2008 |
A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Tegafur | 2008 |
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan | 2009 |
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2008 |
Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2008 |
Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; Taxoids | 2008 |
Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Radiation Dosage; Taxoids; Thorax | 2009 |
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Darbepoetin alfa; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesna; Middle Aged; Neoplasm Staging; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Survival Rate; Taxoids | 2008 |
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazoles; Sulfonamides; Survival Rate; Taxoids | 2008 |
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome | 2008 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
[A randomized phase II trial of docetaxel and doxorubicin in treatment for patients with non-small-cell lung cancer who have failed previous platinum-based chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Doxorubicin; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure; Vomiting | 2008 |
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Survival Analysis; Taxoids | 2008 |
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Pyrazoles; Salvage Therapy; Sulfonamides; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids; Treatment Outcome | 2009 |
Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Severity of Illness Index; Survival Analysis; Taxoids | 2008 |
Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Treatment Outcome | 2009 |
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2009 |
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Interleukin-2; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Recombinant Proteins; Taxoids; Treatment Outcome | 2009 |
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2009 |
Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2009 |
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2009 |
First line chemotherapy with weekly docetaxel and cisplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2009 |
Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2009 |
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Assessing quality of life in a randomized clinical trial: correcting for missing data.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Linear Models; Longitudinal Studies; Male; Markov Chains; Probability; Quality of Life; Statistics as Topic; Surveys and Questionnaires; Taxoids | 2009 |
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Topics: Adult; Aged; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Dosage Calculations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gemcitabine; Histone Chaperones; Humans; Male; Middle Aged; Mutation; Nuclear Proteins; Pharmacogenetics; RNA, Messenger; RNA, Neoplasm; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Astragalus propinquus; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Interactions; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Plant Extracts; Survival Rate; Taxoids | 2009 |
Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Feasibility Studies; Fever; Humans; Infusions, Intravenous; Liver Diseases; Lung Neoplasms; Metabolic Clearance Rate; Monte Carlo Method; Neutropenia; Taxoids | 2009 |
Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; United States; Zoledronic Acid | 2010 |
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Demography; Docetaxel; Female; Hexanones; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Reactive Oxygen Species; Taxoids; Treatment Outcome | 2010 |
Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Carcinoma, Non-Small-Cell Lung; Dipeptides; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Taxoids | 2009 |
[rh-endostatin in combination with docetaxel and carboplatin as adjuvant treatment for non-small lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endostatins; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Taxoids | 2009 |
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Radiotherapy; Taxoids | 2009 |
A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2009 |
Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cytokines; Docetaxel; Enterotoxins; Europe; Female; Humans; Immunoconjugates; Kidney Neoplasms; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Pancreatic Neoplasms; Recombinant Fusion Proteins; Taxoids; Time Factors; Treatment Outcome; United States | 2009 |
A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Survival Analysis; Taxoids | 2010 |
A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Docetaxel; Double-Blind Method; Fatigue; Female; Genetic Association Studies; Genotype; Humans; Infliximab; Lung Neoplasms; Male; Polymorphism, Genetic; Quality of Life; Taxoids; Tumor Necrosis Factor-alpha; Weight Loss | 2010 |
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2009 |
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Taxoids | 2009 |
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Nicotinic; Survival Analysis; Taxoids | 2010 |
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Combinations; Drug Dosage Calculations; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Survival Analysis; Taxoids; Tegafur | 2010 |
Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Infections; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids | 2010 |
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2009 |
First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2010 |
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Taxoids | 2010 |
Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Taxoids | 2010 |
A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taxoids | 2010 |
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Logistic Models; Lung Neoplasms; Male; Mutation; Odds Ratio; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2010 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Concurrent chemoradiation therapy with docetaxel/cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival; Taxoids; Time Factors; Treatment Outcome | 2010 |
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; ErbB Receptors; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nomograms; Radiotherapy, Adjuvant; Suramin; Taxoids; Treatment Outcome | 2010 |
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Retreatment; Taxoids; Time Factors | 2010 |
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2010 |
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Humans; Lung; Lung Neoplasms; Middle Aged; Radiation Pneumonitis; Radiotherapy Dosage; Retrospective Studies; Taxoids; Tumor Burden | 2010 |
Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quality of Life; Singapore; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Young Adult | 2010 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2010 |
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Tennessee; Treatment Outcome | 2010 |
Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Taxoids; Vindesine | 2010 |
Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Quality of Life; Recurrence; Survival Analysis; Sweden; Taxoids; Treatment Outcome | 2011 |
Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2011 |
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Sirolimus; Taxoids | 2010 |
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2010 |
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; United States | 2010 |
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tubulin Modulators; Urologic Neoplasms; Vorinostat | 2012 |
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome; Tumor Burden | 2011 |
Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Radiation-Sensitizing Agents; Recombinant Proteins; Remission Induction; Taxoids; Translational Research, Biomedical; Tumor Stem Cell Assay | 2011 |
Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Survival Rate; Taxoids | 2010 |
A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Taxoids; Tubulin Modulators; Tumor Burden | 2011 |
A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2010 |
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2011 |
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Recurrence; Research Design; Smoking; Taxoids | 2011 |
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Gossypol; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Taxoids | 2011 |
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Quality of Life; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2011 |
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Diketopiperazines; Docetaxel; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Pain; Taxoids; Vomiting | 2012 |
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Survival Rate; Taxoids; Thymidylate Synthase; Treatment Outcome | 2011 |
Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Japan; Lung Neoplasms; Male; Mitomycin; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vindesine | 2011 |
Docetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancer.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Injections; Lung Neoplasms; Middle Aged; Taxoids; Trachea; Tumor Suppressor Protein p53 | 2011 |
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Research Design; Taxoids; Treatment Outcome | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mu
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Genes, ras; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Taxoids; Vinblastine; Vinorelbine | 2011 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome; Tumor Burden | 2011 |
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids; Treatment Outcome | 2012 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Female; Gene Dosage; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Taxoids | 2011 |
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mucositis; Neutropenia; Quinazolines; Taxoids | 2011 |
Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Docetaxel; Dyspnea; Female; Humans; Lung Neoplasms; Male; Survival Rate; Taxoids | 2012 |
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Topics: Amino Acid Sequence; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Neoplasm Staging; Patient Compliance; Peptide Fragments; T-Lymphocytes; Taxoids; Telomerase | 2011 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Quality of Life; Sulfonamides; Taxoids | 2011 |
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Taxoids | 2011 |
Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Dyspnea; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukopenia; Levofloxacin; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ofloxacin; Pain; Taxoids | 2011 |
Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Time Factors | 2012 |
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier O
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2012 |
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neovascularization, Pathologic; Positron-Emission Tomography; Taxoids; Thyroid Gland; Vascular Endothelial Growth Factor A | 2012 |
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Docetaxel; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy.
Topics: Aged; Aged, 80 and over; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Taxoids; Treatment Outcome | 2012 |
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cranial Irradiation; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids | 2012 |
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Taxoids | 2012 |
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Integrins; Lung Neoplasms; Male; Middle Aged; Snake Venoms; Taxoids | 2013 |
Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Taxoids | 2012 |
First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Organoplatinum Compounds; Taxoids | 2012 |
A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale an
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Humans; Lung Neoplasms; Ramucirumab; Research Design; Survival Analysis; Taxoids | 2012 |
A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Taxoids | 2012 |
Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Analysis; Taxoids | 2012 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Prognosis; Proportional Hazards Models; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiotherapy, Conformal; Survival Rate; Taxoids | 2012 |
Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2012 |
Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Oxonic Acid; Taxoids; Tegafur | 2012 |
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids | 2013 |
Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Confidence Intervals; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pemetrexed; Proportional Hazards Models; Taxoids; Treatment Outcome | 2013 |
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Topics: Adult; Aged; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Taxoids | 2013 |
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Taxoids; Treatment Outcome | 2013 |
Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2013 |
Study shows 2-year survival advantage for docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2002 |
A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2002 |
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Infections; Lung Neoplasms; Male; Neutropenia; Paclitaxel; Taxoids | 2002 |
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids | 2002 |
Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Period; Safety; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
[Comparison of effects of three chemotherapy regimens for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2002 |
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2003 |
Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Ifosfamide; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2003 |
Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; White People | 2003 |
Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Orosomucoid; Paclitaxel; Prognosis; Proportional Hazards Models; Taxoids; Time Factors; Treatment Outcome | 2003 |
[Efficacy of docetaxel (TXT) combined with cisplatin (CDDP) in non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2003 |
Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids | 2003 |
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival; Taxoids; Treatment Outcome | 2003 |
Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Remission Induction; Taxoids; Treatment Outcome | 2003 |
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; United States | 2003 |
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Taxoids; Treatment Outcome | 2003 |
A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2003 |
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2003 |
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Taxoids | 2004 |
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Enoxaparin; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomatitis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Confidence Intervals; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Proportional Hazards Models; Survival Analysis; Taxoids | 2003 |
Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Taxoids; Treatment Outcome | 2003 |
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Safety; Survival Analysis; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2004 |
A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Safety; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Survival Analysis; Taxoids; Vomiting | 2004 |
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids; Vindesine | 2004 |
Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pain; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2004 |
Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2004 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mass Screening; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2004 |
Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids | 2004 |
Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Fever; Health Status; Humans; Lung Neoplasms; Male; Neutropenia; Taxoids; Treatment Outcome | 2004 |
Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2004 |
Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Endpoint Determination; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids | 2004 |
Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2004 |
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Diarrhea; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Squamous Cell; Neutropenia; Organoplatinum Compounds; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2004 |
Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids; Treatment Outcome | 2004 |
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Adducts; DNA Repair; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Dose escalation of docetaxel concomitant with hypofractionated, once weekly chest radiotherapy for non-small-cell lung cancer: a phase I study.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Radiation-Sensitizing Agents; Taxoids | 2004 |
Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Time Factors | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2004 |
Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids | 2004 |
Preoperative chemotherapy increases cytokine production after lung cancer surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Cytokines; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Inflammation Mediators; Interleukin-6; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Period; Prospective Studies; Taxoids | 2004 |
Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2004 |
Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids; Treatment Outcome | 2004 |
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Survival Analysis; Taxoids; Vomiting | 2005 |
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids | 2005 |
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tumor Cells, Cultured | 2005 |
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Drug Administration Schedule; Female; Humans; Hydrocortisone; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Taxoids; Vindesine | 2005 |
Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2005 |
Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2005 |
Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2005 |
A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2005 |
Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Lung Neoplasms; Macrophages; Male; Middle Aged; Prognosis; Stromal Cells; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome | 2005 |
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Quinazolines; Survival Analysis; Taxoids | 2005 |
A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Sulindac; Taxoids | 2005 |
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
[A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia | 2005 |
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Interactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Taxoids | 2006 |
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Endostatins; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Nausea; Neoplasm Recurrence, Local; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
[Phase II study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non small cell lung cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2005 |
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2005 |
A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids | 2005 |
Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Endpoint Determination; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Nervous System Diseases; Quality of Life; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome; Vomiting, Anticipatory | 2005 |
A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2006 |
Breath alcohol concentrations in Japanese outpatients following paclitaxel and docetaxel infusion.
Topics: Adult; Aged; Alcoholic Intoxication; Antineoplastic Agents, Phytogenic; Asian People; Breast Neoplasms; Breath Tests; Carcinoma, Non-Small-Cell Lung; Docetaxel; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Outpatients; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiation Dosage; Taxoids; Thorax; Treatment Outcome | 2006 |
Weekly short infusion of taxotere at a 4 week cycle in Chinese patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based non-taxane chemotherapy--a Phase II trial.
Topics: Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Irinotecan; Italy; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2006 |
Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Taxoids; Treatment Outcome | 2006 |
Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Taxoids; Thailand | 2006 |
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Vinblastine | 2006 |
A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2006 |
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Recurrence; Risk Assessment; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2006 |
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Taxoids | 2006 |
Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids | 2006 |
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Topotecan | 2006 |
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Patient Compliance; Platinum; Prospective Studies; Psychomotor Performance; Quality of Life; Sickness Impact Profile; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Health Services for the Aged; Humans; Italy; Lung Neoplasms; Male; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids; Treatment Outcome | 2006 |
[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Survival Rate; Taxoids; Vomiting | 2006 |
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Japan; Lung Neoplasms; Male; Odds Ratio; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immunoconjugates; Lung Neoplasms; Male; Mice; Middle Aged; Quality of Life; Survival Rate; Taxoids; Treatment Outcome; United States | 2006 |
[A randomized control clinical trial of Euruikang (docetaxel) in treatment of advanced non-small cell lung cancer (NSCLC)].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Remission Induction; Taxoids; Young Adult | 2006 |
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2007 |
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Staging; Southwestern United States; Survival Analysis; Survival Rate; Taxoids; Time Factors | 2006 |
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vomiting | 2007 |
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Smoking; Survival Analysis; Taxoids | 2007 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2006 |
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Taxoids; Treatment Outcome; United States | 2006 |
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Taxoids; Time Factors; Treatment Outcome | 2007 |
Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2007 |
Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Evaluation; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Survival Rate; Taxoids | 2007 |
Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2007 |
A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Taxoids | 2007 |
A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Taxoids; Treatment Outcome | 2007 |
Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contraindications; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Radiation-Sensitizing Agents; Retrospective Studies; Severity of Illness Index; Survival Rate; Taiwan; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids | 2007 |
[Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; France; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Surveys and Questionnaires; Survival Rate; Taxoids | 2006 |
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Proportional Hazards Models; Research Design; Retrospective Studies; Sex Factors; Taxoids; Time Factors; Treatment Outcome | 2007 |
An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comorbidity; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Follow-Up Studies; Health Status; Humans; Lung Neoplasms; Male; Nausea; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Time Factors; Vomiting | 2007 |
A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Linear Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Neutropenia; Probability; Proportional Hazards Models; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids | 2006 |
Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).
Topics: Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Karnofsky Performance Status; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Risk Factors; Survival Analysis; Taxoids | 2006 |
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids | 2007 |
A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Taxoids | 2007 |
A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
[Phase I study of docetaxel combined with carboplatin in patients with non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Taxoids | 2006 |
Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prospective Studies; Taxoids; Thrombospondin 1; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Humans; Prospective Studies; Taxoids | 2007 |
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Lung Neoplasms; Male; Maryland; Middle Aged; New York; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2007 |
An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Staging; Patient Selection; Pleural Neoplasms; Severity of Illness Index; Taxoids; Treatment Outcome | 2007 |
Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2007 |
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Metalloporphyrins; Middle Aged; Prognosis; Survival Rate; Taxoids | 2007 |
Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Tegafur; Uracil | 2008 |
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids | 2008 |
Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Follow-Up Studies; Hong Kong; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prodrugs; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2007 |
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Taxoids; Treatment Outcome | 2007 |
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Placebos; Quinazolines; Taxoids | 2007 |
Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; DNA Repair; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mitomycin; Neoplasm Staging; Neoplasms, Squamous Cell; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Sulindac; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Radiofrequency Therapy; Radiotherapy, Adjuvant; Taxoids; Temperature; Treatment Outcome | 2007 |
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2007 |
Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy.
Topics: Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Orosomucoid; Radiotherapy; Reproducibility of Results; Taxoids | 2007 |
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Irinotecan; Male; Middle Aged; Taxoids; Treatment Outcome | 2007 |
A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Analysis; Taxoids | 2008 |
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2008 |
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Taxoids | 2008 |
Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Survival Analysis; Taxoids | 2008 |
The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Salvage Therapy; Taxoids | 2008 |
Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Second-line treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Taxoids | 2009 |
A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Middle Aged; Pilot Projects; Practice Patterns, Physicians'; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Induction chemotherapy followed by parenchyma-sparing surgery in medically inoperable NSCLC-results of a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Taxoids | 2008 |
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Polyglutamic Acid; Quality of Life; Taxoids; Treatment Outcome | 2008 |
Docetaxel in stage III and IV non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids | 1995 |
[Late phase II trial of RP56976 (Docetaxel) in patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Taxoids; Vomiting | 1995 |
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Premedication; Survival Rate; Taxoids | 1995 |
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Hypersensitivity; Drug Resistance; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids | 1995 |
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids | 1994 |
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].
Topics: Adolescent; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1994 |
[Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Docetaxel Cooperative Study Group for Lung Cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 1994 |
Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1996 |
A phase II trial of docetaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1996 |
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1997 |
Clinical studies of docetaxel (Taxotere) and concomitant chest therapy.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Radiation Dosage; Research Design; Taxoids; Thorax | 1997 |
The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Phase I study of docetaxel with concomitant thoracic radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Taxoids; Treatment Outcome | 1998 |
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bayes Theorem; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1998 |
First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome | 1998 |
New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lenograstim; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 1998 |
Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1998 |
Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Treatment Outcome | 1998 |
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Infusions, Intravenous; Likelihood Functions; Lung Neoplasms; Metabolic Clearance Rate; Neoplasms; Paclitaxel; Prospective Studies; Sampling Studies; Specimen Handling; Taxoids | 1997 |
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Recombinant Proteins; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Time Factors; Treatment Outcome | 1998 |
Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 1999 |
Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioblastoma; Humans; Lung Neoplasms; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pelvic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1998 |
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids | 1999 |
[Evaluation of chemotherapy with docetaxel and cisplatin in advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Evaluation; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality of Life; Sickness Impact Profile; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Survival Analysis; Taxoids | 1999 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Paclitaxel; Taxoids | 1999 |
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Europe; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Mexico; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Survival Analysis; Taxoids; United States | 2000 |
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2000 |
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Mas; Recombinant Proteins; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diosmin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisolone; Premedication; Taxoids; Time Factors | 2000 |
Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
[Phase II study of docetaxel in inoperable advanced non small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Water-Electrolyte Balance | 2000 |
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Microtubules; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 2000 |
Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2001 |
A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2001 |
Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Taxoids | 2001 |
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids | 2002 |
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dermatitis; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Taxoids | 2002 |
Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Reference Values; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
560 other study(ies) available for docetaxel anhydrous and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunologic Factors; Immunotherapy; Lung Neoplasms; Ramucirumab; Treatment Outcome | 2022 |
Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Ramucirumab; Retrospective Studies; Treatment Outcome | 2022 |
Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Comparative Effectiveness Research; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Nivolumab; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2021 |
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Ramucirumab; Retrospective Studies | 2022 |
Topics: Artemisia; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Ethanol; Ferroptosis; Humans; Lung Neoplasms; Models, Biological; Plant Extracts; Signal Transduction; STAT3 Transcription Factor; Survivin | 2021 |
Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Japan; Lung Neoplasms; Male; Marketing; Neoplasm Recurrence, Local; Prospective Studies; Ramucirumab | 2022 |
Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2022 |
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Epithelial Cells; Humans; Lung Neoplasms; Ramucirumab; Retrospective Studies; Treatment Outcome | 2022 |
Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Taiwan | 2022 |
Synthetic polymer material modified by d-peptide and its targeted application in the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; Peptides; Polymers; Tumor Microenvironment | 2022 |
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Retrospective Studies | 2022 |
Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Japan; Lung Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years; Ramucirumab | 2022 |
A rare case of docetaxel-induced myositis in a patient with a lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Fatigue; Humans; Lung Neoplasms; Male; Myositis; Pain | 2022 |
DTX-P7, a peptide-drug conjugate, is highly effective for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Lung Neoplasms; Peptides | 2022 |
Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum-Based Chemotherapy on Elderly Lung Cancer.
Topics: Aged; Antigens, Neoplasm; Artificial Intelligence; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Keratin-19; Lung Neoplasms; Pemetrexed; Platinum; Tomography; Tomography, X-Ray Computed | 2022 |
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung Neoplasms; Nivolumab; Paclitaxel; Pemetrexed | 2022 |
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Microtubule Proteins; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Tumor Suppressor Protein p53 | 2022 |
Non-small-cell lung cancer patients harboring
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Tumor Suppressor Protein p53 | 2022 |
Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms | 2022 |
Influence of using history of immune checkpoint inhibitor therapy for neutropenia caused by combination therapy of ramucirumab and docetaxel.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neutropenia; Ramucirumab; Retrospective Studies | 2022 |
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2022 |
PROSPECTS OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER AS A METHOD OF IMPROVING SURVIVAL.
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2022 |
[Multidisciplinary Treatment for Postoperative Recurrent Patients-Report of a Long-Term Survivor].
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Nivolumab; Pemetrexed; Survivors | 2022 |
Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non-small cell lung cancer patients.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Heterografts; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Treatment Outcome; Zebrafish | 2023 |
[Difference in Chemotherapy for Lung Cancer between Asian and Caucasian].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2023 |
Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Ramucirumab; Retrospective Studies | 2023 |
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; NF-E2-Related Factor 2; Platinum; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Taxoids | 2023 |
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Platinum; Ramucirumab; Retrospective Studies; Taxoids | 2023 |
What's Next for Sotorasib in NSCLC?
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Costs; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Survival Analysis | 2023 |
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Lung Neoplasms; Mice | 2023 |
Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; United States | 2023 |
Flashback Foreword: Docetaxel Versus Best Supportive Care in Non-Small-Cell Lung Cancer and Pemetrexed Versus Docetaxel in Second-Line Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Pemetrexed; Treatment Outcome | 2023 |
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras) | 2023 |
Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Prospective Studies; Retrospective Studies; Taxoids | 2023 |
Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Taxoids | 2023 |
Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Docetaxel; Humans; Lung Neoplasms; Quality-Adjusted Life Years | 2023 |
Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Ligands; Lung Neoplasms; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer | 2023 |
Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras) | 2023 |
[Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of
Operable Stage III NSCLC].
Topics: Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Programmed Cell Death 1 Receptor; Prospective Studies; Quality of Life; Reproducibility of Results | 2023 |
IL-1β is involved in docetaxel chemoresistance by regulating the formation of polyploid giant cancer cells in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Giant Cells; Histones; Humans; Lung Neoplasms; Polyploidy | 2023 |
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung; Lung Neoplasms; Retrospective Studies | 2023 |
Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Nivolumab | 2023 |
Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Nivolumab | 2023 |
Immunotherapy as a later-line option for
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Paclitaxel; Taxoids | 2023 |
Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Ramucirumab; Retrospective Studies | 2023 |
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Topics: Aged; Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Randomized Controlled Trials as Topic; Retreatment; Survival Rate | 2019 |
Baicalein enhances the antitumor efficacy of docetaxel on nonsmall cell lung cancer in a β-catenin-dependent manner.
Topics: Animals; Antioxidants; beta Catenin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Therapy, Combination; Flavanones; Humans; Lung Neoplasms; Male; Mice | 2020 |
Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Synergism; Female; Humans; Immunomodulation; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Ramucirumab; Retrospective Studies; Treatment Outcome | 2019 |
[Efforts to Reduce the Risk of Febrile Neutropenia and to Increase the Response Rate to Docetaxel and Ramucirumab Therapy in Patients with Non-Small Cell Lung Cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Ramucirumab; Recombinant Proteins; Retrospective Studies | 2019 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials - an empirical analysis of bias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Female; Historically Controlled Study; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2020 |
First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation | 2019 |
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lung Neoplasms; Male; Markov Chains; Nivolumab; Quality-Adjusted Life Years | 2020 |
Effect of Docetaxel Combined with Cisplatin Preoperative Neoadjuvant Chemotherapy for Stage III NSCLC.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Preoperative Care; Retrospective Studies; Treatment Outcome | 2019 |
Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Factors; ROC Curve; Survival Rate | 2019 |
PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Datasets as Topic; Docetaxel; Drug Resistance, Neoplasm; Dynamins; Humans; Lung Neoplasms; Mice; Mice, SCID; Mitochondria; Mitochondrial Dynamics; Proto-Oncogene Proteins c-pim-1; Reactive Oxygen Species; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Induction of apoptosis increases sensitivity to detect cancer mutations in plasma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Circulating Tumor DNA; Docetaxel; Humans; Liquid Biopsy; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mutation; Specimen Handling; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Drug Synergism; Female; Humans; Immune Checkpoint Inhibitors; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Propensity Score; Ramucirumab; Retrospective Studies; Tegafur | 2020 |
Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD11 Antigens; Cell Line, Tumor; Chemokines; Combined Modality Therapy; Cytokines; Docetaxel; Epidermal Growth Factor; ErbB Receptors; Female; HMGB1 Protein; Humans; Integrin alpha Chains; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Transcriptional Activation | 2020 |
α
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Carriers; Half-Life; Humans; Integrin alpha3beta1; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; Peptides; Tissue Distribution; Xenograft Model Antitumor Assays | 2020 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
Efficacy of hypofractionated radiotherapy combined with docetaxel in middle and advanced non-small cell lung cancer and its effects on serum MMP-9 and VEGF expressions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Matrix Metalloproteinase 9; Vascular Endothelial Growth Factor A | 2021 |
Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Indoles; Lung; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Taxoids; Treatment Outcome | 2020 |
Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Machine Learning; Male; Nivolumab; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2020 |
Doublet therapy effective in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Pemetrexed | 2020 |
The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Safety; Prognosis; Ramucirumab; Retrospective Studies; Survival Rate | 2020 |
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Acceptance of Health Care; Platinum; Ramucirumab; Taxoids | 2021 |
Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Glucocorticoids; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Prednisolone; Radiation Pneumonitis; Retrospective Studies; Withholding Treatment | 2020 |
Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Indoles; Lung Neoplasms; Neoadjuvant Therapy | 2020 |
Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Predictive Value of Tests; Prognosis; Survival Analysis | 2020 |
Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Ramucirumab; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2020 |
Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors | 2020 |
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2020 |
The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Ramucirumab | 2020 |
Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 c
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; GPI-Linked Proteins; Humans; Induction Chemotherapy; Keratin-19; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; ROC Curve; Survival Rate | 2020 |
Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Docetaxel gold complex nanoflowers: A chemo-biological evaluation for their use as nanotherapeutics.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Gold; Humans; Lung Neoplasms; Metal Nanoparticles | 2020 |
Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Telmisartan; Xenograft Model Antitumor Assays | 2020 |
Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Retrospective Studies | 2020 |
Enhanced Antitumor Efficacy of Docetaxel-Loaded Monomethoxy Poly(ethylene glycol)-Poly(D, L-lactide-co-glycolide) Amphiphilic Copolymer Against Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dioxanes; Docetaxel; Drug Carriers; Humans; Lung Neoplasms; Nanoparticles; Polyethylene Glycols | 2020 |
Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Development of psoriasis during docetaxel therapy in a patient with non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Psoriasis; Taxoids; Treatment Outcome | 2020 |
Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC.
Topics: A549 Cells; Aged; Autophagy; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Pyridines | 2020 |
Fabrication, optimisation and
Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cobalt; Curcumin; Docetaxel; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hemolysis; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Lipids; Lung Neoplasms; Microspheres; Nanostructures; Particle Size; Temperature; Tetrazolium Salts; Thiazoles; X-Ray Diffraction | 2020 |
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Indoles; Lung Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2020 |
Formulation and
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Chitosan; Docetaxel; Drug Carriers; Humans; Lung Neoplasms; Nanomedicine; Nanoparticles | 2020 |
Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Docetaxel; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality-Adjusted Life Years | 2020 |
Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Chick Embryo; Chorioallantoic Membrane; Cisplatin; Crizotinib; Docetaxel; Drug Screening Assays, Antitumor; Gefitinib; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms | 2020 |
Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neutropenia; Taxoids | 2021 |
Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Application of Machine Learning for Tumor Growth Inhibition - Overall Survival Modeling Platform.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Machine Learning; Models, Biological; Randomized Controlled Trials as Topic | 2021 |
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Randomized Controlled Trials as Topic; Time Factors; Tubulin Modulators; Young Adult | 2021 |
Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John's wort skin oil.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Hypericum; Lung Neoplasms; Middle Aged; Phytochemicals; Ramucirumab | 2021 |
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring
Topics: AMP-Activated Protein Kinase Kinases; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mutation; NF-E2-Related Factor 2; Protein Serine-Threonine Kinases | 2021 |
Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.
Topics: Adult; Algorithms; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Genetic Variation; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ritonavir | 2021 |
Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2021 |
Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel.
Topics: A549 Cells; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cystine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Homeostasis; Humans; Lung Neoplasms; Male; Mice, Nude; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; Tumor Microenvironment; Up-Regulation | 2021 |
Molecular Analysis of
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Neoplasm Proteins; Paclitaxel; Protein Isoforms; Survival Rate | 2021 |
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Prognosis; Retrospective Studies; Survival Rate | 2022 |
Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2021 |
Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chemistry, Pharmaceutical; Docetaxel; Drug Carriers; Drug Liberation; Exosomes; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |
A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nomograms; Progression-Free Survival; Risk Assessment | 2021 |
Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Progression-Free Survival | 2021 |
Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Delivery Systems; Drug Synergism; Humans; Liposomes; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Transferrin; Xenograft Model Antitumor Assays | 2021 |
Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Progression-Free Survival; Ramucirumab; Retrospective Studies | 2022 |
Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.
Topics: A549 Cells; Angelica; Angiogenesis Inhibitors; Animals; Apoptosis; Astragalus Plant; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Plant Extracts; Protein Kinase Inhibitors; Signal Transduction; STAT3 Transcription Factor; Trichosanthes; Xenograft Model Antitumor Assays | 2021 |
[Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer].
Topics: Aged; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Retrospective Studies | 2021 |
Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Taxoids | 2017 |
Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2017 |
Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Combinations; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pemetrexed; Pyridines; Ribonucleoside Diphosphate Reductase; Taxoids; Tegafur; Thymidylate Synthase; Tubulin; Tumor Suppressor Proteins | 2017 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Approval; Dyspnea; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
The effects of advanced age and serum α
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Orosomucoid; Prospective Studies; Taxoids | 2017 |
A high-content image analysis approach for quantitative measurements of chemosensitivity in patient-derived tumor microtissues.
Topics: Antineoplastic Agents; Automation, Laboratory; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Screening Assays, Antitumor; Humans; Image Processing, Computer-Assisted; Microscopy, Confocal | 2017 |
Assessment of Erythroid and Granulocytic Hematopoietic Lineages in Patients with Non-Small-Cell Lung Carcinoma.
Topics: Anthracyclines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cisplatin; Disaccharides; Docetaxel; Doxorubicin; Erythropoiesis; Granulocytes; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Macrolides; Nitrosourea Compounds; Organoplatinum Compounds; Taxoids | 2017 |
Enhanced antitumor effect on intrapulmonary tumors of docetaxel lung-targeted liposomes in a rabbit model of VX2 orthotopic lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Compounding; Female; Humans; Injections, Intravenous; Liposomes; Lung Neoplasms; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Rabbits; Survival Analysis; Tumor Burden | 2017 |
Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Keratin-19; Lung Neoplasms; Male; Middle Aged; Prognosis; Taxoids | 2017 |
Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Combinations; Gene Silencing; Gene Transfer Techniques; Humans; Inhibitor of Apoptosis Proteins; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Particle Size; Phosphofructokinase-2; Plasmids; RNA-Induced Silencing Complex; RNA, Small Interfering; Surface Properties; Taxoids; Tumor Burden | 2017 |
Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Metastasis; Nivolumab; Quinazolines; Ramucirumab; Taxoids | 2017 |
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Treatment Outcome | 2017 |
High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Pemetrexed; Taxoids; Thymidylate Synthase; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Proportional Hazards Models; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2018 |
Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nivolumab; Proportional Hazards Models; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Nivolumab in HIV-related non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD4 Lymphocyte Count; Cisplatin; Darunavir; Deoxycytidine; Docetaxel; Gemcitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxazines; Piperazines; Pyridones; Ritonavir; Vinorelbine | 2017 |
The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Retrospective Studies; Sepsis; Taxoids; Tazobactam | 2017 |
Verapamil (VER) Enhances the Cytotoxic Effects of Docetaxel and Vinblastine Combined Therapy Against Non-Small Cell Lung Cancer Cell Lines.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Synergism; Drug Therapy, Combination; Gene Expression; Humans; Lung Neoplasms; Taxoids; Verapamil; Vinblastine | 2018 |
The exposure-effect-toxicity correlation of docetaxel and magnesium isoglycyrrhizinate in non-small cell lung tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Docetaxel; Dose-Response Relationship, Drug; Hepatocytes; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Models, Biological; Saponins; Taxoids; Triterpenes; Xenograft Model Antitumor Assays | 2018 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Caspase cleavage of Mcl-1 impairs its anti-apoptotic activity and proteasomal degradation in non-small lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Binding Sites; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Gene Expression; Humans; Lung Neoplasms; Mitochondria; Molecular Docking Simulation; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Proteolysis | 2018 |
Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Cisplatin; Cytostatic Agents; Dihydroxycholecalciferols; Docetaxel; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins c-sis; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Topics: Biomarkers, Tumor; Bridged-Ring Compounds; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Mutation; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2018 |
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nivolumab; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2018 |
α-Conotoxin ImI-modified polymeric micelles as potential nanocarriers for targeted docetaxel delivery to α7-nAChR overexpressed non-small cell lung cancer.
Topics: A549 Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Carcinoma, Non-Small-Cell Lung; Conotoxins; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Micelles; Nanocapsules; Polymers; Random Allocation; Taxoids | 2018 |
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Costs; Health Policy; Humans; Lung Neoplasms; Nivolumab; Survival Analysis | 2018 |
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms | 2018 |
Chondritis of the ear after docetaxel-carboplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged | 2019 |
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel.
Topics: Adult; Aged; Biomarkers, Tumor; Blood Platelets; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Inflammation; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Prognosis; Treatment Outcome | 2018 |
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Organizational Case Studies; Quality-Adjusted Life Years; Taxoids | 2018 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Bortezomib; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Computational Biology; Databases, Factual; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Machine Learning; Multiple Myeloma; Triple Negative Breast Neoplasms | 2018 |
Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Beclin-1; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Docetaxel; Endonucleases; Endoplasmic Reticulum Chaperone BiP; Female; Heat-Shock Proteins; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Republic of Korea; Retrospective Studies | 2019 |
FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.
Topics: Apoptosis; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Self Renewal; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Neoplastic Stem Cells; Taxoids | 2018 |
Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis.
Topics: A549 Cells; Aniline Compounds; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Polarity; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockout Techniques; Humans; Lung Neoplasms; Membrane Proteins; Mitochondria; Proto-Oncogene Proteins; Sulfonamides; Transfection | 2018 |
Avelumab in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Platinum | 2018 |
Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Retreatment; Treatment Outcome | 2019 |
A case report of metastatic lung adenocarcinoma with long-term survival for over 11 years.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Piperazines; Protein Kinase Inhibitors | 2019 |
Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Metastasis; Nivolumab; Survival Rate | 2017 |
Cancer-cell-secreted CXCL11 promoted CD8
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CXCL11; Chemotaxis, Leukocyte; Docetaxel; Female; HMGB1 Protein; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Mice, Nude; Receptor, ErbB-2; Tumor Microenvironment | 2019 |
Inference on covariate effect types for treatment effectiveness in a randomized trial with a binary outcome.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Prognosis; Randomized Controlled Trials as Topic; Research Design | 2019 |
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy; Indoles; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2019 |
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Polyethylene Glycols; Pre-Exposure Prophylaxis; Ramucirumab; Recombinant Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Pre-Exposure Prophylaxis; Ramucirumab; Recombinant Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Polymorphism, Single Nucleotide | 2019 |
Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxonic Acid; Ramucirumab; Retreatment; Tegafur; Treatment Outcome | 2019 |
[Study on the Metabolic Reprogramming of Lung Cancer Cells Regulated by Docetaxel Based on Metabolomics].
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Metabolomics | 2019 |
Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; ErbB Receptors; Female; Humans; Immunoconjugates; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Oligopeptides; Xenograft Model Antitumor Assays | 2019 |
Development and characterization of octreotide-modified curcumin plus docetaxel micelles for potential treatment of non-small-cell lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Curcumin; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Octreotide; Polyethylene Glycols; Polyvinyls | 2019 |
Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pleural Effusion, Malignant; Prognosis; Prospective Studies; Quality of Life; Surgery, Computer-Assisted; Thoracoscopy; Treatment Outcome | 2019 |
Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Endothelium, Vascular; Ki-67 Antigen; Lung Neoplasms; Male; Mice; Mice, Nude; Microvessels; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Sirolimus; Specific Pathogen-Free Organisms; Taxoids; Thrombosis; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Taxoids; Vascular Endothelial Growth Factor A | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Docetaxel; Forkhead Box Protein O1; Forkhead Transcription Factors; Homeodomain Proteins; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Taxoids | 2013 |
Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2013 |
ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non- small cell lung cancer.
Topics: ABO Blood-Group System; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; Female; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2013 |
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncology Nursing; Paclitaxel; Platinum Compounds; Randomized Controlled Trials as Topic; Southwestern United States; Taxoids; Tubulin Modulators; Vinblastine; Vinorelbine | 2013 |
DNA microarray reveals different pathways responding to paclitaxel and docetaxel in non-small cell lung cancer cell line.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Real-Time Polymerase Chain Reaction; Signal Transduction; Taxoids | 2013 |
Poly-L-asparagine nanocapsules as anticancer drug delivery vehicles.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Drug Carriers; Drug Compounding; Drug Delivery Systems; Humans; Lipids; Lung Neoplasms; Nanocapsules; Particle Size; Peptides; Surface-Active Agents; Taxoids | 2013 |
Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Interphase; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Taxoids | 2014 |
Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2013 |
Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine; Weight Gain; Weight Loss | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Drug Therapy, Combination; Humans; Loperamide; Lung Neoplasms; Male; Neoplasm Staging; Taxoids; Tomography, X-Ray Computed | 2013 |
Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Docetaxel; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Tumor Burden; Tumor Cells, Cultured | 2013 |
Rapid and sensitive liquid chromatography coupled with electrospray ionization tandem mass spectrometry method for the analysis of paclitaxel, docetaxel, vinblastine, and vinorelbine in human plasma.
Topics: Antineoplastic Agents; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2014 |
Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Community Networks; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Pemetrexed; Practice Patterns, Physicians'; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Gefitinib and non-small cell lunt cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2013 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Feasibility re-evaluation of 75 mg/m² docetaxel in Japanese patients with previously treated non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Febrile Neutropenia; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Patient Selection; Retreatment; Taxoids; Treatment Outcome | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Taxoids; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Taxoids | 2014 |
Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy; Taxoids | 2014 |
Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Female; Lung Neoplasms; Mice; Mice, Nude; Multimodal Imaging; Nanoparticles; Positron-Emission Tomography; Taxoids; Tomography, X-Ray Computed | 2014 |
Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Tumor Cells, Cultured | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
The TAILOR study: to agree or to disagree?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Research Design; Salvage Therapy; Taxoids | 2014 |
Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclohexanecarboxylic Acids; Docetaxel; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Taxoids; Thiazoles | 2014 |
Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Humans; Immunotherapy; Interleukin-2 Receptor alpha Subunit; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; T-Lymphocytes, Regulatory; Taxoids; Treatment Outcome | 2014 |
Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Lineage; Docetaxel; Female; Humans; Immunophenotyping; Lung Neoplasms; Lymphocyte Depletion; Male; Middle Aged; Neoplasm Staging; T-Lymphocytes, Regulatory; Taxoids | 2014 |
Chitosan cross-linked docetaxel loaded EGF receptor targeted nanoparticles for lung cancer cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cetuximab; Chitosan; Docetaxel; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Nanoparticles; NIH 3T3 Cells; Polyglutamic Acid; Taxoids | 2014 |
Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clarithromycin; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Odds Ratio; Retrospective Studies; Severity of Illness Index; Sex Factors; Taxoids | 2013 |
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Endothelium, Vascular; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2015 |
Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Paclitaxel; Patient Selection; Taxoids; Treatment Outcome | 2014 |
Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Risk Factors; Taxoids; Vinblastine; Vinorelbine | 2014 |
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Feasibility Studies; Flow Cytometry; Humans; Liposomes; Lung Neoplasms; Particle Size; Taxoids | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutamates; Guanine; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pemetrexed; RNA, Messenger; Taxoids | 2014 |
Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Administration Schedule; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2014 |
Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Greece; Guideline Adherence; Humans; Lung Neoplasms; Male; Middle Aged; Practice Guidelines as Topic; Taxoids; Tertiary Care Centers; Vinblastine; Vinorelbine | 2015 |
Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cytochrome P-450 CYP1B1; Docetaxel; Female; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2015 |
HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.
Topics: Anaphase-Promoting Complex-Cyclosome; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Male; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Taxoids | 2015 |
Ramucirumab combination improves OS and PFS in NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Lung Neoplasms; Paclitaxel; Ramucirumab; Stomach Neoplasms; Survival Analysis; Taxoids | 2014 |
The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemokine CCL20; Disease Progression; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Receptors, CCR6; Signal Transduction; T-Lymphocytes, Regulatory; Taxoids | 2015 |
RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Retinoblastoma Protein; Survival Rate; Taxoids; Young Adult | 2015 |
Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fibronectins; Humans; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transforming Growth Factor beta; Tubulin; Vimentin | 2014 |
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids | 2015 |
DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chemokines; DNA Methylation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Taxoids | 2015 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
Immunomodulatory Protein from Ganoderma microsporum Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer Cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Autophagy-Related Protein 5; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fungal Proteins; Ganoderma; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred NOD; Microtubule-Associated Proteins; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; RNA, Small Interfering; Taxoids; Thapsigargin; TOR Serine-Threonine Kinases; Tunicamycin; Vincristine; Xenograft Model Antitumor Assays | 2015 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
[Therapeutic option after failure of first-line chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Evidence-Based Medicine; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Stathmin; Taxoids; Treatment Outcome | 2016 |
Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hemoglobins; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Prognosis; Taxoids; Treatment Outcome | 2015 |
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia | 2017 |
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Harringtonines; Homoharringtonine; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Male; Mice; Mice, Nude; Mitochondria; Phosphorylation; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Taxoids; Transplantation, Heterologous | 2015 |
Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Protein Kinase Inhibitors; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Topics: Afatinib; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retinal Dehydrogenase; Sequence Analysis, DNA; Taxoids | 2015 |
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Ramucirumab; Taxoids; Therapies, Investigational | 2016 |
Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Inhibitory Concentration 50; Lung Neoplasms; Malondialdehyde; Oxidative Stress; Taxoids; Tumor Suppressor Protein p53; Zinc | 2015 |
Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Female; High-Throughput Screening Assays; Lung Neoplasms; Mice; Mice, Nude; Mitosis; Molecular Docking Simulation; Mutation; Neoplasm Proteins; Poly (ADP-Ribose) Polymerase-1; Poly-ADP-Ribose Binding Proteins; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Interaction Domains and Motifs; Structure-Activity Relationship; Taxoids; Time Factors; Transfection; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2015 |
A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against non-small cell lung cancer.
Topics: Albumins; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Carriers; Humans; Mice; Nanoparticles; Polyethylene Glycols; Taxoids; Xenograft Model Antitumor Assays | 2015 |
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Taxoids; Treatment Outcome | 2015 |
Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclobutanes; Deoxycytidine; Docetaxel; Drug Administration Schedule; Endostatins; Female; Gemcitabine; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Perfusion Imaging; Recombinant Proteins; Taxoids; Tomography, Emission-Computed | 2015 |
Docetaxel inhibits the proliferation of non-small-cell lung cancer cells via upregulation of microRNA-7 expression.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Lung Neoplasms; MicroRNAs; Taxoids; Up-Regulation | 2015 |
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Philadelphia; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2015 |
Nedaplatin: a new platinum for squamous lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2015 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
KDR gene silencing inhibits proliferation of A549 cells and enhances their sensitivity to docetaxel.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; RNA Interference; RNA, Messenger; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition.
Topics: Animals; Antineoplastic Agents; BALB 3T3 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; HSP90 Heat-Shock Proteins; Lung; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Nanoparticles; Peptides; Taxoids; Tissue Distribution | 2016 |
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Pembrolizumab for the treatment of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Taxoids; Treatment Outcome | 2016 |
Pembrolizumab Outperforms Docetaxel for NSCLC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Taxoids; Treatment Outcome | 2016 |
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Management; Disease-Free Survival; Docetaxel; Health Services; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Models, Econometric; Models, Statistical; Nivolumab; Quality-Adjusted Life Years; Taxoids; Terminal Care | 2016 |
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Immunosuppressive Agents; Immunotherapy; Lung Neoplasms; Nivolumab; Practice Guidelines as Topic; Survival Rate; Taxoids | 2016 |
PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
Topics: Antibodies; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Taxoids | 2016 |
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Prospective Studies; Proto-Oncogene Proteins p21(ras); Survival Analysis; Taxoids; Treatment Outcome | 2016 |
A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Synergistic and attenuated effect of HSS in combination treatment with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1 tumor xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Synergism; Feeding Behavior; Humans; Lung Neoplasms; Mice, Nude; Plant Proteins; Taxoids; Xenograft Model Antitumor Assays | 2016 |
The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Data Mining; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; Drug Resistance, Neoplasm; Humans; MAP Kinase Signaling System; Precision Medicine; Proto-Oncogene Proteins p21(ras); Taxoids | 2016 |
Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Edema; Female; Flavonoids; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Taxoids; Xenograft Model Antitumor Assays | 2017 |
MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Databases, Nucleic Acid; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; RNA Interference; Taxoids | 2016 |
Docetaxel-loaded PEG-albumin nanoparticles with improved antitumor efficiency against non-small cell lung cancer.
Topics: A549 Cells; Albumins; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Polyethylene Glycols; Taxoids; Xenograft Model Antitumor Assays | 2016 |
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lung Neoplasms; Male; Nivolumab; Quality-Adjusted Life Years; Taxoids | 2016 |
Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Heterografts; Humans; Lactic Acid; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Taxoids | 2016 |
Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Caspase 8; Cell Proliferation; Docetaxel; Female; Fibronectins; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Neoplasm Staging; Phosphorylation; Prognosis; Proto-Oncogene Proteins pp60(c-src); Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gene Knockdown Techniques; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mitochondria; RNA Interference; Taxoids | 2016 |
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Humans; Models, Theoretical; Registries; Surveys and Questionnaires; Taxoids | 2017 |
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2016 |
Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Lung Neoplasms; MicroRNAs; Protein Isoforms; Pyruvate Kinase; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Taxoids; Transfection; Tumor Cells, Cultured; Up-Regulation | 2016 |
Ceritinib Outperforms Chemo as Second-Line Treatment.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crizotinib; Disease-Free Survival; Docetaxel; Drug Therapy; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones; Taxoids; Treatment Outcome | 2016 |
Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Industry corner: perspectives and controversies - The challenges of patient access to new medicines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Industry; Drugs, Investigational; European Union; Health Services Accessibility; Humans; Indoles; Lung Neoplasms; Needs Assessment; Taxoids | 2017 |
Ceritinib versus chemotherapy in ALK-positive lung cancer.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Pemetrexed; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sulfones; Taxoids | 2016 |
miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Taxoids | 2017 |
Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Topics: A549 Cells; Angiogenesis Inhibitors; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Immunoenzyme Techniques; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2017 |
Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Genotype; Humans; Lung Neoplasms; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Prognosis; Taxoids; Tubulin | 2017 |
Designing geriatric-specific trials in advanced lung cancer: What, who and how to study?
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Paclitaxel; Vinorelbine | 2017 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Reprogramming; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Energy Metabolism; Gene Expression Regulation, Neoplastic; Glucose; Humans; Lung Neoplasms; Neoplasm Proteins; PPAR gamma; Reactive Oxygen Species; Signal Transduction; Taxoids; Tumor Hypoxia; Tumor Microenvironment; Uncoupling Protein 2 | 2017 |
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Nivolumab; Programmed Cell Death 1 Receptor; Taxoids | 2016 |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Quinazolines; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2017 |
PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gene Silencing; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mitosis; Prognosis; Proto-Oncogene Proteins; Survival Analysis; Taxoids; Young Adult | 2017 |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Injections, Intralesional; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Otorhinolaryngologic Neoplasms; Pilot Projects; Salivary Gland Neoplasms; Taxoids; Tumor Burden; Wound Healing | 2008 |
[Combination chemotherapy with carboplatin and docetaxel for elderly patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Lung Neoplasms; Male; Retrospective Studies; Taxoids | 2008 |
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2008 |
Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Eruptions; Ectropion; Edema; Erythema; Humans; Male; Middle Aged; Taxoids | 2008 |
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Tumor Suppressor Proteins | 2008 |
Gefitinib or docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2008 |
[Sequential administration of gefitinib and docetaxel as second-line therapy for advanced non-small cell lung cancer: analysis of 82 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome | 2008 |
Subungueal pyogenic granuloma secondary to docetaxel therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Granuloma, Pyogenic; Humans; Klebsiella Infections; Lung Neoplasms; Nail Diseases; Staphylococcal Infections; Taxoids; Treatment Outcome | 2009 |
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Tubulin | 2009 |
Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Indoles; Lung Neoplasms; Mice; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Taxoids | 2009 |
[Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Glutamates; Guanine; Humans; Integrin beta1; Lung Neoplasms; Morpholines; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Taxoids | 2008 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endpoint Determination; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Male; Taxoids; Tubulin | 2009 |
Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Treatment Outcome | 2010 |
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2009 |
Immediate or delayed docetaxel: does progression-free survival really reflect two strategies?
Topics: Carcinoma, Non-Small-Cell Lung; Delayed-Action Preparations; Disease-Free Survival; Docetaxel; Drug Therapy; Humans; Lung Neoplasms; Physiological Phenomena; Survival Analysis; Taxoids | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Docetaxel; Drug Costs; Erlotinib Hydrochloride; Germany; Glutamates; Guanine; Humans; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2008 |
Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Topics: Antineoplastic Agents; Brazil; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost Control; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Sensitivity and Specificity; Taxoids | 2008 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Docetaxel; ErbB Receptors; Humans; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Panitumumab; Phosphorylation; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Drug Prescriptions; Humans; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Practice Patterns, Physicians'; Radiotherapy Dosage; Societies, Medical; Taxoids | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Platinum Compounds; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2010 |
In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration.
Topics: Adhesiveness; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Female; Glioblastoma; Half-Life; Humans; Inhibitory Concentration 50; Injections, Intravenous; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Solubility; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
I am no one. No one is perfect...Therefore I am perfect.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2009 |
Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diarrhea; Docetaxel; Drug Approval; ErbB Receptors; France; Gefitinib; Humans; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Quinazolines; Skin Diseases; Taxoids | 2009 |
Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.
Topics: Aged; Animals; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Impact of incidental irradiation on clinically uninvolved nodal regions in patients with advanced non-small-cell lung cancer treated with involved-field radiation therapy: does incidental irradiation contribute to the low incidence of elective nodal failu
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Taxoids | 2010 |
Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Lung Neoplasms; Microarray Analysis; MicroRNAs; Taxoids | 2010 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Comorbidity; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Quality of Life; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Calcium Channel Blockers; Calcium Channels, L-Type; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Diltiazem; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Lung Neoplasms; Nifedipine; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tubulin; Vincristine | 2010 |
[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
[Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2009 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
Re-challenge chemotherapy for relapsed non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Child; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Markov Chains; Pemetrexed; Quality of Life; Quality-Adjusted Life Years; Spain; Taxoids; Treatment Outcome | 2010 |
Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pneumonectomy; Remission Induction; Taxoids; Treatment Outcome | 2010 |
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Haplotypes; Humans; Linkage Disequilibrium; Polymorphism, Single Nucleotide; Reactive Oxygen Species; Taxoids | 2010 |
Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Precision Medicine; Taxoids; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2010 |
Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 2009 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Identification of candidate molecular markers predicting chemotherapy resistance in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Neoplasm Staging; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Taxoids | 2010 |
Network meta-analysis: importance of appropriate trial selection.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Confidence Intervals; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meta-Analysis as Topic; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Taxoids | 2010 |
EGFR mutations in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2010 |
Docetaxel-induced acral erythema and nail changes distributed to photoexposed areas.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erythema; Facial Dermatoses; Foot Diseases; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Nails; Onycholysis; Taxoids | 2010 |
One more fallen star--ZODIAC and its implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Endpoint Determination; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; Taxoids; Xenograft Model Antitumor Assays | 2010 |
Replication-dependent γ-H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Division; DNA Breaks, Double-Stranded; DNA Repair; DNA Replication; Docetaxel; Histones; Humans; Lung Neoplasms; Taxoids | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[A case of non-small cell lung cancer with hemodialysis which responded to docetaxel monotherapy].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Renal Dialysis; Taxoids | 2010 |
[Cost-effectiveness analysis comparing carboplatin and weekly paclitaxel with cisplatin and docetaxel in the treatment of advanced non-small cell lung carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2010 |
Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Pharmacogenetics; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-akt; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Retrospective Studies; Taxoids | 2010 |
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
FDA-approved drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Taxoids; United States; United States Food and Drug Administration | 2010 |
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Genes, BRCA1; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Repressor Proteins; Retrospective Studies; RNA, Messenger; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Retrospective Studies; Survival Rate; Taxoids; Vomiting | 2010 |
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2011 |
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Budgets; Carcinoma, Non-Small-Cell Lung; Centers for Medicare and Medicaid Services, U.S.; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Economic; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Taxoids; United States | 2011 |
Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Tolerance; Female; Genes, Reporter; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Luciferases, Renilla; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins c-akt; Recombinant Proteins; RNA Interference; Signal Transduction; Taxoids; Transplantation, Heterologous | 2011 |
Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 Enzyme System; Docetaxel; Drug Interactions; Enzyme Induction; Female; Follow-Up Studies; Humans; Intestines; Liver; Lung Neoplasms; Male; Nausea; Retrospective Studies; Taxoids; Vinca Alkaloids; Vomiting | 2011 |
YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Mice; Mice, Nude; Mitosis; Naphthoquinones; Survivin; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cells, Cultured; Docetaxel; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Indoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids | 2011 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Desensitisation to circumvent hypersensitivity reactions; treatment with docetaxel still possible].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Drug Hypersensitivity; Female; Humans; Lung Neoplasms; Middle Aged; Taxoids | 2011 |
Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Retrospective Studies; Salvage Therapy; Taxoids | 2011 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Taxoids | 2011 |
Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Consolidation Chemotherapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Pneumonitis; Survival Rate; Taxoids | 2012 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Clusterin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Neoplasm Metastasis; RNA Interference; Taxoids; Transcription, Genetic | 2012 |
Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Repair; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Regression Analysis; Survival Rate; Taxoids | 2012 |
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Female; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2011 |
Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA Repair; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polymorphism, Genetic; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2011 |
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antagonists; Gene Expression; Glutamates; Guanine; Humans; Immunoblotting; Irinotecan; Lung Neoplasms; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Vinblastine; Vinorelbine | 2011 |
Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Taxoids; Time Factors | 2011 |
Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Kidney Tubules; Male; Middle Aged; Neoplasm Staging; Renal Insufficiency; Taxoids | 2012 |
[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Platinum; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
[A case of locally advanced non-small-cell lung cancer complicated with chronic renal failure and gastric cancer, successfully treated with weekly docetaxel and concurrent thoracic radiotherapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Neoplasm Staging; Neoplasms, Second Primary; Stomach Neoplasms; Taxoids | 2011 |
Lung cyst caused by centrally located bronchogenic carcinoma.
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cough; Cysts; Docetaxel; Fatal Outcome; Hemoptysis; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Smoking; Taxoids; Tomography, X-Ray Computed | 2012 |
A case of stage IIIB lung cancer treated with concurrent chemoradiotherapy followed by successful tumor resection.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Taxoids; Tomography, X-Ray Computed | 2011 |
Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; British Columbia; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Taxoids | 2011 |
[Radiochemotherapy in non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Diagnosis, Differential; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pneumonectomy; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Taxoids; Tomography, X-Ray Computed | 2011 |
Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; China; Combined Modality Therapy; Cranial Irradiation; Docetaxel; Endostatins; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Pneumonectomy; Recombinant Proteins; Smoking; Taxoids; Young Adult | 2012 |
Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Laboratory Techniques; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Services; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Office Visits; Pemetrexed; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Taxoids; United States | 2012 |
Synergistic antitumor efficiency of docetaxel and curcumin against lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Curcumin; Docetaxel; Drug Synergism; Female; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Mice; Mice, Nude; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cranial Irradiation; Docetaxel; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids; Time Factors; Turkey; Vinblastine; Vinorelbine | 2012 |
[Concurrent chemoradiotherapy with carboplatin and docetaxel for stage III non-small-cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids | 2011 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Paclitaxel; Taxoids; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Pharmacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Peritoneal Dialysis, Continuous Ambulatory; Taxoids; Tissue Distribution | 2012 |
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Smoking; Taxoids; Tubulin | 2012 |
Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pneumonectomy; Taxoids; Time Factors; Treatment Outcome | 2012 |
The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prognosis; Taxoids; Tubulin | 2013 |
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Reproducibility of Results; Severity of Illness Index; Taxoids; Treatment Outcome; Vinblastine | 2012 |
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Thailand; Treatment Outcome | 2012 |
Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Taxoids | 2012 |
Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclobutanes; Docetaxel; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Organoplatinum Compounds; Paclitaxel; Taxoids; Tubulin Modulators; Tumor Burden; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2012 |
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Etoposide; Female; Fluid Therapy; Gemcitabine; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2012 |
Isolation, identification, semi-synthesis of aziditaxel derivatives and their biological evaluation.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Taxoids | 2012 |
Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoradiotherapy; Docetaxel; Drug Synergism; Endocytosis; Feasibility Studies; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Scanning; Nanoconjugates; Paclitaxel; Polymers; Radiation-Sensitizing Agents; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Longer overall survival in a patient with advanced non-small cell lung cancer treated with Chinese medicine and chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drugs, Chinese Herbal; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Tomography, X-Ray Computed | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Analysis of chemotherapy and molecular therapy efficiency in advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2012 |
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Humans; Inhibitory Concentration 50; Lung Neoplasms; Lymphatic Metastasis; MicroRNAs; Neoplasm Invasiveness; PTEN Phosphohydrolase; Radiation Tolerance; RNA Interference; Signal Transduction; Taxoids; Up-Regulation | 2013 |
Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Proportional Hazards Models; Radiation Dosage; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Female; Gene Expression; Humans; Indoles; Lung Neoplasms; Mice; Mice, Nude; Mutation; Niacinamide; Oligonucleotides; Taxoids; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Docetaxel-induced photo-recall phenomenon.
Topics: Administration, Topical; Adrenal Cortex Hormones; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatitis, Phototoxic; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Taxoids | 2012 |
Effect analysis of chemoradiotherapy after operation in patients with stage III A non-small cell lung cancer.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Period; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chromatography, Liquid; Cisplatin; Deoxycytidine; Docetaxel; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Proteomics; Radiotherapy, Intensity-Modulated; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2013 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Prospective Studies; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2012 |
FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Proportional Hazards Models; RNA, Messenger; Taxoids; Vinblastine; Vinorelbine | 2013 |
A step towards treating KRAS-mutant NSCLC.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Taxoids | 2013 |
[Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Taxoids | 2012 |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.
Topics: Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Stability; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Particle Size; Poloxamer; Random Allocation; Rats; Rats, Sprague-Dawley; Taxoids; Xenograft Model Antitumor Assays | 2013 |
Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Carriers; Gene Expression Regulation, Neoplastic; Humans; Lipids; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nanostructures; Pyrazoles; Sulfonamides; Taxoids | 2013 |
Chemotherapy extravasations: prevention, identification, management, and documentation.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Documentation; Education, Nursing, Continuing; Evidence-Based Nursing; Extravasation of Diagnostic and Therapeutic Materials; Humans; Lung Neoplasms; Male; Taxoids | 2013 |
The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms; Paclitaxel; Taxoids | 2002 |
Gastrointestinal toxicity associated with weekly docetaxel treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Digestive System; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enterocolitis; Fatal Outcome; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Organ Failure; Neoplasm Staging; Paclitaxel; Risk Assessment; Taxoids | 2002 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Capillaries; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Division; Cells, Cultured; Chemotaxis; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelium, Vascular; Fibrosarcoma; Glioblastoma; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays | 2003 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids; Tumor Cells, Cultured | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2003 |
Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Cell Division; Docetaxel; Female; Humans; In Situ Nick-End Labeling; Keratins; Ki-67 Antigen; Lung Neoplasms; Poly(ADP-ribose) Polymerases; Rats; Rats, Nude; Sulindac; Survival Rate; Taxoids; Tumor Cells, Cultured | 2003 |
Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Paclitaxel; Phenotype; Polymerase Chain Reaction; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 2003 |
Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Platinum Compounds; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Epiphora induced by intermittent docetaxel (taxotere) in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lacrimal Apparatus Diseases; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2003 |
Special patients, special treatments.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Fever; Gemcitabine; Health Status; Humans; Lung Neoplasms; Middle Aged; Neutropenia; Population Dynamics; Taxoids | 2003 |
Successful docetaxel tolerance induction.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Lung Neoplasms; Male; Taxoids | 2003 |
Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Ifosfamide; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prognosis; Quality of Life; Salvage Therapy; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2003 |
[Effects of docetaxel dosage in combination chemotherapy with carboplatin against advanced non-small cell lung cancer].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Taxoids | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Reply to "Radiation pneumonitis and docetaxel".
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2004 |
Two-dimensional radiotherapy and docetaxel in treatment of stage III non-small cell lung carcinoma: no good survival due to radiation pneumonitis.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Radiation Pneumonitis; Risk Factors; Taxoids; Time Factors | 2004 |
Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pleural Effusion; Postoperative Complications; Preoperative Care; Survival Rate; Taxoids | 2004 |
Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB.
Topics: Acute Disease; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromosome Aberrations; Docetaxel; Humans; Karyotyping; Leukemia, Myeloid; Lung Neoplasms; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Taxoids | 2004 |
Correspondence re L. J. Wirth et al., Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase I study. Clin Cancer Res 2003;9:1698-704.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Remission Induction; Taxoids; Time Factors; Treatment Outcome | 2004 |
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Incidence; Lung Diseases; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2004 |
Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Prospective Studies; Survival Rate; Taxoids | 2004 |
A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Endpoint Determination; Health Care Costs; Humans; Lung Neoplasms; Models, Economic; State Medicine; Survival Rate; Taxoids; Treatment Outcome; United Kingdom | 2004 |
[Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2004 |
A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.
Topics: Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gastrointestinal Agents; Humans; Infliximab; Lung Neoplasms; Male; Pilot Projects; Taxoids; Weight Loss | 2004 |
Necessity of identifying the patterns of failure after concurrent radiochemotherapy part of a combined modality approach in patients with stage III non-small cell lung cancer [Sakai et al., Lung Cancer 2004;43:195-201].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endpoint Determination; Humans; Lung Neoplasms; Patient Care Planning; Prognosis; Taxoids; Treatment Outcome | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Successful management of a patient with stage IIIA non-small cell lung cancer using sensitivity-based induction chemotherapy--report of a case.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Taxoids | 2004 |
Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured | 2005 |
Erlotinib hydrochloride.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Expert Testimony; Humans; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Treatment Outcome | 2005 |
Integration of docetaxel in the management of non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2004 |
Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids | 2005 |
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Lung Neoplasms; Phenylenediamines; Taxoids; Tumor Cells, Cultured | 2005 |
Doxetaxel in previously treated non-small cell lung cancer patients: clinical efficacy and quality of life.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Male; Middle Aged; Quality of Life; Surveys and Questionnaires; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
[Multi-target tumor therapy].
Topics: Antimetabolites, Antineoplastic; Asbestosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Enzyme Inhibitors; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Neoplasm Recurrence, Local; Pemetrexed; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Screening Assays, Antitumor; Humans; Isocoumarins; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Taxoids | 2005 |
Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Antipyrine; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytochrome P-450 Enzyme System; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Suramin; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
Effects of navelbine and docetaxel on gene expression in lung cancer cell strains.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Cluster Analysis; Clusterin; Docetaxel; Dose-Response Relationship, Drug; Galectin 1; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; Metallothionein; Oligonucleotide Array Sequence Analysis; Taxoids; Tissue Inhibitor of Metalloproteinase-1; Vinblastine; Vinorelbine | 2005 |
[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2005 |
Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Genes, p53; HeLa Cells; Humans; Lung Neoplasms; RNA Interference; Taxoids; Tubulin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2006 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
[Effect of induction chemotherapy followed by surgery for bulky N2, T4 non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Prospective Studies; Survival Analysis; Taxoids | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
[Modern chemotherapy achieves longer life].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Evidence-Based Medicine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
Advances in the treatment of second-line non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Salvage Therapy; Survival Analysis; Taxoids; Vitamin B 12 | 2005 |
Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Docetaxel; Drug Carriers; Esophageal Neoplasms; Feasibility Studies; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Polymerase Chain Reaction; Stomach Neoplasms; Taxoids; Telomerase; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2006 |
Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Topics: Aerosols; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; Drug Synergism; Ethanol; Humans; Hydrocarbons, Fluorinated; In Situ Nick-End Labeling; Lung Neoplasms; Membrane Proteins; Metered Dose Inhalers; Particle Size; Polymerase Chain Reaction; PPAR gamma; Pyrazoles; RNA, Messenger; Solubility; Sulfonamides; Taxoids | 2006 |
[Successful chemotherapy with carboplatin and docetaxel for an elderly patient with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quality of Life; Taxoids | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
Long-term survival after second-line therapy with docetaxel and carboplatin and monthly pamidronic acid in a woman with metastatic non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Docetaxel; Female; Humans; Longitudinal Studies; Lung Neoplasms; Lymphatic Metastasis; Pamidronate; Taxoids; Treatment Outcome | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Intramedullary metastases due to non microcytic lung carcinoma.
Topics: Adenocarcinoma; Bone Marrow Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Docetaxel; Frontal Lobe; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Spinal Neoplasms; Taxoids; Thoracic Vertebrae; Vinblastine; Vinorelbine | 2006 |
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Celecoxib; Dinoprostone; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Injections, Intravenous; Interleukin-8; Lung Neoplasms; Mice; Neoplasm Transplantation; Pyrazoles; Sulfonamides; Taxoids; Transplantation, Heterologous | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Kidney Failure, Chronic; Lung Neoplasms; Lymphatic Metastasis; Renal Dialysis; Taxoids; Time Factors; Tomography, X-Ray Computed | 2007 |
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Topics: Alternative Splicing; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclooxygenase 2; Docetaxel; Drug Synergism; Gene Expression Regulation, Neoplastic; Growth Hormone-Releasing Hormone; Humans; Insulin-Like Growth Factor I; Mice; Mice, Nude; Organ Size; Phosphoproteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Radioimmunoassay; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; RNA, Messenger; Taxoids; Transplantation, Heterologous | 2006 |
Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Treatment Outcome | 2006 |
Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Survival Analysis; Survivors; Taxoids; Time Factors | 2006 |
Quality of life assessment in the TAX 326 study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Patient Compliance; Platinum; Psychomotor Performance; Quality of Life; Sickness Impact Profile; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients: four clinical specified cases.
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed | 2007 |
[Results in 42 non-resectable NSCLC IIA-B patients with initial concurrent Taxotere-Cisplatin chemoradiotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Research Design; Survival Rate; Taxoids | 2007 |
NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Down-Regulation; Drug Combinations; Glycogen Synthase Kinases; HIV Protease Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nelfinavir; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Taxoids; Tumor Suppressor Protein p53 | 2006 |
15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Immunologic Factors; In Situ Nick-End Labeling; Lung Neoplasms; Mice; PPAR gamma; Prostaglandin D2; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Transplantation, Heterologous | 2007 |
[A case of hyponatremia associated with combination therapy of systemic chemotherapy and paroxetine].
Topics: Aged; Antidepressive Agents, Second-Generation; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lung Neoplasms; Paroxetine; Selective Serotonin Reuptake Inhibitors; Taxoids | 2006 |
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Genes, p53; Genetic Therapy; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Transfection; Tumor Cells, Cultured | 2007 |
Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Male; Oncogenes; Ploidies; Probability; Sensitivity and Specificity; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2007 |
Fatal ischemic bowel necrosis possibly due to docetaxel and cisplatin in a patient with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Fatal Outcome; Humans; Intestines; Ischemia; Lung Neoplasms; Male; Middle Aged; Necrosis; Taxoids | 2007 |
Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Experimental; Taxoids; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2007 |
In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cell Transformation, Neoplastic; Colonic Neoplasms; Docetaxel; Drug Synergism; Enzyme Inhibitors; Humans; In Vitro Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Microtubules; Mitogen-Activated Protein Kinases; Paclitaxel; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Signal Transduction; Taxoids; Transcriptional Activation; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2007 |
Docetaxel as monotherapy in the treatment of advanced non-small-cell lung cancer in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Patient Selection; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survivin; Taxoids; Tumor Cells, Cultured | 2007 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Japan; Lung Neoplasms; Male; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Down-Regulation; Drug Delivery Systems; Drug Resistance, Neoplasm; Gene Silencing; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Taxoids | 2007 |
Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2007 |
Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diagnosis, Differential; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Infant, Newborn; Lung Neoplasms; Neoplasm Staging; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy Trimester, Second; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Taxoids; Tomography, X-Ray Computed | 2008 |
Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Imatinib Mesylate; Immunohistochemistry; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Pyrimidines; Taxoids; Xenograft Model Antitumor Assays | 2007 |
[Lung cancer treatment in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2007 |
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Taxoids | 2008 |
Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Taxoids; Treatment Outcome | 2007 |
Gemcitabine combination in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids | 2007 |
Induction chemoradiotherapy prior to surgery for non-small cell lung cancer invading the left atrium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Heart Atria; Heart Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Remission Induction; Taxoids | 2008 |
The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2008 |
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2008 |
[Management of non-small cell lung carcinoma following docetaxel-cisplatin. Results of an epidemiologic survey].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Taxoids | 2007 |
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2007 |
Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Male; Multiple Myeloma; Neoplasms, Second Primary; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2008 |
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 17; Cisplatin; Data Interpretation, Statistical; Docetaxel; Female; Gene Dosage; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Peptide Fragments; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Diclofenac; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2008 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Docetaxel: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Taxoids | 1995 |
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Taxoids; Topoisomerase I Inhibitors | 1997 |
The development of docetaxel (Taxotere) in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
[Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].
Topics: Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Hypersensitivity; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Paclitaxel; Prednisolone; Pulmonary Edema; Taxoids | 1998 |
Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.
Topics: Adult; Antineoplastic Agents, Phytogenic; Body Weight; Capillary Leak Syndrome; Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Hemodynamics; Humans; Lung Neoplasms; Male; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: recent results and future developments.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Interactions; Flow Cytometry; Humans; Lung Neoplasms; Paclitaxel; Radiation Dosage; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Tumor Cells, Cultured | 1999 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Weight Loss | 2000 |
Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Hydrocortisone; Least-Squares Analysis; Linear Models; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Docetaxel in the management of breast and non-small-cell lung cancers. ASCO 2000, 22nd annual San Antonio Breast Cancer Symposium, and ECCO 10. Abstracts.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2000 |
Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Hand; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel as second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Orosomucoid; Paclitaxel; Prognosis; Proportional Hazards Models; Regression Analysis; Reproducibility of Results; Survival Analysis; Taxoids | 2000 |
Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cisplatin; Docetaxel; Drug Interactions; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Combination chemotherapy of carboplatin and docetaxel for advanced non-small cell lung cancer (NSCLC)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Chemotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Taxoids | 2001 |
Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cross Infection; Docetaxel; Female; Humans; Hydrocortisone; Immunosuppressive Agents; Lung Neoplasms; Male; Methylprednisolone; Paclitaxel; Pneumonia; Pneumothorax; Respiration, Artificial; Taxoids | 2001 |
Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Docetaxel; Drug Costs; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Sensitivity and Specificity; Survival Rate; Taxoids | 2002 |
Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Clinical observation of taxotere in the treatment of advanced non-small-cell lung cancer and breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Docetaxel combination produces 2-year survival advantage in NSCLC patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Costs and Cost Analysis; Docetaxel; Hospitalization; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy; Retrospective Studies; Sensitivity and Specificity; Taxoids | 2002 |
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Docetaxel; Drug Administration Schedule; Female; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mediastinal Neoplasms; Neoplasms, Experimental; Paclitaxel; Rats; Rats, Nude; Sulindac; Survival Rate; Taxoids; Tetrazolium Salts; Thiazoles | 2002 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids | 2002 |